number,PMID,gene,disease,body fluid,sequencing method,experiment,Drug resistance,disease prognosis,characteration of tumors,prospects for detection,metastasis biomarker,therapy,others
1,33878340,BRAF,Non-Small Cell Lung Cancer,_,NGS(Guardant360),"We retrospectively evaluated 370 adult patients with NSCLC treated at the City of Hope between November 2015 and August 2019 to assess the usefulness of ctDNA in mutation identification, survival, concordance with matched tissue samples in 32 genes, and tumor evolution",_,"Overall survival was shorter in patients harboring BRAF mutations (HR, 2.35; 95% CI, 1.24-4.6; P = .009)",_,_,_,_,_
2,33878340,PI3KCA,Non-Small Cell Lung Cancer,_,NGS(Guardant360),"We retrospectively evaluated 370 adult patients with NSCLC treated at the City of Hope between November 2015 and August 2019 to assess the usefulness of ctDNA in mutation identification, survival, concordance with matched tissue samples in 32 genes, and tumor evolution",_,"Overall survival was shorter in patients harboring PIK3CA mutations (HR, 2.77; 95% CI, 1.56-4.9; P < .001)",_,_,_,_,_
3,33878340,KRAS,Non-Small Cell Lung Cancer,_,NGS(Guardant360),"We retrospectively evaluated 370 adult patients with NSCLC treated at the City of Hope between November 2015 and August 2019 to assess the usefulness of ctDNA in mutation identification, survival, concordance with matched tissue samples in 32 genes, and tumor evolution",_,"Overall survival was shorter in patients harboring KRAS mutations (HR, 2.32; 95% CI, 1.30-4.1; P = .004)",_,_,_,_,_
4,34664256,TP53,Diffuse Large B-Cell Lymphoma,plasma,cSMART,"In the present study, we developed a prospective and observational study by designing a panel targeting 17 genes to determine the value of ctDNA in prognosis and disease monitoring using cSMART in DLBCL.",_,"Patients with mutated TP53 had significantly shorter OS than those with wild-type TP53 (P = 0.037). A similar trend, although not significant, was observed in PFS (P = 0.1)",_,_,_,_,_
5,34664256,B2M,Diffuse Large B-Cell Lymphoma,plasma,cSMART,"In the present study, we developed a prospective and observational study by designing a panel targeting 17 genes to determine the value of ctDNA in prognosis and disease monitoring using cSMART in DLBCL.",_,Patients with mutations in B2M had both shorter OS and PFS (P = 0.0077 and P = 0.031; ),_,_,_,_,_
6,33122747,BRAF,Melanoma,plasma,dPCR,"In once clinical study, We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to clinical outcome.",_,Patients who had detectable levels of ctDNA had a shorter progression-free survival when compared to patients with undetectable mutation (p = 0.01),_,_,_,_,_
7,33122747,NRAS,Melanoma,plasma,dPCR,"In once clinical study, We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to clinical outcome.",_,Patients who had detectable levels of ctDNA had a shorter progression-free survival when compared to patients with undetectable mutation (p = 0.01),_,_,_,_,_
8,33122747,TERT,Melanoma,plasma,dPCR,"In once clinical study, We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to clinical outcome.",_,Patients who had detectable levels of ctDNA had a shorter progression-free survival when compared to patients with undetectable mutation (p = 0.01),_,_,_,_,_
9,30240661,KRAS,Pancreatic Adenocarcinoma,plasma,ddPCR,"In once clincal study,We collected liquid biopsy samples from 194 patients undergoing treatment for localized or metastatic pancreatic adenocarcinoma from April 7, 2015, through October 13, 2017 (425 blood samples collected before [baseline] and during therapy). Additional liquid biopsy samples were collected from 37 disease control individuals. Droplet digital polymerase chain reaction was used to determine KRAS mutant allele fraction (MAF) from ctDNA and exoDNA purified from plasma. For the longitudinal analysis, we analyzed exoDNA and ctDNA in 123 serial blood samples from 34 patients. We performed analysis including Cox regression, Fisher exact test, and Bayesian inference to associate KRAS MAFs in exoDNA and ctDNA with prognostic and predictive outcomes.",_,"On univariate analysis, patients with metastases and detectable ctDNA at baseline status had significantly shorter times of progression-free survival (PFS) (hazard ratio [HR] for death, 1.8; 95% CI, 1.1-3.0; P = .019), and overall survival (OS) (HR, 2.8; 95% CI, 1.4-5.7; P = .0045) compared with patients without detectable ctDNA. A multianalyte approach showed detection of both ctDNA and exoDNA MAFs ¡Ý5% at baseline status to be a significant predictor of OS (HR, 7.73, 95% CI, 2.61-22.91, P = .00002) on multivariate analysis.","exoDNA and ctDNA KRAS MAFs at presentation were significantly correlated with tumor size as measured by total sum of lesion diameters (P = .035 and P = .0008, respectively)",_,"ctDNA tumor burden, as measured by KRAS MAF at presentation, was also significantly associated with survival (P = .03). Patients with liver metastatic lesions had a significantly greater KRAS MAF in exoDNA and ctDNA than patients with isolated lung and peritoneal lesions (P = .04). This correlation was likely affected by the fact that patients with metastasis to the liver have larger volume of lesions than those with isolated lung and peritoneal metastases.",_,_
10,32253118,KRAS,Lung Adenocarcinoma,plasma,ddPCR,Consecutive patients diagnosed with KRAS mutant lung adenocarcinoma in the tumor biopsy were included in this study. Plasma samples were obtained at different time points during the course of the disease. KRAS mutations in plasma were quantified using digital PCR and correlated with mutations in tumor and with radiological response and progression.,_,"The dynamics of KRAS mutational load predicted response in 93% and progression in 63% of cases, 33 and 50 days respectively in advance of radiological evaluation. Progression-free survival for patients in whom ctDNA was not detectable in plasma after treatment initiation was significantly longer than for those in whom ctDNA remained detectable (7.7 versus 3.2 months; HR: 0.44, p=0.004).",_,Predict tumor response and progression to chemotherapy in advance of radiographic evaluation. The liquid biopsies for ctDNA-based molecular analyses are a reliable tool for KRAS testing in clinical practice,_,_,_
11,34009695,VHL,Clear Cell Renal Cell Carcinoma,plasma,dPCR,"In the present study, we first aimed to establish a highly sensitive assay to detectVHLmutations using a combination of digital PCR (dPCR) and multiplex PCR¨Cbased targeted sequencing. Second, we profiled theVHLstatus in plasma cfDNA in patients with ccRCC and investigated clinical categories correlated withVHLmutations in cfDNA and evaluated their clinical utility.",_,_,the VAF of VHL mutation changed consistent with tumor size by radiographic imaging during systemic treatment.,_,_,_,_
12,33547199,RAS,Metastatic Colorectal Cancer,plasma,NGS,"We included patients with left-sided, RAS/BRAF wild-type, HER2-negative, and microsatellite stable mCRC, treated with upfront panitumumab/FOLFOX-4 in the Valentino study. We performed amplicon-based genomic profiling of 14 genes in baseline plasma samples and compared these data with tumor tissue ultra-deep sequencing results. Specific gene mutations in circulating tumor DNA (ctDNA) and their clonality were associated with progression-free survival (PFS), overall survival (OS), and radiological dynamics.",_,both PFS and OS were significantly worse in patients bearing a RAS mutation in ctDNA versus RAS wild-type subgroup,_,_,_,_,_
13,33547199,PIK3CA,Metastatic Colorectal Cancer,plasma,NGS,"We included patients with left-sided, RAS/BRAF wild-type, HER2-negative, and microsatellite stable mCRC, treated with upfront panitumumab/FOLFOX-4 in the Valentino study. We performed amplicon-based genomic profiling of 14 genes in baseline plasma samples and compared these data with tumor tissue ultra-deep sequencing results. Specific gene mutations in circulating tumor DNA (ctDNA) and their clonality were associated with progression-free survival (PFS), overall survival (OS), and radiological dynamics.",_,A trend for a worse PFS and OS could be observed in patients bearing simultaneously PIK3CA and KRAS mutations compared with patients carrying only one of them.,_,_,_,_,_
14,32196518,EGFR,Non-Small Cell Lung Cancer,plasma,PANAmutyperTMR EGFR and KRAS detection kit,Consecutive cases of NSCLC with matching surgically resected tissue specimens and peripheral or specimen blood samples were eligible for this study. EGFR and KRAS mutations in plasma ctDNA and formalin-fixed paraffin-embedded tissue were analyzed using peptide nucleic acid clamping-assisted method. The plasma and tissue results were compared according to clinicopathological features,_,_,The presence of ctDNA in plasma was significantly associated with higher pathological tumor stage (p = 0.008),_,significantly associated with nodal metastasis (p = 0.013),_,"significantly associated with solid adenocarcinoma pattern (p = 0.002),tumor necrosis (p = 0.002)"
15,32196518,KRAS,Non-Small Cell Lung Cancer,plasma,PANAmutyperTMR EGFR and KRAS detection kit,Consecutive cases of NSCLC with matching surgically resected tissue specimens and peripheral or specimen blood samples were eligible for this study. EGFR and KRAS mutations in plasma ctDNA and formalin-fixed paraffin-embedded tissue were analyzed using peptide nucleic acid clamping-assisted method. The plasma and tissue results were compared according to clinicopathological features,_,_,The presence of ctDNA in plasma was significantly associated with higher pathological tumor stage (p = 0.008),_,significantly associated with nodal metastasis (p = 0.013),_,"significantly associated with solid adenocarcinoma pattern (p = 0.002),tumor necrosis (p = 0.002)"
16,32196518,EGFR,Non-Small Cell Lung Cancer,plasma,PANAmutyperTMR EGFR and KRAS detection kit,Consecutive cases of NSCLC with matching surgically resected tissue specimens and peripheral or specimen blood samples were eligible for this study. EGFR and KRAS mutations in plasma ctDNA and formalin-fixed paraffin-embedded tissue were analyzed using peptide nucleic acid clamping-assisted method. The plasma and tissue results were compared according to clinicopathological features,_,_,"tumors shedding EGFR mutant ctDNA in plasma had significantly larger tumor diameter (median [range], 5.45 [4.9¨C6.0] cm vs. 2.5 [0.8¨C3.5] cm; p = 0.027), tumor volume (median [range], 64.0 [44.60~83.40] cm3 vs. 5.45 [0.48¨C21.80] cm3; p = 0.027), and higher mitotic rate (median [range] per 10 HPFs, 16 vs 0 [0¨C5]; p = 0.009) than non-shedding tumors",_,"detection of EGFR mutated ctDNA was significantly associated with nodal metastasis (p = 0.029), vascular invasion (p = 0.029)",_,associated to solid adenocarcinoma pattern (p = 0.010) and tumor necrosis (p = 0.010) of primary tumor
17,33831609,EGFR,Non-Small Cell Lung Cancer,plasma,dpcr,"A total of 830 plasma samples from 228 patients with stage IV, EGFR-positive NSCLC who were treated with first-line TKIs were analysed by digital polymerase chain reaction (dPCR).",_,"in patients with  osimertinib treatment ,Patients with ctDNA detected at an MAF ¡Ý7% in the pre-treatment sample had significantly worse PFS and OS;baseline with detectable mutation patients with afatinib, erlotinib or gefitinib treatment have similar condition,after treatment(3,6 month),lower detection have longer PFS and  OS",_,_,_,_,_
18,30862692,PIK3CA,Breast Cancer,plasma,ddpcr,"We aim to evaluate whether circulating tumor DNA (ctDNA) is associated with response to anti-HER2-targeted therapy.Plasma DNA collected before NAT, at week 2, and before surgery from patients enrolled in the NeoALTTO trial was assessed using digital PCR for PIK3CA and TP53 mutation detection.",_,"ctDNA detection at baseline, considered as a binary variable, was associated with decreased odds of achieving pCR",_,_,_,_,_
19,30862692,TP53,Breast Cancer,plasma,ddpcr,"We aim to evaluate whether circulating tumor DNA (ctDNA) is associated with response to anti-HER2-targeted therapy.Plasma DNA collected before NAT, at week 2, and before surgery from patients enrolled in the NeoALTTO trial was assessed using digital PCR for PIK3CA and TP53 mutation detection.",_,"ctDNA detection at baseline, considered as a binary variable, was associated with decreased odds of achieving pCR",_,_,_,_,_
20,35273907,EGFR,Non-Small Cell Lung Cancer,plasma,_,"In this study, 221 tumor tissues and 174 plasma samples from NSCLC patients were analyzed by hybridization capture-based next-generation sequencing (NGS) panel including 95 cancer-associated genes. Tumor response assessments were applied to 137 patients with advanced-stage (III and IV) NSCLC who first received targeted agents",_,"related  to poor response rate, the response rate (RR = CR + PR) was 44.44% (4/9) in patients with EGFR alterations alone, while only 12.5% (2/16) in patients with EGFR&TP53 co-alterations.",_,_,_,_,_
21,35273907,TP53,Non-Small Cell Lung Cancer,plasma,_,"In this study, 221 tumor tissues and 174 plasma samples from NSCLC patients were analyzed by hybridization capture-based next-generation sequencing (NGS) panel including 95 cancer-associated genes. Tumor response assessments were applied to 137 patients with advanced-stage (III and IV) NSCLC who first received targeted agents",_,"related  to poor response rate, the response rate (RR = CR + PR) was 44.44% (4/9) in patients with EGFR alterations alone, while only 12.5% (2/16) in patients with EGFR&TP53 co-alterations.",_,_,_,_,_
22,30706231,TP53,Colorectal Cancer,plasma,Illumina HiSeq 2500,"Between November 2014 and November 2015, 60 patients with CRC were identified and prospectively enrolled. During liver resection, blood was drawn from peripheral (PERIPH), portal (PV), and hepatic (HV) veins, and 3-4 weeks postoperatively from a peripheral vein (POSTOP). Kappa statistics were used to compare mutated (mt) genes in tissue and ctDNA. Disease-specific and disease-free survival (DSS and DFS) were assessed from surgery with Kaplan-Meier and Cox methods.",_,"Detection of PERIPH mtTP53 was associated with worse DSS (2y:79%, 95%CI:48-93%) compared to patients lacking detection,Larger tumors were also associated with detection and higher VAF of mtTP53 in PERIPH and perihepatic blood.",_,_,_,_,_
23,30706231,APC,Colorectal Cancer,plasma,Illumina HiSeq 2500,"Between November 2014 and November 2015, 60 patients with CRC were identified and prospectively enrolled. During liver resection, blood was drawn from peripheral (PERIPH), portal (PV), and hepatic (HV) veins, and 3-4 weeks postoperatively from a peripheral vein (POSTOP). Kappa statistics were used to compare mutated (mt) genes in tissue and ctDNA. Disease-specific and disease-free survival (DSS and DFS) were assessed from surgery with Kaplan-Meier and Cox methods.",_,_,mtAPC detection was associated with larger tumors.,_,_,_,_
24,31439584,EGFR,Non-Small Cell Lung Cancer,plasma,cobasEGFR Mutation Test v2 (cobas plasma) assay,Tumor tissue EGFRm status was determined at screening using the central cobas tissue test or a local tissue test. Baseline circulating tumor (ct)DNA EGFRm status was retrospectively determined with the central cobas plasma test,_,_,"Importantly, at baseline, the median target lesion tumor size was significantly greater in those patients with a cobas plasma EGFRm-positive status (55 mm) than those with an EGFRm-negative status (35 mm)",_,_,_,_
25,27712015,KRAS,Metastatic Colorectal Cancer,plasma,Ion Proton sequencer.,"Patients were randomized in a 1:1 ratio to receive either panitumumab at 6 mg/kg with FOLFIRI once every 2 weeks or bevacizumab at 5 mg/kg with FOLFIRI every 2 weeks in one cycle. Randomization was stratified according to institutions and three groups by Khne prognostic index.19 Treatment was discontinued upon disease progression, occurrence of unacceptable severe toxicity, or patient request. Radiologic tumor evaluations were repeated every 8 weeks during the first year and every 12 weeks thereafter by each investigator according to RECIST version 1.1. Adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events version 4.0.",_,_,_,_,_,"RAS and BRAF mutation in ctDNA could be a negative predictive marker for panitumumab; Patients with any RAS or BRAF mutation showed worse OS in FOLFIRI plus panitumumab arm than in FOLFIRI plus bevacizumab arm (median 5.4 vs 8.2 months; HR, 0.42).",_
26,27712015,NRAS,Metastatic Colorectal Cancer,plasma,Ion Proton sequencer.,"Patients were randomized in a 1:1 ratio to receive either panitumumab at 6 mg/kg with FOLFIRI once every 2 weeks or bevacizumab at 5 mg/kg with FOLFIRI every 2 weeks in one cycle. Randomization was stratified according to institutions and three groups by K hne prognostic index.19 Treatment was discontinued upon disease progression, occurrence of unacceptable severe toxicity, or patient request. Radiologic tumor evaluations were repeated every 8 weeks during the first year and every 12 weeks thereafter by each investigator according to RECIST version 1.1. Adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events version 4.0.",_,_,_,_,_,"RAS and BRAF mutation in ctDNA could be a negative predictive marker for panitumumab; Patients with any RAS or BRAF mutation showed worse OS in FOLFIRI plus panitumumab arm than in FOLFIRI plus bevacizumab arm (median 5.4 vs 8.2 months; HR, 0.43).",_
27,27712015,BRAF,Metastatic Colorectal Cancer,plasma,Ion Proton sequencer.,"Patients were randomized in a 1:1 ratio to receive either panitumumab at 6 mg/kg with FOLFIRI once every 2 weeks or bevacizumab at 5 mg/kg with FOLFIRI every 2 weeks in one cycle. Randomization was stratified according to institutions and three groups by K hne prognostic index.19 Treatment was discontinued upon disease progression, occurrence of unacceptable severe toxicity, or patient request. Radiologic tumor evaluations were repeated every 8 weeks during the first year and every 12 weeks thereafter by each investigator according to RECIST version 1.1. Adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events version 4.0.",_,_,_,_,_,"RAS and BRAF mutation in ctDNA could be a negative predictive marker for panitumumab; Patients with any RAS or BRAF mutation showed worse OS in FOLFIRI plus panitumumab arm than in FOLFIRI plus bevacizumab arm (median 5.4 vs 8.2 months; HR, 0.44).",_
28,34312841,TNFAIP3,Hodgkin Lymphoma,plasma,"NextSeq sequencer (Illumina, San Diego, CA, USA)","cell free DNA (cfDNA) isolated from plasma collected at diagnosis, before any treatment start (n= 60 patients), and paired normal genomic or additional cfDNA samples during treatment (data not shown), for comparative purposes to confirm the somatic origin of mutations",_,_,_,_,_,_,"we observed that mutations in LRRN3, CSF2RB and B2 M genes were particularly enriched in nodular sclerosis HL compared with other subtypes£¬TNFAIP3 and SOCS1 mutations were significantly enriched within the group of patients with higher levels of LDH"
29,34312841,SOCS1,Hodgkin Lymphoma,plasma,"NextSeq sequencer (Illumina, San Diego, CA, USA)","cell free DNA (cfDNA) isolated from plasma collected at diagnosis, before any treatment start (n = 60 patients), and paired normal genomic or additional cfDNA samples during treatment (data not shown), for comparative purposes to confirm the somatic origin of mutations",_,_,_,_,_,_,"we observed that mutations in LRRN3, CSF2RB and B2 M genes were particularly enriched in nodular sclerosis HL compared with other subtypes£¬TNFAIP3 and SOCS1 mutations were significantly enriched within the group of patients with higher levels of LDH"
30,35046520,PIK3CA,Urothelial Cancer,plasma,NextSeq 500 or HiSeq 2500,We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC.,_,"Patients with detectable PIK3CA ctDNA GAs at any time point (n = 10/53) had shorter overall survival in univariate analysis (HR: 3.27, 95% CI:1.08¨C9.92, p = 0.03) and multivariate analysis (HR: 2.87, p = 0.038).",_,_,_,_,_
31,35046520,KRAS,Gastroenteropancreatic Neuroendocrine Carcinomas,plasma,NGS,"The CIRCAN-NEC study included patients with GEPNEC or NEC from an unknown primary, scheduled to begin first- or second-line chemotherapy. Blood samples were collected prior to chemotherapy initiation, at first evaluation, and during disease progression. ctDNA was sequenced by next-generation sequencing (NGS). Molecular response was defined as a decrease of at least 30% of the mutant allele fraction",_,"patients with KRAS (HR = 3.60, 95% CI [1.06-12.04]) and BRAF (HR = 4.25, 95% CI [1.11-16.40]) mutations had shorter progression-free survival (PFS) under platinum-etoposide",_,_,_,_,_
32,35046520,BRAF,Gastroenteropancreatic Neuroendocrine Carcinomas,plasma,NGS,"The CIRCAN-NEC study included patients with GEPNEC or NEC from an unknown primary, scheduled to begin first- or second-line chemotherapy. Blood samples were collected prior to chemotherapy initiation, at first evaluation, and during disease progression. ctDNA was sequenced by next-generation sequencing (NGS). Molecular response was defined as a decrease of at least 30% of the mutant allele fraction",_,"patients with KRAS (HR = 3.60, 95% CI [1.06-12.04]) and BRAF (HR = 4.25, 95% CI [1.11-16.40]) mutations had shorter progression-free survival (PFS) under platinum-etoposide",_,_,_,_,_
33,35046520,RB1,Gastroenteropancreatic Neuroendocrine Carcinomas,plasma,NGS,"The CIRCAN-NEC study included patients with GEPNEC or NEC from an unknown primary, scheduled to begin first- or second-line chemotherapy. Blood samples were collected prior to chemotherapy initiation, at first evaluation, and during disease progression. ctDNA was sequenced by next-generation sequencing (NGS). Molecular response was defined as a decrease of at least 30% of the mutant allele fraction",_,2 patients with RB1 mutations had shorter PFS under FOLFIRI-based chemotherapy.,_,_,_,_,_
34,33893289,ESR1,Breast Cancer,plasma,droplet digital PCR (ddPCR) and error corrected targeted sequencing,"Here we define the genomic profile of metastatic breast cancer using ctDNA sequencing from patients within plasmaMATCH, a prospective platform trial leveraging ctDNA analysis in patients with metastatic breast cancer for which the primary outcomes have been published28. In this ad-hoc analysis we investigate how the profile of somatic genetic alterations in ctDNA differs from that obtained by tumour tissue sequencing. Using the rich clinical data set associated with the clinical trial, we explore the clinical and pathological associations of advanced breast cancer genomics, and define the processes that generate the genomic diversity of metastatic breast cancer.",_,"We demonstrate diverse subclonal resistance mutations, including enrichment of HER2 mutations in HER2 positive disease, co-occurring ESR1 and MAP kinase pathway mutations in HR + HER2- disease that associate with poor overall survival (p = 0.0092)",_,_,"Bone disease was positively associated with ESR1 and GATA3 alterations, Liver disease showed a positive association with ESR1 alterations (q < 0.0001), In HR + HER2- disease ESR1 mutations were positively associated with liver and bone disease (q = 0.004 and q = 0.02, respectively)",_,_
35,33893289,GATA3,Breast Cancer,plasma,droplet digital PCR (ddPCR) and error corrected targeted sequencing,"Here we define the genomic profile of metastatic breast cancer using ctDNA sequencing from patients within plasmaMATCH, a prospective platform trial leveraging ctDNA analysis in patients with metastatic breast cancer for which the primary outcomes have been published28. In this ad-hoc analysis we investigate how the profile of somatic genetic alterations in ctDNA differs from that obtained by tumour tissue sequencing. Using the rich clinical data set associated with the clinical trial, we explore the clinical and pathological associations of advanced breast cancer genomics, and define the processes that generate the genomic diversity of metastatic breast cancer.",_,_,_,_,Bone disease was positively associated with ESR1 and GATA3 alterations,_,ESR1 and TP53 alterations were mutually exclusive (q < 0.0001)
36,33893289,PIK3CA,Breast Cancer,plasma,droplet digital PCR (ddPCR) and error corrected targeted sequencing,"Here we define the genomic profile of metastatic breast cancer using ctDNA sequencing from patients within plasmaMATCH, a prospective platform trial leveraging ctDNA analysis in patients with metastatic breast cancer for which the primary outcomes have been published28. In this ad-hoc analysis we investigate how the profile of somatic genetic alterations in ctDNA differs from that obtained by tumour tissue sequencing. Using the rich clinical data set associated with the clinical trial, we explore the clinical and pathological associations of advanced breast cancer genomics, and define the processes that generate the genomic diversity of metastatic breast cancer.",_,multiple PIK3CA mutations in HR + disease that associate with short progression free survival on fulvestrant (p = 0.0036),_,_,_,_,PIK3CA and AKT1 alterations were mutually exclusive (q = 0.001)
37,31658042,BRAF,Colorectal Cancer,plasma/urine,ddPCR,Blood and urine specimens were collected from 150 individuals with metastatic colorectal cancer (mCRC). Patients had multiple metastases and advanced stages of cancer. Common genetic mutations including KRAS and BRAF genetic abnormalities were evaluated. Patients were also serially monitored and compared.,_,_,_,"Among the identified mutations, matched tumor tissue profiles compared to results from plasma ctDNA was 92%. For urine cell free DNA, the concordance among the identified mutations was 91%. Both sample types were closely matched to reference standards of tissue biopsy and indicated good clinical utility. Serial measurements indicated trends within each patient group that was linked with disease outcome.",_,_,_
38,31658042,KRAS,Colorectal Cancer,plasma/urine,ddPCR,Blood and urine specimens were collected from 150 individuals with metastatic colorectal cancer (mCRC). Patients had multiple metastases and advanced stages of cancer. Common genetic mutations including KRAS and BRAF genetic abnormalities were evaluated. Patients were also serially monitored and compared.,_,_,_,"Among the identified mutations, matched tumor tissue profiles compared to results from plasma ctDNA was 92%. For urine cell free DNA, the concordance among the identified mutations was 91%. Both sample types were closely matched to reference standards of tissue biopsy and indicated good clinical utility. Serial measurements indicated trends within each patient group that was linked with disease outcome.",_,_,_
39,31563523,TP53,Urothelial Cancer,plasma,_,"we analysed the ctDNA in BRAF and NRAS-mutated melanoma patients at baseline (n = 48) and within 8 weeks of treatment initiation (n = 25) to determine whether ctDNA correlates with treatment response and clinical benefit. We also analysed the dynamic changes in ctDNA in response to MAPK inhibitors and immunotherapies during response and after progression. Furthermore, we evaluated the ctDNA for the presence of mutations associated with resistance to BRAF inhibitor therapy.",_,ctDNA fraction of >2% was significantly associated with worse overall survival (p=0.039),_,_,_,_,_
40,31563523,TERT,Urothelial Cancer,plasma,_,"we analysed the ctDNA in BRAF and NRAS-mutated melanoma patients at baseline (n = 48) and within 8 weeks of treatment initiation (n = 25) to determine whether ctDNA correlates with treatment response and clinical benefit. We also analysed the dynamic changes in ctDNA in response to MAPK inhibitors and immunotherapies during response and after progression. Furthermore, we evaluated the ctDNA for the presence of mutations associated with resistance to BRAF inhibitor therapy.",_,ctDNA fraction of >2% was significantly associated with worse overall survival (p=0.039),_,_,_,_,_
41,31563523,ERBB2,Urothelial Cancer,plasma,_,"we analysed the ctDNA in BRAF and NRAS-mutated melanoma patients at baseline (n = 48) and within 8 weeks of treatment initiation (n = 25) to determine whether ctDNA correlates with treatment response and clinical benefit. We also analysed the dynamic changes in ctDNA in response to MAPK inhibitors and immunotherapies during response and after progression. Furthermore, we evaluated the ctDNA for the presence of mutations associated with resistance to BRAF inhibitor therapy.",_,ctDNA fraction of >2% was significantly associated with worse overall survival (p=0.039),_,_,_,_,_
42,35688061,RAS,Colorectal Cancer,plasma,_,"A total of 64 patients who received modified FOLFOXIRI regimen (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, levofolinate 200 mg/m2, and fluorouracil 2400 mg/m2) plus bevacizumab biweekly were enrolled. The primary endpoint was the objective response rate (ORR). Plasma samples were collected at pre-treatment, 8 weeks after treatment, and progression in participants included in the biomarker study. The levels of circulating tumour DNA (ctDNA) and specific KRAS and NRAS variants were evaluated using real-time PCR assays",_,Our biomarker study demonstrated no RAS mutations in ctDNA at disease progression in 62% of patients with RAS-mutant mCRC. Both OS and post-progression survival were better in patients with clearance of RAS mutations in ctDNA after triplet-based chemotherapy,_,_,_,_,_
43,34376535,FGFR2,Gastric Cancer,plasma,"Illumina NextSeq 550 platform (Illumina, Inc.)","We assessed genomic characteristics of FGFR2-amplified advanced gastric cancer in a nationwide ctDNA screening study. We also analyzed FGFR2 amplification status in paired tissue and plasma samples with advanced gastric cancer. In addition, we examined patients with FGFR2-amplified advanced gastric cancer identified by ctDNA sequencing who received FGFR inhibitors.",_,Patients with such FGFR2 amplifications have a poor prognosis when treated with standard nontargeted therapies but may benefit from FGFR inhibitor treatment.,_,the utility of ctDNA sequencing for the detection of FGFR2 amplification that is missed by tissue analysis,_,_,_
44,34376535,MET,Gastric Cancer,plasma,"Illumina NextSeq 550 platform (Illumina, Inc.)","We assessed genomic characteristics of FGFR2-amplified advanced gastric cancer in a nationwide ctDNA screening study. We also analyzed FGFR2 amplification status in paired tissue and plasma samples with advanced gastric cancer. In addition, we examined patients with FGFR2-amplified advanced gastric cancer identified by ctDNA sequencing who received FGFR inhibitors.",_,_,_,_,_,"concurrent MET amplification detected by ctDNA sequencing was associated with limited clinical efficacy of FGFR inhibition, suggesting that combined FGFR and MET inhibition may be indicated in such cases.",_
45,32279416,TP53,Hepatocellular Carcinoma,plasma,NGS(Illumina) ,"Seventy-three HCC patients were enrolled and randomly divided into a training cohort and a validation cohort in a 2:1 ratio, and preoperative blood and surgical tissue samples were obtained. Genomic alterations were analysed using targeted deep sequencing with a 1021-gene panel",_,_,_,_,"The frequency of TP53 was significantly higher in the MVI©\positive(Microvascular invasion) group than in the MVI©\negative group (79.3% vs 36.4%, P = .03)",_,_
46,31395942,KRAS,Colorectal Cancer,plasma,commercial version of anchored multiplex PCR (AMP),"the primary aim of this phase II study of mCRC patients treated with FOLFIRI based first-line therapy, was to assess whether changes in plasma cfDNA and ctDNA, during the first months of treatment, could be used as an early marker of FOLFIRI effectiveness.",_,"Patients with high ctDNA levels (¡Ý75th centile) at pre-treatment  had a shorter PFS (157 days versus 226 days) than patients with low pre-treatment ctDNA levels;post treatment, We observed a shorter PFS in patients with a ¡Ý 10-fold reduction in ctDNA (n = 6, HR = 3.20, 95%CI = 1.10¨C9.20, p = 0.02).",_,_,_,_,_
47,31395942,BRAF,Colorectal Cancer,plasma,commercial version of anchored multiplex PCR (AMP),"the primary aim of this phase II study of mCRC patients treated with FOLFIRI based first-line therapy, was to assess whether changes in plasma cfDNA and ctDNA, during the first months of treatment, could be used as an early marker of FOLFIRI effectiveness.",_,"Patients with high ctDNA levels (¡Ý75th centile) at pre-treatment  had a shorter PFS (157 days versus 226 days) than patients with low pre-treatment ctDNA levels;post treatment, We observed a shorter PFS in patients with a ¡Ý 10-fold reduction in ctDNA (n = 6, HR = 3.20, 95%CI = 1.10¨C9.20, p = 0.02).",_,_,_,_,_
48,31395942,NRAS,Colorectal Cancer,plasma,commercial version of anchored multiplex PCR (AMP),"the primary aim of this phase II study of mCRC patients treated with FOLFIRI based first-line therapy, was to assess whether changes in plasma cfDNA and ctDNA, during the first months of treatment, could be used as an early marker of FOLFIRI effectiveness.",_,"Patients with high ctDNA levels (¡Ý75th centile) at pre-treatment  had a shorter PFS (157 days versus 226 days) than patients with low pre-treatment ctDNA levels;post treatment, We observed a shorter PFS in patients with a ¡Ý 10-fold reduction in ctDNA (n = 6, HR = 3.20, 95%CI = 1.10¨C9.20, p = 0.02).",_,_,_,_,_
49,34250387,KRAS,Non-Small Cell Lung Cancer,plasma,ddPCR,"Patients with advanced EGFR-mutant NSCLC across three phase I NCI osimertinib combination trials were analyzed in this study, and an institutional cohort of patients with KRAS-, EGFR-, and BRAF-mutant advanced NSCLC receiving systemic treatment was used for validation. Plasma was collected before treatment initiation and serially before each cycle of therapy, and key driver mutations in ctDNA were characterized by droplet digital polymerase chain reaction. Timing of plasma versus imaging response was compared in a separate cohort of patients with EGFR-mutant NSCLC treated with osimertinib. Across cohorts, we also studied ctDNA variability before treatment start.",_,"Using serial analysis of key KRAS, EGFR, and BRAF driver mutations, we find that plasma ctDNA response among patients with advanced NSCLC receiving systemic therapy is an early phenomenon and that the vast majority can be seen within the first cycle of therapy. Decreases in mutation abundance were observed as early as 7 days following treatment initiation and the median time to nadir among patients who achieved complete clearance was 23.5 days (IQR, 21.0-31.3). Our findings suggest that plasma ctDNA changes in response to treatment initiation often occur well before the earliest standard imaging timepoints, and that early ctDNA analysis has the potential to fill this gap as an early marker of drug effect",_,_,_,_,_
50,34250387,BRAF,Non-Small Cell Lung Cancer,plasma,ddPCR,"Patients with advanced EGFR-mutant NSCLC across three phase I NCI osimertinib combination trials were analyzed in this study, and an institutional cohort of patients with KRAS-, EGFR-, and BRAF-mutant advanced NSCLC receiving systemic treatment was used for validation. Plasma was collected before treatment initiation and serially before each cycle of therapy, and key driver mutations in ctDNA were characterized by droplet digital polymerase chain reaction. Timing of plasma versus imaging response was compared in a separate cohort of patients with EGFR-mutant NSCLC treated with osimertinib. Across cohorts, we also studied ctDNA variability before treatment start.",_,"Using serial analysis of key KRAS, EGFR, and BRAF driver mutations, we find that plasma ctDNA response among patients with advanced NSCLC receiving systemic therapy is an early phenomenon and that the vast majority can be seen within the first cycle of therapy. Decreases in mutation abundance were observed as early as 7 days following treatment initiation and the median time to nadir among patients who achieved complete clearance was 23.5 days (IQR, 21.0-31.3). Our findings suggest that plasma ctDNA changes in response to treatment initiation often occur well before the earliest standard imaging timepoints, and that early ctDNA analysis has the potential to fill this gap as an early marker of drug effect",_,_,_,_,_
51,34250387,EGFR,Non-Small Cell Lung Cancer,plasma,ddPCR,"Patients with advanced EGFR-mutant NSCLC across three phase I NCI osimertinib combination trials were analyzed in this study, and an institutional cohort of patients with KRAS-, EGFR-, and BRAF-mutant advanced NSCLC receiving systemic treatment was used for validation. Plasma was collected before treatment initiation and serially before each cycle of therapy, and key driver mutations in ctDNA were characterized by droplet digital polymerase chain reaction. Timing of plasma versus imaging response was compared in a separate cohort of patients with EGFR-mutant NSCLC treated with osimertinib. Across cohorts, we also studied ctDNA variability before treatment start.",_,"Using serial analysis of key KRAS, EGFR, and BRAF driver mutations, we find that plasma ctDNA response among patients with advanced NSCLC receiving systemic therapy is an early phenomenon and that the vast majority can be seen within the first cycle of therapy. Decreases in mutation abundance were observed as early as 7 days following treatment initiation and the median time to nadir among patients who achieved complete clearance was 23.5 days (IQR, 21.0-31.3). Our findings suggest that plasma ctDNA changes in response to treatment initiation often occur well before the earliest standard imaging timepoints, and that early ctDNA analysis has the potential to fill this gap as an early marker of drug effect",_,_,_,_,_
52,27166360,MEF2B,Diffuse Large B-Cell Lymphoma,plasma,ddPCR,"In this phase 2 clinical trial, we evaluated panobinostat, an orally available pan-HDI in patients with relapsed or refractory transformed or de novo DLBCL (rrDLBCL), randomized to the HDI alone or in combination with rituximab. Our study design allowed for quantitative assessment of tumor response to therapy by obtaining pretreatment (day 0) and day 15 tissue biopsies and simultaneous collection of plasma for analysis of circulating tumor DNA (ctDNA). Using these samples, we evaluated pretreatment biopsies for mutations commonly associated with DLBCL, including HME genes, as well as for COO and MYC and BCL2 expression. We used day-15 biopsies to assess for changes in H3 acetylation and expression of common lymphoma markers after therapy.",_,"panobinostat induces very durable responses in some patients with relapsed DLBCL, and early responses can be predicted by mutations in MEF2B or a significant change in ctDNA level at 15 days after treatment initiation",_,_,_,panobinostat,"DLBCL-associated MEF2B hot-spot mutations, such as those observed in these patients, reduce the expression of MEF2B targets and affect DLBCL cell migration in vitro."
53,32379501,KRAS,Colorectal Cancer,plasma,"ddPCR(QX200 (Bio-Rad, CA, USA).)",200 advance-stage patients with metastatic disease were selected and followed-up. Serial blood draws were used to quantify CTCs and ctDNA,_,"As a prognosis indicator, results demonstrated that patients who had positive CTCs and plasma DNA had worse outcomes",_,_,_,_,_
54,32623075,TP53,Lung Adenocarcinoma,plasma,HiSeq4000 NGS plaforms (Illumina) ,Tumor tissues and matched postoperative plasma samples were collected from a total of 82 (p)stage I LUAD patients. Comprehensive genomic profiling was performed using capture-based hybrid next generation sequencing by targeting 422 cancer relevant genes.,_,_,"GGO and non-GGO subgroups indicated the frequency of TP53 mutations in non-GGO was markedly higher than that in GGO (47 % vs 21 %, P < 0.05)( ground-glass opacity (GGO) and solid nodules (non-GGO))",_,_,_,_
55,32623075,EGFR,Lung Adenocarcinoma,plasma,HiSeq4000 NGS plaforms (Illumina) ,Tumor tissues and matched postoperative plasma samples were collected from a total of 82 (p)stage I LUAD patients. Comprehensive genomic profiling was performed using capture-based hybrid next generation sequencing by targeting 422 cancer relevant genes.,_,a significant association between the presence of EGFR mutations in ctDNA and DFS (P < 0.01).,_,_,_,_,_
56,32020432,ESR1,Breast Cancer,plasma,"ION S5 system (Thermo Fisher Scientifc, Waltham, MA, USA).",A total of 56 HR-MBC patients were enrolled. Cell-free DNA (cfDNA) was extracted from plasma and sequenced by using Oncomine Breast cancer cfDNA assay in this study.,_,patients with ESR1 mutation showed shorter PFS than those without mutation (log-rank p = 0.047),_,_,_,_,_
57,29438522,RAS,Colorectal Cancer,plasma,AmpliSeq Colon and Lung Cancer Panel V2,_,_,_,_,This prospective trial demonstrates excellent concordance between RAS status in plasma and tumor tissue from patients with colorectal cancer and liver metastases.,_,_,_
58,33708847,TP53,Breast Cancer,plasma,HiSeq 3000 Sequencing System,"We performed ctDNA panel-captured sequencing of 958 blood samples from MBC patients including 494 hormone receptor (HR)-positive cases, 130 human epidermal growth factor receptor 2-positive cases, and 177 triple-negative breast cancer (TNBC) cases. The somatic mutations and potential targets were assessed. Progression-free survival (PFS) was analyzed using the Kaplan-Meier method.",_,"TP53, ERBB2, or coexisting TP53/PIK3CA mutations in MBC were remarkably related with shorter PFS.",_,_,_,_,_
59,33708847,ERBB2,Breast Cancer,plasma,HiSeq 3000 Sequencing System,"We performed ctDNA panel-captured sequencing of 958 blood samples from MBC patients including 494 hormone receptor (HR)-positive cases, 130 human epidermal growth factor receptor 2-positive cases, and 177 triple-negative breast cancer (TNBC) cases. The somatic mutations and potential targets were assessed. Progression-free survival (PFS) was analyzed using the Kaplan-Meier method.",_,"TP53, ERBB2, or coexisting TP53/PIK3CA mutations in MBC were remarkably related with shorter PFS.",_,_,_,_,_
60,33708847,PIK3CA,Breast Cancer,plasma,HiSeq 3000 Sequencing System,"We performed ctDNA panel-captured sequencing of 958 blood samples from MBC patients including 494 hormone receptor (HR)-positive cases, 130 human epidermal growth factor receptor 2-positive cases, and 177 triple-negative breast cancer (TNBC) cases. The somatic mutations and potential targets were assessed. Progression-free survival (PFS) was analyzed using the Kaplan-Meier method.",_,"TP53, ERBB2, or coexisting TP53/PIK3CA mutations in MBC were remarkably related with shorter PFS.",_,_,_,_,_
61,26560360,ESR1,Breast Cancer,plasma,Bio-Rad QX200 droplet ddPCR system,"We collected a series of plasma DNA samples from patients with advanced breast cancer to assess the potential utility of ESR1 mutation analysis in ctDNA. We developed multiplex digital PCR assays for hot-spot ligand binding domain mutations and used these assays to screen for ESR1 mutations. In parallel, a subset of patients had biopsy samples obtained contemporaneously with plasma samples to assess agreement with tumor biopsy, and repeat plasma sampling to assess reproducibility and the ability to mail samples in preservative tubes. We investigated the relationship between detection of ESR1 mutation and sensitivity to subsequent hormonal therapy. We also identified the clinical and pathological features that associated with the presence of an ESR1 mutation and validated these associations in an independent series of 49 tumor biopsies taken on progression on aromatase inhibitor therapy",_,"Patients with ESR1 mutation(s) detected in plasma had a substantially shorter progression-free survival (PFS) on subsequent AI-based therapy, whether given as therapy after disease progression (HR 3.7, 95% CI 1.9-76.9, p=0.008 log rank test) or including the duration of AI given as maintenance therapy after response to prior chemotherapy ( HR 3.1, 95%CI 1.9-23.1, p=0.0041 log rank test).",_,_,_,_,_
62,35902848,LRP1B,Non-Small Cell Lung Cancer,plasma,_,"We collected plasma samples of 51 advanced NSCLC patients without EGFR/ALK/ROS1 alteration at baseline and/or after two treatment cycles of ICIs plus chemotherapy. A blood-based intratumor heterogeneity (bITH) score was calculated based on the allele frequencies of somatic mutations using a 520-gene panel. bITH-up was defined as a ¡Ý 10% increase in bITH score from baseline, with a second confirmatory measurement after treatment.",_,"LRP1B mutation and KEAP1 mutation were significantly associated with PFS in multivariate analysis (LRP1B mutation: HR, 0.15; 95% CI, 0.03¨C0.72; P = 0.018; KEAP1 mutation: HR, 4.26; 95% CI, 1.18¨C15.32; P = 0.027) . Patients with LRP1B mutation had higher ORR than those with LRP1B wild type, while there were no difference in ORR between KEAP1 mutation and wild typeMultivariate COX analysis showed that LRP1B mutation remained to be significantly associated with better PFS, which was independent of PD-L1, bTMB, tumor size, and CRP level.",_,_,_,_,_
63,35902848,KEAP1,Non-Small Cell Lung Cancer,plasma,_,"We collected plasma samples of 51 advanced NSCLC patients without EGFR/ALK/ROS1 alteration at baseline and/or after two treatment cycles of ICIs plus chemotherapy. A blood-based intratumor heterogeneity (bITH) score was calculated based on the allele frequencies of somatic mutations using a 520-gene panel. bITH-up was defined as a ¡Ý 10% increase in bITH score from baseline, with a second confirmatory measurement after treatment.",_,"LRP1B mutation and KEAP1 mutation were significantly associated with PFS in multivariate analysis (LRP1B mutation: HR, 0.15; 95% CI, 0.03¨C0.72; P = 0.018; KEAP1 mutation: HR, 4.26; 95% CI, 1.18¨C15.32; P = 0.027),KEAP1 mutation was associated with higher bTMB, lower LIPI score and greater number of metastatic organs",_,_,_,_,_
64,31261969,TP53,Multiple Myeloma,plasma,OnTargetTMMutation Detection (OMD),MM mutational characterisation was performed on ctDNA and paired BM samples from 76 patients utilising the highly sensitive OnTargetTM Mutation Detection (OMD) platform to determine the prognostic significance of ctDNA detectable RAS-RAF and TP53 mutations,_,Patients with PL-specific TP53 mutations had significantly shorter OS compared to patients with no PL-TP53 mutations (p = 0.003),_,_,_,_,_
65,33126883,CEBPA,Gastric Cancer,plasma,NGS,_,_,"Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06).",_,_,_,_,"Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs)"
66,33126883,FGFR4,Gastric Cancer,plasma,NGS,_,_,"Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06).",_,_,_,_,"Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs)"
67,33126883,MET,Gastric Cancer,plasma,NGS,_,_,"Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06).",_,_,_,_,"Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs)"
68,33126883,KMT2B,Gastric Cancer,plasma,NGS,_,_,"Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06).",_,_,_,_,"Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs)"
69,33126883,TGFBR2,Gastric Cancer,plasma,NGS,_,_,"Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy (p < 0.05).",_,_,_,_,_
70,33126883,RHOA,Gastric Cancer,plasma,NGS,_,_,"Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy (p < 0.05).",_,_,_,_,_
71,33126883,PREX2,Gastric Cancer,plasma,NGS,_,_,"Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy (p < 0.05).",_,_,_,_,_
72,30346475,KRAS,Pancreatic Cancer,plasma,_,"The aim of the present study was to explore the potential of repeated mutKRAS ctDNA measurements for response prediction and therapy monitoring in advanced PC patients. We used the BEAMing technology to determine levels of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 in 284 plasma samples of 54 patients with advanced PC receiving gemcitabine-based chemotherapy. Absolute levels and kinetics of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 were correlated to radiological response, progression-free and overall survival",_,"The presence of mutKRAS ctDNA, as well as higher levels of CA 19-9, CEA and CYFRA 21-1 before initiation of the first-line chemotherapy, was significantly correlated to an adverse overall survival. During therapy, changes in mutKRAS ctDNA levels were more rapid and pronounced than changes in protein-based tumor markers. A decrease in mutKRAS ctDNA levels during therapy was an early indicator of response to therapy. Repeated mutKRAS ctDNA measurements during follow-up appeared to be superior to protein-based tumor markers in detecting progressive disease (sensitivity: 83%, specificity: 100%)",_,_,_,_,_
73,34382998,KRAS,Colorectal Cancer,plasma,the automated Idylla qPCR-based platform,"This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis was done.",Baseline evaluation of RAS and BRAF mutations in plasma ctDNA may select patients that could benefit from treatment (cetuximab plus avelumab).,"Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004).",_,_,_,_,_
74,34382998,NRAS,Colorectal Cancer,plasma,the automated Idylla qPCR-based platform,"This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S493R mutation analysis was done.",Baseline evaluation of RAS and BRAF mutations in plasma ctDNA may select patients that could benefit from treatment (cetuximab plus avelumab).,"Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004).",_,_,_,_,_
75,34382998,BRAF,Colorectal Cancer,plasma,the automated Idylla qPCR-based platform,"This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S494R mutation analysis was done.",Baseline evaluation of RAS and BRAF mutations in plasma ctDNA may select patients that could benefit from treatment (cetuximab plus avelumab).,"Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004).",_,_,_,_,_
76,33793001,KMT2D,Gastric Cancer,plasma,"HiSeq 3000 (Illumina, USA)","ctDNA for high-throughput sequencing was obtained from gastric cancer patients, and the high-frequency mutant gene KMT2D was identified. Immunohistochemical examination was conducted to assess the expression of KMT2D in gastric cancer tissues. KMT2D knockdown was performed to establish the stably transfected gastric cancer cells. Then, CCK8, plate clone formation assay, and Transwell assay were conducted, and a subcutaneous tumor-bearing model was induced in nude mice to investigate the changes in cell proliferation and invasion capability. Transcriptome sequencing was also performed to investigate the differences in cellular gene expression.",_,_,_,_,_,_,"The findings of this study revealed that KMT2D could be an oncogene capable of promoting gastric cancer proliferation.The knockdown of KMT2D inhibited the proliferation, invasion, and tumor formation capacity of the gastric cancer cells, causing differences in the gene expression profiles, and the expression of different functional gene clusters was up- or downregulated"
77,32664549,BRAF,Melanoma,plasma,the Cobas BRAF/NRAS Mutation Test (Roche),"The purpose of this study was to determine whether the detection of ctDNA, based on the identification of BRAF and NRAS mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. In total, 68 BRAF or NRAS-mutated stage IV or unresectable stage III metastatic cutaneous melanoma patients were included and tested for the presence of BRAF and NRAS mutations in circulating DNA before treatment initiation, using the Cobas BRAF/NRAS Mutation Test (Roche)",_,"ctDNA detection was associated with AJCC stage, along with the number and nature of metastases.At initiation of first-line treatment, ctDNA detection was associated with poor prognosis in Progression Free Survival (PFS) and Overall Survival (OS) in univariate analysis (log-rank: p = 0.002 and p < 0.0001, respectively). In multivariate analysis, ctDNA detection was an independent factor of poor prognosis in OS, after adjustment for AJCC stage, number and nature of metastases and gender (HR = 4.384; 95% CI: (1.308; 14.699); p = 0.017) , ctDNA detection was not associated with either PFS or OS at non-first-line treatment initiation, in univariate analysis (log-rank: p = 0.054 and 0.763, respectively).",_,_,_,_,_
78,32664549,NRAS,Melanoma,plasma,the Cobas BRAF/NRAS Mutation Test (Roche),"The purpose of this study was to determine whether the detection of ctDNA, based on the identification of BRAF and NRAS mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. In total, 68 BRAF or NRAS-mutated stage IV or unresectable stage III metastatic cutaneous melanoma patients were included and tested for the presence of BRAF and NRAS mutations in circulating DNA before treatment initiation, using the Cobas BRAF/NRAS Mutation Test (Roche)",_,"ctDNA detection was associated with AJCC stage, along with the number and nature of metastases.At initiation of first-line treatment, ctDNA detection was associated with poor prognosis in Progression Free Survival (PFS) and Overall Survival (OS) in univariate analysis (log-rank: p = 0.002 and p < 0.0001, respectively). In multivariate analysis, ctDNA detection was an independent factor of poor prognosis in OS, after adjustment for AJCC stage, number and nature of metastases and gender (HR = 4.384; 95% CI: (1.308; 14.699); p = 0.017) , ctDNA detection was not associated with either PFS or OS at non-first-line treatment initiation, in univariate analysis (log-rank: p = 0.054 and 0.763, respectively).",_,_,_,_,_
79,32807235,TP53,Prostate Cancer,plasma,MiSeq£¨Illumina Inc.£©,"We performed whole-genome sequencing of tumour-normal pairs in eight patients with clinically localised disease undergoing prostatectomy, identifying high confidence genomic aberrations. A bespoke DNA capture and amplification panel against the highest prevalence, highest confidence aberrations for each individual was designed and used to interrogate ctDNA isolated from plasma prospectively obtained pre- and post- (24 h and 6 weeks) surgery. In a separate cohort (n = 189), we identified the presence of ctDNA TP53 mutations in preoperative plasma in a retrospective cohort and determined its association with biochemical- and metastasis-free survival.",_,"CtDNA is uncommonly detected in localised prostate cancer, but its presence portends more rapidly progressive disease.Detection of ctDNA TP53 mutations was associated with a significantly shorter metastasis-free survival (6.2 vs. 9.5 years (HR 2.4; 95% CIs 1.2-4.8, p = 0.014)",_,_,_,_,_
80,32463456,EGFR,Lung Cancer,plasma,ddpcr(Qx200),"From August 15, 2016, to May 15, 2018, 49 patients with metastatic EGFR-mutant lung cancers were enrolled in this interventional clinical trial, conducted at a single academic cancer center. In the phase 1 portion of the study, a standard 3 + 3 dose de-escalation design was used to determine the maximum tolerated dose of osimertinib and bevacizumab. In the phase 2 portion of the study, patients were treated at the maximum tolerated dose defined in the phase 1 portion. Statistical analysis was performed from August 1 to October 1, 2019.All patients received osimertinib, 80 mg daily, and bevacizumab, 15 mg/kg once every 3 weeks.The primary objective of the phase 2 portion of the study was to determine the number of patients receiving the combination of osimertinib and bevacizumab who were progression free at 12 months. Secondary end points included overall response rate, median PFS, overall survival, and definition of the toxic effects of the combination treatment.",_,"patients with  osimertinib plus bevacizumab treatment,  Persistent detection of EGFR-mutant circulating tumor (ct)DNA at 6 weeks was associated with shorter median PFS (clearance at 6 weeks, 16.2 months [95% CI, 13 months to not reached]; and no clearance at 6 weeks, 9.8 months [95% CI, 4 months to not reached]; P = .04) and median overall survival (clearance at 6 weeks, not reached; and no clearance at 6 weeks, 10.1 months [95% CI, 6 months to not reached]; P = .002)",_,_,_,_,_
81,33934494,KRAS,Colorectal Cancer,plasma,an allele©\specific blocker quantitative PCR (ASB qPCR)( IntPlex),"We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib©\treated metastatic colorectal cancer (mCRC) patients. We analyzed longitudinally collected plasma cfDNA of 43 mCRC patients prospectively enrolled in the phase II TEXCAN trial by IntPlex qPCR. Qualitative (KRAS, NRAS, BRAFV600E mutations) and quantitative (total cfDNA concentration, mutant ctDNA concentration, mutant ctDNA fraction) parameters were correlated with overall survival (OS) and progression©\free survival (PFS).",_,"When assessing the RAS mutant ctDNA concentrations, we observed that mCRC patients with baseline RAS mutant ctDNA concentration of > 2 ng¡¤mL 1 (the threshold established from the relationship between RAS mutant ctDNA concentrations and the risk of death using the restricted cubic spline regression analysis; data not shown) had shorter OS than those with below the threshold (log©\rank P = 0.0154; ). To a lesser extent, patients with a RAS mutation load of > 6% had shorter OS than the rest of patients (log©\rank P = 0.0200; )",_,_,_,_,_
82,33934494,NRAS,Colorectal Cancer,plasma,an allele©\specific blocker quantitative PCR (ASB qPCR)( IntPlex),"We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib©\treated metastatic colorectal cancer (mCRC) patients. We analyzed longitudinally collected plasma cfDNA of 43 mCRC patients prospectively enrolled in the phase II TEXCAN trial by IntPlex qPCR. Qualitative (KRAS, NRAS, BRAFV600E mutations) and quantitative (total cfDNA concentration, mutant ctDNA concentration, mutant ctDNA fraction) parameters were correlated with overall survival (OS) and progression©\free survival (PFS).",_,"When assessing the RAS mutant ctDNA concentrations, we observed that mCRC patients with baseline RAS mutant ctDNA concentration of > 2 ng¡¤mL 1 (the threshold established from the relationship between RAS mutant ctDNA concentrations and the risk of death using the restricted cubic spline regression analysis; data not shown) had shorter OS than those with below the threshold (log©\rank P = 0.0154; ). To a lesser extent, patients with a RAS mutation load of > 6% had shorter OS than the rest of patients (log©\rank P = 0.0200; )",_,_,_,_,_
83,33383664,KRAS,Colorectal Cancer,plasma,real time PCR,mCRC patients undergoing standard first-line chemotherapy with known T-KRAS/NRAS/BRAF status were enrolled in the present prospective study. PL mutations were assessed within 2 weeks before chemotherapy start with real time PCR and correlated with T status and Progression free survival (PFS). Clinical and biochemical variables including also total number of tumor lesions (TNL) and the sum of maximum diameter (SMD) of all lesions were assessed as potential predictors of T/PL discordance.,_,"PL(plasma) mutations further refined prognosis: RAS wild type in T(tumor tissue) and mutated in PL had significantly shorter PFS than concordant RAS wild type in T and PL: mPFS 9.6 vs. 23.3 months, respectively, p = 0.02. Patients RAS mutated in T and wild type in PL had longer PFS than concordant RAS mutated in T and PL: 24.4 vs. 7.8 months, respectively, p = 0.008. At a multivariate cox regression analysis for PFS, PL mutations were independent prognostic factor superior to T analysis (HR 0.13, p = 0.0008).",_,_,_,_,_
84,33383664,NRAS,Colorectal Cancer,plasma,real time PCR,mCRC patients undergoing standard first-line chemotherapy with known T-KRAS/NRAS/BRAF status were enrolled in the present prospective study. PL mutations were assessed within 2 weeks before chemotherapy start with real time PCR and correlated with T status and Progression free survival (PFS). Clinical and biochemical variables including also total number of tumor lesions (TNL) and the sum of maximum diameter (SMD) of all lesions were assessed as potential predictors of T/PL discordance.,_,"PL(plasma) mutations further refined prognosis: RAS wild type in T(tumor tissue) and mutated in PL had significantly shorter PFS than concordant RAS wild type in T and PL: mPFS 9.6 vs. 23.3 months, respectively, p = 0.02. Patients RAS mutated in T and wild type in PL had longer PFS than concordant RAS mutated in T and PL: 24.4 vs. 7.8 months, respectively, p = 0.008. At a multivariate cox regression analysis for PFS, PL mutations were independent prognostic factor superior to T analysis (HR 0.13, p = 0.0008).",_,_,_,_,_
85,33383664,BRAF,Colorectal Cancer,plasma,real time PCR,mCRC patients undergoing standard first-line chemotherapy with known T-KRAS/NRAS/BRAF status were enrolled in the present prospective study. PL mutations were assessed within 2 weeks before chemotherapy start with real time PCR and correlated with T status and Progression free survival (PFS). Clinical and biochemical variables including also total number of tumor lesions (TNL) and the sum of maximum diameter (SMD) of all lesions were assessed as potential predictors of T/PL discordance.,_,"PL(plasma) mutations further refined prognosis: RAS wild type in T(tumor tissue) and mutated in PL had significantly shorter PFS than concordant RAS wild type in T and PL: mPFS 9.6 vs. 23.3 months, respectively, p = 0.02. Patients RAS mutated in T and wild type in PL had longer PFS than concordant RAS mutated in T and PL: 24.4 vs. 7.8 months, respectively, p = 0.008. At a multivariate cox regression analysis for PFS, PL mutations were independent prognostic factor superior to T analysis (HR 0.13, p = 0.0008).",_,_,_,_,_
86,29549923,KRAS,Colorectal Cancer,plasma,ddpcr,"For liquid biopsy tests, we extracted blood from 140 CRC patients with matched tumor samples. Circulating tumor cells (CTCs) and tumor DNA (ctDNA) were extracted before surgery and treatment. Samples were quantified and tested for mutations in KRAS, NRAS and BRAF. Kaplan-Meier analyses were performed for different groups of patients for association to overall survival.",_,Monitoring CRC patients' molecular changes in response to treatment via CTCs and ctDNA can provide real-time information to disease changes. The study demonstrated that the emergence of secondary mutations were strongly associated to poorer survival after treatment.,_,_,_,_,_
87,29549923,NRAS,Colorectal Cancer,plasma,ddpcr,"For liquid biopsy tests, we extracted blood from 140 CRC patients with matched tumor samples. Circulating tumor cells (CTCs) and tumor DNA (ctDNA) were extracted before surgery and treatment. Samples were quantified and tested for mutations in KRAS, NRAS and BRAF. Kaplan-Meier analyses were performed for different groups of patients for association to overall survival.",_,Monitoring CRC patients' molecular changes in response to treatment via CTCs and ctDNA can provide real-time information to disease changes. The study demonstrated that the emergence of secondary mutations were strongly associated to poorer survival after treatment.,_,_,_,_,_
88,29549923,BRAF,Colorectal Cancer,plasma,ddpcr,"For liquid biopsy tests, we extracted blood from 140 CRC patients with matched tumor samples. Circulating tumor cells (CTCs) and tumor DNA (ctDNA) were extracted before surgery and treatment. Samples were quantified and tested for mutations in KRAS, NRAS and BRAF. Kaplan-Meier analyses were performed for different groups of patients for association to overall survival.",_,Monitoring CRC patients' molecular changes in response to treatment via CTCs and ctDNA can provide real-time information to disease changes. The study demonstrated that the emergence of secondary mutations were strongly associated to poorer survival after treatment.,_,_,_,_,_
89,33959414,TP53,Gastric Cancer,plasma,"NGS(the HiSeq 3000 sequencing system (Illumina, Inc))",The aim of this study was mainly to assess the clinical utility of TP53 mutation and MET amplification in ctDNA as biomarkers for monitoring disease progression of AGC.We used multigene NGS-panel technology to study the characteristics of ctDNA gene mutations and screen the key mutant genes in AGC patients. The Kaplan-Meier method was used to calculate the survival probability and log-rank test was used to compare the survival curves of TP53 mutation and MET amplification in ctDNA of AGC patients. The survival time was set from the blood test time to the follow-up time to observe the relationship between the monitoring index and tumor prognosis.,_,TP53 is one of common frequently mutant genes in ctDNA of AGC patients.TP53 mutation in ctDNA could predict disease progression of AGC patients.Kaplan-Meier analysis showed that patients with TP53 mutant in ctDNA had shorter overall survival (OS) than these with TP53 wild (P < 0.001).,_,_,_,_,_
90,34449963,KRAS,Breast Cancer,plasma,ddpcr,"we investigated changes in ctDNA levels as a proxy of early tumor response to ICI for progression©\free survival (PFS), DCB, and OS in cohort of 100 patients with advanced lung adenocarcinoma using this approach.",_,"We found that changes in ctDNA levels were strongly associated with tumor response. A > 30% decrease in ctDNA at t1 correlated with a longer PFS and OS. In total, 80% of patients with a DCB of ¡Ý 26 weeks displayed a > 30% decrease in ctDNA levels. For patients with a PD-L1 tumor proportion score of ¡Ý 1%, decreasing ctDNA levels were associated with a higher frequency a DCB (80%) and a prolonged median PFS (85 weeks) and OS (101 weeks) compared with patients with no decrease in ctDNA (34%; 11 and 39 weeks, respectively). This study shows that monitoring of ctDNA dynamics is an easy-to-use and promising tool for assessing PFS, DCB, and OS for ICI-treated NSCLC patients.",_,_,_,_,_
91,34449963,BRAF,Breast Cancer,plasma,ddpcr,"we investigated changes in ctDNA levels as a proxy of early tumor response to ICI for progression©\free survival (PFS), DCB, and OS in cohort of 100 patients with advanced lung adenocarcinoma using this approach.",_,"We found that changes in ctDNA levels were strongly associated with tumor response. A > 30% decrease in ctDNA at t1 correlated with a longer PFS and OS. In total, 80% of patients with a DCB of ¡Ý 26 weeks displayed a > 30% decrease in ctDNA levels. For patients with a PD-L1 tumor proportion score of ¡Ý 1%, decreasing ctDNA levels were associated with a higher frequency a DCB (80%) and a prolonged median PFS (85 weeks) and OS (101 weeks) compared with patients with no decrease in ctDNA (34%; 11 and 39 weeks, respectively). This study shows that monitoring of ctDNA dynamics is an easy-to-use and promising tool for assessing PFS, DCB, and OS for ICI-treated NSCLC patients.",_,_,_,_,_
92,34500472,TP53,Lymphoma,plasma,LyV4.0 CAPP-seq Assay,_,_,"Among baseline variants in ctDNA, only TP53 mutations (detected in 25.4% of patients) were associated with shorter progression-free survival;",_,_,_,_,_
93,34057135,EGFR,Non-Small Cell Lung Cancer,plasma,ddpcr,"This observational study enrolled advanced or metastatic NSCLC patients, with confirmed tumor EGFRm, receiving treatment with first- or second-generation EGFR-TKIs. Blood samples for the detection of plasma EGFRm were collected at the time of response evaluation and processed using the Target Selector  assay. The main outcomes were the detection rate of plasma EGFRm, median Progression-Free Survival (PFS) and Overall Survival (OS) according to plasma EGFR mutational status.",_,"In NSCLC patients receiving EGFR-TKIs, the detection of plasma EGFRm at the time of tumor response evaluation is associated with poor clinical outcomes.The detection rate of plasma EGFRm was significantly higher in patients with disease progression than in patients with partial response or stable disease (68.3% versus 33.3%; P< 0.01). PFS and OS were significantly longer in patients without plasma EGFRm than among patients with plasma EGFRm (14.3 months [95% CI, 9.25-19.39] vs 11.0 months [95% CI, 8.61-13.46]; P= 0.034) and (67.8 months [95% CI, 39.80-95.94] vs 32.0 months [95% CI, 17.12-46.93]; P= 0.006), respectively.",_,_,_,_,_
94,32420063,EGFR,Non-Small Cell Lung Cancer,plasma,ddpcr( the QX-200TM ddPCR system ),"We enrolled 141 patients with advanced EGFR-mutated NSCLC who underwent second-line osimertinib treatment for T790M-positive disease. After initiation of osimertinib, we obtained plasma samples from 108 patients. Plasma ctDNA was tested for EGFR mutations by means of droplet digital PCR and was termed positive if any EGFR mutation was detected.",_,"Patients with persistence of activating EGFR mutations in plasma ctDNA within eight weeks after osimertinib initiation have worse prognosis and may require the addition of chemotherapy or other treatments in order to achieve better outcome.In multivariable analysis, ctDNA status remained significantly associated with PFS and OS (HR 4.87, 95% CI: 2.81-8.44, P<0.0001; HR 3.49, 95% CI: 1.88-6.50, P<0.0001). Patients with persistence of activating EGFR mutations within eight weeks had shorter durations of PFS (HR 6.17, 95% CI: 3.03-12.56, P<0.0001) and OS (HR 4.83, 95% CI: 2.25-10.36, P<0.0001) than patients with total clearance of the activating EGFR mutation. Persistence of activating EGFR mutations in plasma ctDNA remained an independent predictor of poor PFS and OS in multivariable analyses.",_,_,_,_,_
95,32757294,ALK,Non-Small Cell Lung Cancer,plasma,NGS,"The authors analyzed 97 plasma specimens from 75 patients with ALK-positive lung cancer to identify ALK and non-ALK alterations. Disease burden was estimated by tabulating lesions per organ and calculating lesion diameters, areas, and volumes. Disease burden was correlated with the allelic frequency (AF) of plasma alterations.",_,"In patients with ALK-positive lung cancer, the maximum plasma alteration AF and maximum ALK alteration AF correlate with the extrathoracic burden of disease and are more predictive of tumor burden compared with the ALK fusion AF alone.Using the maximum plasma alteration AF and maximum ALK alteration AF as independent surrogates of ctDNA burden, a higher disease burden measurement on imaging was found to be associated with higher ctDNA burden.",_,_,"all the disease sites assessed, the ctDNA burden correlated most with involvement of the liver, bones, and adrenal glands.",_,_
96,26154128,MLL,Pancreatic Adenocarcinoma,plasma,NGS( Illumina HiSeq 2000/2500 and Illumina MiSeq instrumentation),_,_,"Through integrated genomic analyses, we have identified MLL genes as markers of improved prognosis£»patients with MLL, MLL2, MLL3 and ARID1A mutation have better OS and survival",_,_,_,_,"These analyses indicated that tumours with MLL alterations had expression dysregulation of chromatin-regulating genes, including members of the SWI/SNF chromatin remodeling complex that have been altered in a variety of human cancers, in addition to genes involved in cell cycle progression and other aspects of cellular proliferation."
97,26154128,MLL2,Pancreatic Adenocarcinoma,plasma,NGS( Illumina HiSeq 2000/2500 and Illumina MiSeq instrumentation),_,_,"Through integrated genomic analyses, we have identified MLL genes as markers of improved prognosis£»patients with MLL, MLL2, MLL3 and ARID1A mutation have better OS and survival",_,_,_,_,"These analyses indicated that tumours with MLL alterations had expression dysregulation of chromatin-regulating genes, including members of the SWI/SNF chromatin remodeling complex that have been altered in a variety of human cancers, in addition to genes involved in cell cycle progression and other aspects of cellular proliferation."
98,26154128,MLL3,Pancreatic Adenocarcinoma,plasma,NGS( Illumina HiSeq 2000/2500 and Illumina MiSeq instrumentation),_,_,"Through integrated genomic analyses, we have identified MLL genes as markers of improved prognosis£»patients with MLL, MLL2, MLL3 and ARID1A mutation have better OS and survival",_,_,_,_,"These analyses indicated that tumours with MLL alterations had expression dysregulation of chromatin-regulating genes, including members of the SWI/SNF chromatin remodeling complex that have been altered in a variety of human cancers, in addition to genes involved in cell cycle progression and other aspects of cellular proliferation."
99,26154128,ARID1A,Pancreatic Adenocarcinoma,plasma,NGS( Illumina HiSeq 2000/2500 and Illumina MiSeq instrumentation),_,_,"Through integrated genomic analyses, we have identified MLL genes as markers of improved prognosis£»patients with MLL, MLL2, MLL3 and ARID1A mutation have better OS and survival",_,_,_,_,"These analyses indicated that tumours with MLL alterations had expression dysregulation of chromatin-regulating genes, including members of the SWI/SNF chromatin remodeling complex that have been altered in a variety of human cancers, in addition to genes involved in cell cycle progression and other aspects of cellular proliferation."
100,33209498,TP53,Liver Cancer,plasma,NGS(Illumina HiSeq 3000),"Forty-two patients with unresectable liver cancer were prospective enrolled in this study. Pre-treatment, in-treatment plasma samples and available matched tissue samples were collected. Targeted-capture sequencing of 1,021 genes that are frequently mutated in solid tumors.",_,"PD patients were enriched in TP53 mutation group compared with TP53 wildtype group (P=0.0221), indicated TP53 mutation may be a potential factor of poor prognosis in advanced liver cancer",_,_,_,_,_
101,35046521,TP53,Hepatocellular Carcinoma,urine,_,Candidate markers in urine were selected from HCC and controls. We then enrolled 609 patients from five medical centres to test the selected urine panel. A two-stage model was developed to combine AFP and urine panel as a screening test.,_,_,_,"Urine ctDNA has promising diagnostic utility in patients in HCC, especially in those with low AFP and can be used as a potential non-invasive HCC screening test.",_,_,_
102,28454414,EGFR,Non-Small Cell Lung Cancer,plasma,denaturing high-performance liquid chromatography,"The present study investigated whether EGFR mutations detected in both tissue and plasma samples, compared to detection in a single sample, had different predictive value with regard to the benefit of EGFR-TKI treatment in patients with advanced NSCLC in various therapeutic settings. In addition, we attempted to determine a simple and effective method for predicting responses to second- or higher lines EGFR-TKI treatments when repeat biopsy couldn't be performed.",_,"The present study demonstrated that, among patients treated with first-line EGFR-TKI, those with co-existing EGFR mutations in tissue samples and ctDNA (B+/T+) had superior PFS times compared with those with EGFR mutations detected only in tissues or ctDNA. However, among those treated with EGFR-TKIs as second-line or subsequent therapy, patients with EGFR mutations detected using real-time ctDNA (B+/T-) had a prolonged PFS compared with patients whose EGFR mutations were detected using initial tissue samples (B-/T+). These results suggest that EGFR mutations detected in the tissues and/or ctDNA may have different predictive values with regard to the response to EGFR-TKIs in different therapeutic backgrounds.",_,_,_,_,_
103,33990090,TP53,Colorectal Cancer,plasma,NGS(Illumina Nextseq500/Novoseq6000),A total of 292 Chinese patients with mCRPC enrolled from 8 centers. Multigene targeted sequencing was performed on 306 ctDNA samples and 23 matched tumor biopsies. The frequency of genomic alterations were compared with the Stand Up to Cancer-Prostate Cancer Foundation (SU2C-PCF) cohort. The Kaplan-Meier method was used to evaluate progression-free survival (PFS) following standard systemic treatments for mCRPC. Cox regression analyses were performed to determine prognostic factors associated with PFS resulting from treatments for mCRPC.,associated with resistance to abiraterone or docetaxel.,_,_,_,_,_,_
104,33990090,RB1,Colorectal Cancer,plasma,NGS(Illumina Nextseq500/Novoseq6000),A total of 292 Chinese patients with mCRPC enrolled from 8 centers. Multigene targeted sequencing was performed on 306 ctDNA samples and 23 matched tumor biopsies. The frequency of genomic alterations were compared with the Stand Up to Cancer-Prostate Cancer Foundation (SU2C-PCF) cohort. The Kaplan-Meier method was used to evaluate progression-free survival (PFS) following standard systemic treatments for mCRPC. Cox regression analyses were performed to determine prognostic factors associated with PFS resulting from treatments for mCRPC.,associated with resistance to abiraterone or docetaxel.,_,_,_,_,_,_
105,33990090,CDK12,Colorectal Cancer,plasma,NGS(Illumina Nextseq500/Novoseq6000),A total of 292 Chinese patients with mCRPC enrolled from 8 centers. Multigene targeted sequencing was performed on 306 ctDNA samples and 23 matched tumor biopsies. The frequency of genomic alterations were compared with the Stand Up to Cancer-Prostate Cancer Foundation (SU2C-PCF) cohort. The Kaplan-Meier method was used to evaluate progression-free survival (PFS) following standard systemic treatments for mCRPC. Cox regression analyses were performed to determine prognostic factors associated with PFS resulting from treatments for mCRPC.,_,"In multivariate Cox regression analysis, a CDK12 defect was significantly associated with inferior PFS after abiraterone treatment.",_,_,_,_,_
106,29152076,KRAS,Pancreatic Ductal Adenocarcinoma,plasma,ddPCR( Bio-Rad QX200 ),_,_,"The presence of KRAS mutations in the cfDNA of patients with PDAC was associated with poor disease specific survival (p=0.018, hazard ratio=2.889, 95% confidence interval (CI) =1.2-7.3) . The median survival time was 60 days for KRAS positive PDAC and 197 days for KRAS negative PDAC.","The presence of KRAS mutations in cfDNA was significantly associated with the tumour being sited at the body, tail or neck of the pancreas (p=0.015) compared to the head of the pancreas. ",_,_,_,_
107,31109923,FGFR2,Intrahepatic Cholangiocarcinoma,plasma,_,"we report the results of clinical and translational studies of TAS-120 in the treatment of patients with FGFR2 fusion-positive ICC who progressed on BGJ398 or Debio1347, including patients in whom secondary FGFR2 kinase mutations were detected just prior to TAS-120 initiation. We performed complementary studies investigating FGFR2-mediated signaling mechanisms in ICC models and determined the efficacy of these second- and third-generation FGFR inhibitors against clinically observed FGFR2 kinase domain mutations. Our findings reveal genotype-phenotype correlations for drug sensitivity that inform personalized targeted therapy in FGFR-activated ICC.",_,_,_,_,_,"ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models.",_
108,36465410,PCLO,Diffuse Large B-Cell Lymphoma,plasma,NGS(Illumina NovaSeq 2),"A total of 169 newly diagnosed Chinese DLBCL patients were included in this study, among which 85 patients were divided into a training set and 84 were assigned into a validation set. The mutation profile of a 59-gene panel was analyzed by targeted next generation sequencing (NGS) of the patients' ctDNA samples. Differences in clinical factors between patients with and without ctDNA mutations were analyzed. In addition, we also explored gene mutation frequencies between GCB and non-GCB subtypes, and the relationship between gene mutation status, clinical factors, mean VAF (variant allele frequencies) and the patients' overall survival (OS) and progression-free survival (PFS).",_,PCLO mutations were associated with poor OS and PFS.,_,_,_,_,_
109,33145402,HER2,Breast Cancer,plasma,NGS(HiSeq 3000 Sequencing System),we used targeted capture sequencing to analyse circulating tumour DNA (ctDNA) to determine the frequency and spectrum of HER2 mutations in patients with advanced breast cancer and to analyse the relationships between HER2 mutations and their effects on the efficacy of anti-HER2 therapies.,HER2 gene mutation analysis is potentially useful to identify biomarkers of trastuzumab resistance in HER2 amplification-positive patients.,"on pyrotinib treatment,A multivariate Cox regression analysis indicated that patients with HER2 mutations had a shorter progression-free survival (PFS) than HER2 wild-type patients (median PFS 4.7 months vs. 11.0 months, hazard ratio 2.65, 95% confidence interval 1.25-5.65, P = 0.011).",_,_,_,"Patients with HER2-mutated, non-amplified metastatic breast cancers may benefit from pyrotinib.",_
110,30893632,ESR1,Breast Cancer,plasma,NGS( the HiSeq 3000 Sequencing System),The mutation frequency of 1021 genes was examined prior to chemotherapy in ctDNA of 44 estrogen receptor-positive metastatic breast cancer patients. These genes were evaluated again in a subset of patients (n=24) following chemotherapy. Mutation frequency was defined as the percentage of mutations found in ctDNA compared to total cell-free DNA.,endocrine therapy,_,_,_,_,mTOR inhibition may be a useful chemotherapy adjuvant to suppress chemotherapy-induced gene mutations,"After chemotherapy, ESR1 and GATA3 mutations were coupled with PI3K-AKT1 pathway¨Crelated gene mutations"
111,30893632,GATA3,Breast Cancer,plasma,NGS( the HiSeq 3000 Sequencing System),The mutation frequency of 1021 genes was examined prior to chemotherapy in ctDNA of 44 estrogen receptor-positive metastatic breast cancer patients. These genes were evaluated again in a subset of patients (n=24) following chemotherapy. Mutation frequency was defined as the percentage of mutations found in ctDNA compared to total cell-free DNA.,endocrine therapy,_,_,_,_,mTOR inhibition may be a useful chemotherapy adjuvant to suppress chemotherapy-induced gene mutations,"After chemotherapy, ESR1 and GATA3 mutations were coupled with PI3K-AKT1 pathway¨Crelated gene mutations"
112,30893632,PIK3CA,Breast Cancer,plasma,NGS( the HiSeq 3000 Sequencing System),The mutation frequency of 1021 genes was examined prior to chemotherapy in ctDNA of 44 estrogen receptor-positive metastatic breast cancer patients. These genes were evaluated again in a subset of patients (n=24) following chemotherapy. Mutation frequency was defined as the percentage of mutations found in ctDNA compared to total cell-free DNA.,endocrine therapy,_,_,_,_,mTOR inhibition may be a useful chemotherapy adjuvant to suppress chemotherapy-induced gene mutations,"After chemotherapy, ESR1 and GATA3 mutations were coupled with PI3K-AKT1 pathway¨Crelated gene mutations"
113,35197718,CDKN2A,Non-Small Cell Lung Cancer,plasma,NGS(  Illumina MiSeq or HiSeq4000 NGS platforms),Nine PD-L1 positive advanced NSCLC patients were prospectively enrolled and received pembrolizumab monotherapy. Pretreatment tissue and/or plasma samples were collected as baseline reference. Serial plasma samples were collected after 3 and 6 weeks of treatment as well as at disease progression. All samples underwent targeted next-generation sequencing.,might contribute to the pembrolizumab resistance,_,_,_,_,_,_
114,35197718,MITF,Non-Small Cell Lung Cancer,plasma,NGS(  Illumina MiSeq or HiSeq4000 NGS platforms),Nine PD-L1 positive advanced NSCLC patients were prospectively enrolled and received pembrolizumab monotherapy. Pretreatment tissue and/or plasma samples were collected as baseline reference. Serial plasma samples were collected after 3 and 6 weeks of treatment as well as at disease progression. All samples underwent targeted next-generation sequencing.,might contribute to the pembrolizumab resistance,_,_,_,_,_,_
115,31647198,EGFR,Lung Adenocarcinoma,plasma,ddPCR,"ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues.",_,These data showed that mEGFR ctDNA detection using ddPCR is useful in the advanced stages and its presence predicted  poor clinical outcome in lung adenocarcinoma.,_,_,These data showed that mEGFR ctDNA detection using ddPCR is useful in the advanced stages and its presence predicted distant metastasis in lung adenocarcinoma.,_,_
116,35280779,RAS,Colorectal Cancer,plasma,NGS( NovaSeq 6000 platform ),A single-center study was conducted retrospectively. Plasma samples from mCRC patients who received anti-EGFR therapies were collected at baseline and continuous treatment points. The ctDNA was extracted and sequenced with a target panel of tumor-related genes via next-generation sequencing (NGS). Clinical information was also collected and analyzed.,_,"For PFS, RAS status at baseline (P = 0.002) were poor prognostic indicators; For OS, RAS status at baseline (P = 0.002) were poor prognostic indicators;",_,_,_,_,_
117,33014846,MIKI67,Non-Small Cell Lung Cancer,plasma,NGS( the Illumina Novaseq 6000  system),"In this study, we therefore performed a pilot study by recruiting a total of 22 NSCLC patients who failed to previous lines of chemotherapy, chemoradiotherapy, TKI therapy, surgery, or any combination of the therapies, and investigated the clinical efficacy of Camrelizumab, a humanized, high-affinity IgG4-kappa mAb against PD-1, combined with Apatinib, a small molecular drug targeting vascular endothelial growth factor receptor-2 (VEGFR-2). Since the traditional biomarkers for immunotherapy, such as the PD-L1 expression and tumor mutation burden (TMB) appeared to have limited predicting values in several clinical trials using combined immunotherapy , we investigated the values of a few new biomarkers in predicting and monitoring the therapeutic response and prognosis in second-line or higher settings when ICI was combined with anti-angiogenic therapy.",_,ctDNA may be a novel monitoring biomarker for therapeutic response and predicting biomarker for prognosis in future combined therapy involving PD-1 blockade.MIKI67 mutations  were independent risk factors and PFS predictors for multiline combined anti-angiogenic/ICI combined therapy.,_,_,_,_,_
118,36028483,KRAS,Pancreatic Ductal Adenocarcinoma,plasma,NGS( the Illumina NovaSeq 6000),"Here, we present results of a multi-center, randomized, phase II trial (PA.7; NCT02879318) that aimed to assess the safety and efficacy of combination chemotherapy/ICI in mPDAC by comparing gemcitabine, nab-paclitaxel plus durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) versus gemcitabine with nab-paclitaxel alone. Durvalumab and tremelimumab are monoclonal antibody (mAb) ICIs that act through inhibition of programmed death-ligand 1 (PD-L1) and CTLA-4, respectively, and their combination has been shown to be safe in a phase Ib trial. As part of an exploratory objective of the trial, we perform bioinformatics analysis of baseline ctDNA sequencing to assess the utility of incorporating plasma sequencing as a correlative dataset in prospective mPDAC trials.",_,Exploratory baseline circulating tumor DNA (ctDNA) sequencing revealed increased survival for patients with KRAS wildtype tumors in both the combination immunotherapy (p = 0.001) and chemotherapy (p = 0.004) groups. These data support the utility of ctDNA analysis in PDAC and the prognostic value of ctDNA-based KRAS mutation status.,_,_,_,_,_
119,33889507,TTN,Non-Small Cell Lung Cancer,plasma,NGS( Illumina Novoseq6000 instrument in PE150 mode),"In this retrospective analysis, 92 patients with advanced NSCLC from two independent cohorts who received ICB treatment were included. A probe panel covering all exons of TTN was developed and validated to detect TTN mutation in ctDNA. Baseline plasma samples were collected and subjected to ctDNA sequencing with the TTN probe panel.",_,Progression-free survival was significantly improved in patients with the mutated TTN (212 days and 334.5 days for cohort 1 and 2) compared to those without the mutation (113 days and 147 days for cohort 1 and 2).,_,_,_,"The presence of mutated TTN in pre-treatment peripheral blood was associated with favorable objective response and survival with ICB administration. Therefore, circulatory TTN mutation may be applicable for guiding ICB immunotherapy in patients with NSCLC.",_
120,36082136,CDK12,Prostate Cancer,plasma,_,case report,_,_,_,_,_,"CDK12-mutated prostate cancer patients are likely to benefit from platinum-based chemotherapy, especially with the help of dynamic ctDNA-based liquid biopsies to monitor their CDK12 mutation status",_
121,35380256,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,"A total of 122 patients with NSCLC who underwent tissue and liquid next generation sequencing (NGS) tests were included. 66 patients with detected EGFR mutation in both tumor-tissue and plasma were included into the EGFRt+, p+ group, and 56 patients with EGFR mutation detected only in tumor-tissue were included into the EGFRt+, p- group. The differences in clinical characteristics, concomitant mutations and prognosis between the two groups were compared.",_,"Co-detection of EGFR mutation in tumor tissue and plasma is an independent prognostic factor for first-line EGFR-TKIs treatment. Moreover, combination therapy could be a promising approach to improve the outcome for these patients.The combination of TP53 mutated status and EGFRm status in plasma showed a better completion of risk stratification for PFS (Log-rank P < 0.001).","EGFRt+, p+ in the NGS test was particularly relevant to the size of tumors and TP53 mutation",_,"FGFR t+, p+ in the NGS test was particularly relevant to  liver metastasis, bone metastasis.",_,_
122,35096147,KRAS,Colorectal Cancer,plasma,NGS(Illumina Novaseq6000),"We included 41 patients with initially unresectable mCRC, treated with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX)/5-fluorouracil/leucovorin/irinotecan (FOLFIRI) with/without bevacizumab (Bev)/cetuximab (Cet). Blood samples were prospectively collected at two timepoints: at baseline and after four cycles of first-line treatment. Mutational status of 1086 genes were studied in ctDNA by targeted next-generation sequencing (NGS). Molecular mutational burden (MMB) was defined as mean mutation frequency among obtained mutations for each gene. To evaluate the association between molecular characteristics of cfDNA and therapeutic response better, we divided these patients into MMB-high and MMB-low group according to the median value of MMB (0.3).",_,"Levels of KRAS MMB might aid in monitoring therapeutic efficacy in mCRC patients at pretreatment/after four cycles of first-line treatment. By comparing the baseline levels of KRAS MMB in the two subgroups, we found that PD cases were all MMB-high, whereas non-PD cases were mainly in MMB-low subgroup. Furthermore, patients with low-KRAS MMB had superior response rate, significantly longer progression-free survival (PFS) and longer overall survival (OS) than high-KRAS MMB group.",_,_,_,_,_
123,31185703,EGFR,Non-Small Cell Lung Cancer,plasma,SABER / MassARRAY,"In this study, we determined the EGFR mutation status of LUAD patients using lung cancer tissues and compared the efficiency of the ARMS and SABER/MassARRAY methods in detecting EGFR mutations in ctDNA isolated from the plasma of these patients. The relationship between the EGFR status and clinical outcomes of LUAD patients who received first-line EGFR-TKI therapy was also evaluated.",_,"patients with EGFR mutations(L858R/ex19 del) in plasma ctDNA had significantly shorter progression-free survival (9.0 months, 95% CI 7.0-11.8, vs. 15.0 months, 95% CI 11.7-28.2; p = 0.02) and overall survival (30.6 months, 95% CI 12.4-37.2, vs. 55.6 months, 95% CI 25.8-61.8; p = 0.03) compared to those without detectable EGFR mutations. The detection of EGFR mutations in plasma ctDNA is a promising, minimally invasive, and reliable alternative to tumor biopsy, and the presence of EGFR mutations in plasma ctDNA after first-line EGFR-TKI therapy is associated with poor prognosis.",_,_,_,_,_
124,28790159,KRAS,Colorectal Cancer,plasma,ddpcr(QX200 digital-droplet PCR),"Patients with RAS mutant mCRC with biopsiable metastases were enrolled in this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment and at day 15 post-treatment. Median values of volume transfer constant (Ktrans), enhancing fraction (EF) and their product KEF (summarised median values of Ktrans¡Á EF) were generated. Circulating tumour (ct) DNA was collected monthly until progressive disease and tested for clonal RAS mutations by digital-droplet PCR. Tumour vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue biopsies.",_,"RAS mutant clones decay in ctDNA after 8 weeks of treatment was associated with better PFS (HR 0.21 (95% CI 0.06 to 0.71), p=0.01) and OS (HR 0.28 (95% CI 0.07-1.04), p=0.06).",_,_,_,_,_
125,33569316,TP53,Non-Small Cell Lung Cancer,plasma,NGS(Nextseq500),"Capture-based targeted sequencing was performed on the baseline and longitudinal plasma samples collected from 72 and 57 patients, respectively, using a 168-gene panel.",_,Analysis revealed that inferior overall survival (OS) was correlated with various baseline molecular features including high allelic fraction (AF) of EGFR sensitizing mutations (P=0.045),_,_,_,_,_
126,33569316,EGFR,Non-Small Cell Lung Cancer,plasma,NGS(Nextseq500),"Capture-based targeted sequencing was performed on the baseline and longitudinal plasma samples collected from 72 and 57 patients, respectively, using a 168-gene panel.",_,_,_,_,_,_,"Molecular PD, reflected by the emergence of new mutation or increased AF of existing mutations, was detected at an average lead time of 2.5 months prior to radiological PD. Patients with molecular PD were more likely to harbor CNA (P=0.035) and TP53 mutations (P=0.023)."
127,30209161,TP53,Prostate Cancer,plasma,_,"Between March 2014 and April 2017, we recruited patients with mCRPC (n = 168) prior to ARSi in a cohort study encompassing 10 European centers. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumor cells (CTC) and circulating tumor DNA (ctDNA). Targeted CTC RNA sequencing (RNA-seq) allowed the detection of eight AR splice variants (ARV). Low-pass whole-genome and targeted gene-body sequencing of AR and TP53 was applied to identify amplifications, loss of heterozygosity, mutations, and structural rearrangements in ctDNA. Clinical or radiologic progression-free survival (PFS) was estimated by Kaplan-Meier analysis, and independent associations were determined using multivariable Cox regression models.",_,"under ARSi(Abiraterone or Enzalutamide) treatment,In an all-comer cohort, tumor burden estimates and TP53 outperform any AR perturbation to infer prognosis;Patients with a TP53 perturbation had a shorter PFS compared to patients who were wild-type (median, 3.0 vs 8.7 months, p < 0.0001) ; PSA follow-up data at 10-12 weeks demonstrated fewer confirmed ¡Ý50% PSA responses in TP53-perturbed patients (15.4% vs 46.8%, ¦Ö2 test: p = 0.008). In MV-Cox analysis, a perturbed TP53 status was independently associated with poor outcome (HR 1.88, 95%CI 1.18-3.00, p = 0.008), together with ctDNA fraction (HR 1.02, 95%CI 1.01-1.03, p = 0.0005) and presence of visceral metastases (HR 1.72, 95%CI 1.05-2.84, p = 0.032). Logrank testing identified a shorter OS in TP53-perturbed disease (median, 7.8 vs 26.7 months, p < 0.0001).",_,_,_,_,_
128,33442424,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,"We detected EGFR and KRAS mutations in paired plasma and tumor tissue samples from 147 NSCLC patients. Of these, EGFR/KRAS ctDNA mutations and protein biomarkers were comparatively analyzed in 87 individuals. In addition, tissue samples of 20 patients were subjected to repeat multi-gene detection, and pre- and post-operative paired samples of 28 patients were subjected to multi-gene detection. Clinical information was obtained to complement the prognostic value of the combined assay results and post-operative new ctDNA mutation status.",_,EGFR/KRAS mutations were highly consistent in ctDNA and tumor DNA. Combining the detection of EGFR and KRAS mutations in ctDNA with the detection of protein biomarkers increased cancer detection sensitivity to 74.7% (65/87). None of the healthy controls tested positive using the combined assay (100% specificity). Combined assay results independently associated with recurrence-free survival. Post-operative new ctDNA mutation status independently associated with overall survival and recurrence-free survival. ,_,_,_,_,_
129,33442424,KRAS,Non-Small Cell Lung Cancer,plasma,NGS,"We detected EGFR and KRAS mutations in paired plasma and tumor tissue samples from 147 NSCLC patients. Of these, EGFR/KRAS ctDNA mutations and protein biomarkers were comparatively analyzed in 87 individuals. In addition, tissue samples of 20 patients were subjected to repeat multi-gene detection, and pre- and post-operative paired samples of 28 patients were subjected to multi-gene detection. Clinical information was obtained to complement the prognostic value of the combined assay results and post-operative new ctDNA mutation status.",_,EGFR/KRAS mutations were highly consistent in ctDNA and tumor DNA. Combining the detection of EGFR and KRAS mutations in ctDNA with the detection of protein biomarkers increased cancer detection sensitivity to 74.7% (65/87). None of the healthy controls tested positive using the combined assay (100% specificity). Combined assay results independently associated with recurrence-free survival. Post-operative new ctDNA mutation status independently associated with overall survival and recurrence-free survival. ,_,_,_,_,_
130,32211100,TP53,Gastric Cancer,plasma,NGS( the HiSeq3000 Sequencing System),We performed next-generation sequencing (NGS) of ctDNA from 23 gastric cancer patients. Then the genetic information and clinical information were statistically analyzed.,_,"TP53 was a common mutant gene and its mutation frequency and type of mutation were related to the outcome of advanced gastric cancer treatment. The frequency of mutations of the gene was related to therapeutic outcome, especially in the ineffective group(treatment ineffective) of this study.",_,_,_,_,_
131,34430359,EGFR,Non-Small Cell Lung Cancer,plasma,Scorpion amplified refractory mutation system (ARMS),"Stage I¨CIII NSCLC patients with tissue EGFR mutations were enrolled in this study (n=174). The ctDNA EGFR mutations were identified in paired preoperative plasma samples. EGFR mutation testing was performed using Scorpion amplified refractory mutation system (ARMS) technology. The correlation between ctDNA EGFR mutation status and clinicopathologic parameters was analyzed. By combining at least 5 years of follow-up data, we assessed the relationship between ctDNA EGFR mutation status and disease-free survival (DFS) and overall survival (OS).",_,"The overall 5-year survival rate was 18.5% versus 76.9% for ctDNA EGFR mutation-positive and ctDNA EGFR mutation-negative patients, respectively. For patients with ctDNA EGFR mutation positive, the median OS and DFS were 29.00¡À2.55 and 19.00¡À2.50 months, respectively, which were both significantly better than those in the ctDNA EGFR mutation-negative subgroup (P<0.001). ctDNA EGFR mutation was an independent risk factor of OS and DFS [hazard ratio (HR) 3.289, 95% confidence interval (CI), 1.816-5.956, P<0.001; HR, 4.860, 95% CI, 2.660-8.880, P<0.001].",_,_,_,_,_
132,35116746,EGFR,Non-Small Cell Lung Cancer,plasma,Illumina CN500 platform,"A total of 36 patients with advanced non-small cell lung cancer (NSCLC) were enrolled in this study, including 28 cases of adenocarcinoma and 8 cases of squamous cell carcinoma. Next-generation sequencing based ctDNA detection, tissue DNA (tDNA) detection, corresponding survival analysis, and retrospective statistics were performed to explore the feasibility of clinical practice directed by molecular characteristics in NSCLC.",_,_,_,_,_,"Twenty-one patients with EGFR mutation and subsequently treated with EGFR-tyrosine kinase inhibitor (TKI) combined chemotherapy, had significantly longer PFS than those with EGFR wild type and treated with chemotherapy in next 5-year monitoring test (18.00¡À4.41 vs. 7.33¡À1.58 months, P=0.024).",_
133,32218822,TP53,Ovarian Cancer,plasma,Cancer Personalized Profiling by deep Sequencing (CAPP-Seq),"In the present study, we applied CAPP-seq, a ctDNA-based form of targeted NGS, to compare the variant allele frequency (VAF) of tumor-derived somatic mutations in ctDNA measured pre- and post-NAC in plasma samples obtained from ovarian cancer patients receiving NAC. We also examined the changes of the bTMB during NAC treatment as a potential novel biomarker.",_,_,_,"Gene mutation can be profiled and monitored using liquid biopsy-based CAPP-Seq in patients with advanced ovarian cancer with NAC treatment, and TP53 mutation in the ctDNA and bTMB may be novel biomarkers that can be used for patient monitoring during NAC treatment(the rate of TP53 mutation in the NAC-resistant cases was significantly higher compared with NAC-sensitive cases).",_,_,_
134,29416754,KRAS,Ovarian Cancer,plasma,pancreatic ductal adenocarcinoma,"Blood samples from patients with metastatic PDAC prior to and during palliative treatment were collected. ctDNA and corresponding tumor tissue were analyzed by targeted next generation sequencing and droplet digital PCR for the 7 most frequently mutated genes in PDAC (TP53, SMAD4, CDKN2A, KRAS, APC, ATM, and FBXW7). Findings were correlated with clinical and imaging data.",_,"The combined mutational allele frequency (CMAF) of KRAS and TP53 was chosen to reflect the amount of ctDNA. The median CMAF level significantly decreased during treatment (P = 0.0027) and increased at progression (P = 0.0104). CA19-9 analyses did not show significant differences. In treatment na ve patients, the CMAF levels during therapy significantly correlated with progression-free survival (Spearman, r = -0.8609, P = 0.0013).",_,_,_,_,_
135,35117043,EGFR,Non-Small Cell Lung Cancer,plasma,ddpcr(the MX3000P real-time PCR system ),"Plasma and matched tissue specimens from patients with advanced lung adenocarcinoma were collected prior to icotinib treatment. The ARMS method was used to detect EGFR mutation status in DNA extracted from tissue specimens, while the EGFR mutation status in ctDNA extracted from plasma specimens was determined by ddPCR. The therapeutic effects of icotinib were compared between patients with EGFR-activating mutations detected by ddPCR in ctDNA and ARMS in tissue DNA.",_,"under icotinib treatment,Patients with sensitive EGFR mutations in plasma specimens detected with ddPCR had a higher ORR and DCR compared with patients with sensitive EGFR mutations in tissue detected with the ARMS method.",_,_,_,_,_
136,30174861,EGFR,Non-Small Cell Lung Cancer,plasma,ADx-ARMS (amplification refractory mutation system) kit,"Plasma DNA samples from 1,001 patients with stage III/IV NSCLC who received ¡Ü1st line chemotherapy were collected from 65 hospitals. EGFR mutations were tested by amplification refractory mutation system (ARMS) method. The EGFR mutation rate was calculated and the associations between EGFR status and patients' demographic data, disease status as well as treatment pattern were explored.",_,_,_,ctDNA based EGFR mutation test is feasible and could be a surrogate when tissue biopsy is not available.,_,_,_
137,35100697,BRAF,Non-Small Cell Lung Cancer,plasma,_,_,_,"Our results confirm that baseline RAS and BRAF testing in ctDNA discriminates survival. The emergence of RAS/BRAF mutations has limited relevance for the time to progression to anti-epidermal growth factor receptor therapy.The median overall survival (OS) of baseline patients with RAS and BRAF mutations in ctDNA was 22.3 months (95% CI, 15.6 to 29 months) and 8.9 months (95% CI, 6.3 to 11.4 months), respectively, which was significantly inferior to the median OS of 40.4 months (95% CI, 35.9 to 44.9 months) in two patients with wild-type disease (P < .001). Acquisition of RAS/BRAF mutations occurred in nine of 63 patients (14%) with progressive disease (PD; ie, blood draw within 1 month before PD or after PD) compared with six of 73 patients (8%) with no PD or blood extraction for ctDNA analysis before 1 month of PD (P = .47). Median OS in patients with RAS/BRAF acquisition was 23.9 months (95% CI, 19.7 to 27.9 months) compared with 40.6 months (95% CI, not reached to not reached) in patients who remained free of mutations (P = .016).",_,_,_,_,_
138,35100697,RAS,Non-Small Cell Lung Cancer,plasma,_,_,_,"Our results confirm that baseline RAS and BRAF testing in ctDNA discriminates survival. The emergence of RAS/BRAF mutations has limited relevance for the time to progression to anti-epidermal growth factor receptor therapy.The median overall survival (OS) of baseline patients with RAS and BRAF mutations in ctDNA was 22.3 months (95% CI, 15.6 to 29 months) and 8.9 months (95% CI, 6.3 to 11.4 months), respectively, which was significantly inferior to the median OS of 40.4 months (95% CI, 35.9 to 44.9 months) in two patients with wild-type disease (P < .001). Acquisition of RAS/BRAF mutations occurred in nine of 63 patients (14%) with progressive disease (PD; ie, blood draw within 1 month before PD or after PD) compared with six of 73 patients (8%) with no PD or blood extraction for ctDNA analysis before 1 month of PD (P = .47). Median OS in patients with RAS/BRAF acquisition was 23.9 months (95% CI, 19.7 to 27.9 months) compared with 40.6 months (95% CI, not reached to not reached) in patients who remained free of mutations (P = .016).",_,_,_,_,_
139,33777770,ESR1,Breast Cancer,plasma,ddpcr(the QX200 ddPCR system),We conducted a prospective study in a cohort of HR+/HER2- mBC patients to assess the concordance of ESR1 mutation evaluated on matched tumor tissue samples from a metastatic lesion and ctDNA from plasma.,_,_,_,The total concordance rate between ESR1 status on tumor tissue and plasma was 91%. Our results confirm the potential role of liquid biopsy as a non-invasive alternative to tissue biopsy for ESR1 mutation assessment in mBC patients.,_,_,_
140,33920470,BRAF,Melanoma,plasma,dpcr,"This validation study was undertaken to confirm that early ctDNA kinetics, interpreted using well-defined evaluation criteria, could predict responses to anti-PD1 immunotherapy alone or in combination with anti-CTLA-4 in an independent prospective cohort of metastatic melanoma patients.",_,"ctDNA detection at first-line anti-PD1 initiation was an independent prognostic factor for OS and PFS in multivariate analysis. Overall, early ctDNA quantitative monitoring may allow the detection of primary resistances of metastatic melanoma to anti-PD1 immunotherapies.",_,_,_,_,_
141,33920470,NRAS,Melanoma,plasma,dpcr,"This validation study was undertaken to confirm that early ctDNA kinetics, interpreted using well-defined evaluation criteria, could predict responses to anti-PD1 immunotherapy alone or in combination with anti-CTLA-4 in an independent prospective cohort of metastatic melanoma patients.",_,"ctDNA detection at first-line anti-PD1 initiation was an independent prognostic factor for OS and PFS in multivariate analysis. Overall, early ctDNA quantitative monitoring may allow the detection of primary resistances of metastatic melanoma to anti-PD1 immunotherapies.",_,_,_,_,_
142,30323979,TP53,Breast Cancer,plasma,Illumina HiSeq 3000 and NextSeq 500 instruments,"Through next generation sequencing, this study evaluated the circulating tumor DNA (ctDNA) of advanced breast cancer patients to prospectively explore the relationship between specific DNA mutations and prognosis as well as therapeutic decision making. The target region covered 1021 gene totally. Clinical characteristics, treatment and outcome data were collected. ",_,The presence of a TP53 mutation was associated with worse OS.,_,_,_,_,_
143,29490986,TP53,Squamous Cell Carcinoma Of The Head And Neck,plasma,NGS,"BERIL-1 was a multicenter, randomized, double-blind, placebo-controlled phase II study. Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on/after one previous platinum-based chemotherapy regimen in the recurrent or metastatic setting were treated with either buparlisib plus paclitaxel or placebo plus paclitaxel. Archival tumor tissue and ctDNA samples were analyzed for molecular alterations and immune infiltration using next-generation sequencing or immunohistochemistry.",_,_,_,_,_,"The BERIL-1 biomarker analyses showed that patients with TP53 alterations, HPV-negative status, low mutational load, or high infiltration of TILs or CD8-positive cells derived survival benefit with the combination of buparlisib and paclitaxel.",_
144,29541205,TP53,Colorectal Cancer,plasma,NGS,"In the present study, next generation sequencing (NGS) technology was used to reveal significant associations between changes in ctDNA and different stages of CRC progression in order to examine the value of ctDNA in the clinical diagnosis and treatment of patients with CRC.",_,"In 1 patient with metastatic rectal cancer, the rate of TP53 mutation increased from 8.95 (preoperative) to 71.4% (postoperative), and a new phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit Î± mutation emerged. This patient succumbed to mortality six months following surgery, however there were no marked changes in CEA levels during periodic detection of CEA levels. In summary, ctDNA has a high sensitivity and specificity in prediction of the prognosis of patients with CRC.",_,_,_,_,_
145,36185208,BRCA1,Prostate Cancer,plasma,NGS,_,_,_,_,_,_,_,BRCA1 mutations tend to co-segregate with mutations in other molecular pathways contributing to prostate cancer progression. These hypothesis-generating data may explain the differential response to PARP inhibition and guide towards the development of combinatorial drug regimens in those with BRCA1 mutation.
146,36185208,BRCA2,Prostate Cancer,plasma,NGS,_,_,_,_,_,_,_,BRCA2 may be the main driver mutation
147,36248329,EGFR,Lung Adenocarcinoma,plasma,_,_,_,"8 months after the operation, the EGFR del19 mutation re-emerged in the blood, accompanied by a newly emerged solitary nodule (2 mm) that was later confirmed to be metastatic. Soon afterward, ctDNA detection revealed the EGFR T790M mutation, and the mediastinal lymph nodes rapidly enlarged. The patient's treatment was switched to Osimertinib and the ctDNA detection results showed the EGFR T790M gene mutation frequencies steadily decreased to zero. During the treatment period, ctDNA detection accurately predicted each change in disease burden and revealed genotype alterations. The patient ultimately developed severe metastases in the liver after developing resistance to Osimertinib.",_,_,_,_,_
148,34282791,ALK,Neuroblastoma,plasma,ddpcr,"Various pre-analytical conditions tested to optimize circulating-tumor DNA (ctDNA) copy number changes evaluations. Plasma samples from 10 patients diagnosed with neuroblastoma assessed for SCA and MNA using single nucleotide polymorphism (SNP) array approach currently used for neuroblastoma diagnosis, with MNA status assessed independently using digital-droplet PCR (ddPCR). Three patients (one in common with the previous 10) tested for ALK activating mutations p.F1174L and p.F1245I using ddPCR.",_,"MNA and ALK mutation dynamic change was assessed in longitudinal samples from 4 and 3 patients (one patient with both), respectively, accurately reflected response to treatment in 6/6 (100%) and disease recurrence in 5/6 (83%) of cases. Samples taken prior to targeted treatment with the ALK inhibitor Lorlatinib and 6-8 weeks on treatment showed reduction/increase in ALK variants according to response to treatment.",_,_,_,_,_
149,35050760,RAS,Colorectal Cancer,plasma,OncoBEAM RAS CRC kits,"We enrolled patients whose plasma samples were collected in prospective phase II trials, the JACCRO CC-08 (n = 36) and CC-09 (n = 25), which evaluated rechallenge chemotherapy with anti-EGFR mAb for KRAS wild-type mCRC. RAS in ctDNA was analyzed at the time points of baseline, 8 weeks, and progression using OncoBEAM RAS CRC kit.",_,"RAS status in ctDNA was significantly associated with clinical outcomes in patients with mCRC receiving rechallenge treatment with anti-EGFR mAb.The DCR was 33% in patients with RAS mutations in ctDNA, whereas it was 80% in patients without RAS mutation at baseline. Patients with RAS mutation at baseline had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without RAS mutation (median PFS, 2.3 v 4.7 months; hazard ratio [HR], 6.2; P = .013; median OS, 3.8 v 16.0 months; HR, 12.4; P = .0028). Six of 10 patients without RAS mutation at baseline acquired RAS mutations at progression. Postprogression survival after rechallenge treatment was numerically shorter in patients with RAS mutation at progression.",_,_,_,_,_
150,31877464,ESR1,Breast Cancer,plasma,NGS(Illumina Hiseq Technology),"We performed longitudinal dynamic mutation analyses of plasma samples from 45 patients with metastatic breast cancer (MBC) and sequencing paired biopsy tissues, using a targeted NGS panel of 425 genes. These patients were treated at the Second Affiliated Hospital of Dalian Medical University between January 2017 and February 2019 with written informed consent.","the change of allele frequency of ESR1 mutations was an important biomarker, which could predict endocrine resistance of ER+ MBC.",the combination of everolimus in four cases with acquired ESR1 mutations showed longer PFS than other therapies without everolimus.,_,_,_,everolimus,_
151,31179079,EGFR,Non-Small Cell Lung Cancer,plasma,ARMS,Eligible patients (stage IIIA/B/IV locally advanced/metastatic treatment-naive advanced NSCLC) provided diagnostic tissue/cytology and plasma samples. DNA extracted from tissue/cytology samples was subjected to EGFR mutation testing as per local practice; a designated laboratory performed ctDNA extraction/mutation testing of plasma samples. The primary outcome was EGFR mutation status concordance between matched tumor and plasma samples.,_,_,_,Data confirm ctDNA as an alternative sample for EGFR mutation analysis in patients with advanced NSCLC.,_,_,_
152,36332363,CDH1,Invasive Lobular Carcinoma,plasma,NGS(Guardant360),"In once clinical study,We retrospectively analysed 980 clinically annotated patients (121 ILC, 792 IDC, and 67 mixed histology) from three academic centers with ctDNA evaluation by Guardant360 . Single nucleotide variations (SNVs), copy number variations (CNVs), and oncogenic pathways were compared across histologies.",_,_,_,_,_,_,"In multivariable analysis, HR+ HER2 negative ILC was significantly associated with mutations in CDH1 (odds ratio (OR) 9.4, [95% CI 3.3-27.2]), ERBB2 (OR 3.6, [95% confidence interval (CI) 1.6-8.2]), and PTEN (OR 2.5, [95% CI 1.05-5.8]) genes. In an independent cohort of nearly 7000 metastatic breast cancer patients, CDH1 was significantly co-mutated with targetable alterations (PIK3CA, ERBB2) and mutations associated with endocrine resistance (ARID1A, NF1, RB1, ESR1, FGFR2) (Benjamini-Hochberg Procedure, all q < 0.05)."
153,36332363,ERBB2,Invasive Lobular Carcinoma,plasma,NGS(Guardant360),"In once clinical study,We retrospectively analysed 980 clinically annotated patients (121 ILC, 792 IDC, and 67 mixed histology) from three academic centers with ctDNA evaluation by Guardant360 . Single nucleotide variations (SNVs), copy number variations (CNVs), and oncogenic pathways were compared across histologies.",_,_,_,_,_,_,"In multivariable analysis, HR+ HER2 negative ILC was significantly associated with mutations in CDH1 (odds ratio (OR) 9.4, [95% CI 3.3-27.2]), ERBB2 (OR 3.6, [95% confidence interval (CI) 1.6-8.2]), and PTEN (OR 2.5, [95% CI 1.05-5.8]) genes."
154,36332363,PTEN,Invasive Lobular Carcinoma,plasma,NGS(Guardant360),"In once clinical study,We retrospectively analysed 980 clinically annotated patients (121 ILC, 792 IDC, and 67 mixed histology) from three academic centers with ctDNA evaluation by Guardant360 . Single nucleotide variations (SNVs), copy number variations (CNVs), and oncogenic pathways were compared across histologies.",_,_,_,_,_,_,"In multivariable analysis, HR+ HER2 negative ILC was significantly associated with mutations in CDH1 (odds ratio (OR) 9.4, [95% CI 3.3-27.2]), ERBB2 (OR 3.6, [95% confidence interval (CI) 1.6-8.2]), and PTEN (OR 2.5, [95% CI 1.05-5.8]) genes."
155,34290508,ATM,Colorectal Cancer,plasma,_,case report,_,_,_,_,_,The XELOXIRI-bevacizumab regimen is a feasible and effective regimen for patients with mCRC. Mutations in the ATM genes may characterize a subset of patients with a better prognosis who are more sensitive to chemotherapy plus biological agents.,_
156,34513603,PI3KCA,Triple Negative Breast Cancer,plasma,_,case report,_,The detection of PIK3CA mutation in TNBC after neoadjuvant treatment might be associated with early relapse or rapid disease progression.,_,_,_,_,_
157,31611986,EGFR,Non-Small Cell Lung Cancer,plasma,NGS(Illumina HiSeq2500),"The present study enrolled 99 patients with NSCLC who were baseline or previously treated at the Hunan Cancer Hospital (Changsha, China) between September 2017 and April 2018. The specimens included 59 plasma and 40 tissue samples. ",_,_,_,_,_,_,"the present study demonstrated that EGFR amplification coexisted with EGFR mutations, including SNVs and INDELs, but was mutually exclusive with the EGFR T790M mutation. Furthermore, no patients with concurrent ERBB2 mutation and amplification were observed. All four patients that possessed the EGFR T790M mutation also harbored other EGFR mutations. To investigate the patterns of concurrent alterations and mutual exclusivity, pairwise associations between somatic events were examined. Mutual exclusivity was observed between alterations in EGFR and TP53 [odds ratio (OR)=0.324; P=0.020;] and between those in EGFR and KRAS (OR=0.091; P=0.008) in patients with NSCLC"
158,31611986,TP53,Non-Small Cell Lung Cancer,plasma,NGS(Illumina HiSeq2500),"The present study enrolled 99 patients with NSCLC who were baseline or previously treated at the Hunan Cancer Hospital (Changsha, China) between September 2017 and April 2018. The specimens included 59 plasma and 40 tissue samples. ",_,_,_,_,_,_,"the present study hypothesized that there may be a correlation between the MAFs of TP53 and EGFR in individual patients. As expected, a significantly linear relationship was observed (r=0.773; P=0.005;). However, when the MAFs of TP53 and KRAS were compared, no linear correlation was identified (r=0.700; P=0.233; ). In addition, the present study observed significant differences in the MAF of EGFR between patients with and without TP53 mutations (P=0.001;);the number of variants in each patient was analyzed in the context of various mutant genes. The results revealed that patients with TP53 mutations harbored more variant numbers when compared with patients without TP53 mutations in baseline tumors (P=0.011)"
159,30949415,EGFR,Non-Small Cell Lung Cancer,plasma,_,"In this study, we recruited 464 patients with NSCLC between March 2014 and March 2015. Circulating tumor DNA (ctDNA) was isolated from plasma and identified EGFR gene mutations. Demographic characteristics, pathological data, safety and three-year survival were compared in patients with different EGFR gene mutations. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), disease control rate (DCR) and overall survival (OS). ",_,"the median OS in patients with EGFR 21 exon mutation was significantly higher than those of patients with EGFR 19 exon or other mutations. In conclusion, applied with chemotherapy and EGFR-TKI, Chinese NSCLC patients with EGFR gene 21 exon mutation could have better clinical response and long-term survival than those with other kinds of mutation.",_,_,_,_,_
160,36318332,EGFR,Non-Small Cell Lung Cancer,cerebrospinal fluid,_,"From April 2018 to November 2021, patients with EGFR-mutant NSCLC who underwent cerebrospinal fluid (CSF) sampling under the clinical suspicion of LM were enrolled. The patients' clinicodemographic characteristics, treatment history including whole-brain radiation therapy (WBRT), overall survival (OS), and intracranial progression-free survival (icPFS) were measured. EGFR mutations in cell-free tumor DNA (ctDNA) of CSF, including T790M mutation, were analyzed.",_,_,_,_,_,Osimertinib is effective in patients with EGFR-mutant NSCLC who developed LM and prior third-generation EGFR-TKI use was associated with poor survival in these patients. The role of WBRT warrants further investigation.,_
161,33995588,BRCA2,Ovarian Cancer,_,_,case report,_,_,_,_,_,maybe targeted by PARP inhibitor,_
162,33995588,BRCA1,Breast Cancer,_,_,case report,_,_,_,_,_,maybe targeted by PARP inhibitor,_
163,30147360,ESR1,Breast Cancer,_,_,"We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed.",_,"Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17-1.66; P<0.0001) and OS (HR: 1.65, 95% CI: 1.36-2.01; P<0.0001) compared to wild-type ESR1.Subgroup analysis showed that plasma ESR1 mutations were associated with shorter PFS after AI-based treatment, but were not significantly predictive of outcome on fulvestrant-containing therapy (HR: 1.26, 95% CI: 0.98-1.62; P=0.077).",_,_,_,_,_
164,35159044,BRAF,Melanoma,plasma,_,"We included patients with liquid biopsy performed between 1 January 2018 and 15 August 2020 to achieve at least a 12-month follow-up. All patients had undergone BRAF mutation testing by liquid biopsy, and tissue sample testing was also performed when possible. Collected data included basic demographic data, stage of the disease, times of requesting and obtaining the results of BRAF mutation testing from liquid biopsy and tissue sample if available, reasons for performing a liquid biopsy, and data about eventual treatment with BRAF inhibitors.",BRAF/MEK inhibitors,_,_,"ctDNA is a feasible source of genetic material for BRAF mutation assessment in clinical practice in advanced melanoma patients, especially when a tissue sample is not available or in patients with rapidly progressive disease.",_,_,_
165,32695676,TP53,Breast Cancer,plasma,NGS,Matched plasma and mononuclear cells from 290 Chinese women with metastatic BC were sequenced using either of the two commercially-available panels consisting of 520 cancer-related and 108 BC-related genes. Both panels cover the same critical regions of 91 genes. The circulating tumor DNA mutation profile from our cohort was then compared with publicly-available metastatic BC datasets from Memorial Sloan Kettering Cancer Center (MSKCC) and Pan-cancer analysis of whole genomes (PCAWG).,_,_,_,_,"Maximum allelic fraction (maxAF) of TP53, RB1, and PIK3CA mutations were associated with multiple organ metastasis",_,_
166,32695676,RB1,Breast Cancer,plasma,NGS,Matched plasma and mononuclear cells from 290 Chinese women with metastatic BC were sequenced using either of the two commercially-available panels consisting of 520 cancer-related and 108 BC-related genes. Both panels cover the same critical regions of 91 genes. The circulating tumor DNA mutation profile from our cohort was then compared with publicly-available metastatic BC datasets from Memorial Sloan Kettering Cancer Center (MSKCC) and Pan-cancer analysis of whole genomes (PCAWG).,_,_,_,_,"Maximum allelic fraction (maxAF) of TP53, RB1, and PIK3CA mutations were associated with multiple organ metastasis",_,_
167,32695676,PIK3CA,Breast Cancer,plasma,NGS,Matched plasma and mononuclear cells from 290 Chinese women with metastatic BC were sequenced using either of the two commercially-available panels consisting of 520 cancer-related and 108 BC-related genes. Both panels cover the same critical regions of 91 genes. The circulating tumor DNA mutation profile from our cohort was then compared with publicly-available metastatic BC datasets from Memorial Sloan Kettering Cancer Center (MSKCC) and Pan-cancer analysis of whole genomes (PCAWG).,_,_,_,_,"Maximum allelic fraction (maxAF) of TP53, RB1, and PIK3CA mutations were associated with multiple organ metastasis; Patients with PIK3CA was more likely to have liver metastasis (P < 0.02).",_,_
168,32695676,PTEN,Breast Cancer,plasma,NGS,Matched plasma and mononuclear cells from 290 Chinese women with metastatic BC were sequenced using either of the two commercially-available panels consisting of 520 cancer-related and 108 BC-related genes. Both panels cover the same critical regions of 91 genes. The circulating tumor DNA mutation profile from our cohort was then compared with publicly-available metastatic BC datasets from Memorial Sloan Kettering Cancer Center (MSKCC) and Pan-cancer analysis of whole genomes (PCAWG).,_,_,_,_,"Patients with PIK3CA, PTEN, and RB1 mutation were more likely to have liver metastasis (P < 0.02).",_,_
169,32695676,RB1,Breast Cancer,plasma,NGS,Matched plasma and mononuclear cells from 290 Chinese women with metastatic BC were sequenced using either of the two commercially-available panels consisting of 520 cancer-related and 108 BC-related genes. Both panels cover the same critical regions of 91 genes. The circulating tumor DNA mutation profile from our cohort was then compared with publicly-available metastatic BC datasets from Memorial Sloan Kettering Cancer Center (MSKCC) and Pan-cancer analysis of whole genomes (PCAWG).,_,_,_,_,"Patients with PIK3CA, PTEN, and RB1 mutation were more likely to have liver metastasis (P < 0.02).",_,_
170,31850201,KRAS,Pancreatic Cancer,plasma,ddpcr(Qx200),Plasma samples were collected from 110 PC and 52 pancreatic benign (PB) disease patients. The detection of KRAS mutation in ctDNA was performed using droplet digital PCR and compared with that in matched tumor tissue. We assessed the utility of KRAS MAFs in ctDNA and tissue for pancreatic malignancy assessment.,_,_,The MAF of KRAS in ctDNA was related to the clinical stage of PC (p = 0.001). Mutant KRAS ctDNA could improve the sensitivity in early diagnosis of PC as a complement to CA19-9. Our study suggested that KRAS mutation in ctDNA could be a valuable circulating biomarker for the malignancy assessment in PC.,_,The KRAS MAF in ctDNA was obviously associated with the presence of distant metastasis (p < 0.001),_,_
171,33377634,ERBB2,Gastric Cancer,plasma,NGS(Illumina HiSeq4000),"From 40 GC patients received HER2-targeted therapy, a total of 327 peripheral blood plasma specimens was collected including baseline and treatment time points. Circulating tumor DNA (ctDNA) was extracted and sequenced with a target panel of 425 genes. Experimental validation of resistant mutations was carried out in NIH-3T3 cell line.",_,_,_,_,_,survival analysis indicated that patients harboring both HER2 (ERBB2) positivity and high TMB might gain more therapeutic benefits from immune checkpoint inhibitors instead of HER2-targeted regimens,_
172,34359813,BRAF,Melanoma,plasma,ddpcr,_,_,patients with undetectable ctDNA after 12¨C18 weeks of treatment had a 7.4 times longer median PFS compared to patients with still detectable ctDNA (30.2 vs. 4.0 months; hazard ratio (HR) 12.6 (95% confidence interval [95% CI] 4.3¨C36.8)). A similar difference was observed for CSS (not reached vs. 10.2 months; HR 14.6 (95% CI 3.3¨C64.6)).,higher mBRAF levels were observed in patients with liver metastasis (p = 0.05).,_,_,_,"mBRAF abundance moderately correlated with levels of LDH ( ¦Ñ = 0.50, p < 0.001), weakly correlated with S100 levels (¦Ñ = 0.35, p = 0.03), and strongly correlated with total cell-free circulating DNA (¦Ñ = 0.83, p < 0.001)."
173,34192651,TP53,Lung Adenocarcinoma,plasma,ddpcr,"Circulating tumor DNA was prospectively collected at baseline in advanced treatment-na ve EGFR-mutant lung adenocarcinoma patients treated with gefitinib in an open-label, single-arm, prospective, multicenter, phase 2 clinical trial (BENEFIT trial) and analyzed using next-generation sequencing.",_,"The median progression-free survival (PFS) and overall survival (OS) of patients with TP53-wild type tumors were significantly longer than those of patients with TP53-mutant tumors. Mutations in exons 5-8 accounted for 80.9% of TP53 mutations. Mutations in TP53 exons 6 and 7 were significantly associated with inferior PFS and OS compared to wild-type TP53. TP53 mutation also influenced the prognosis of patients with different EGFR mutations. Patients with TP53 and EGFR exon 19 mutations had significantly longer PFS and OS than patients with TP53 and EGFR L858R mutations, and both groups had worse survival than patients with only EGFR mutations. Patients with TP53 mutations, especially in exons 6 and 7, had a lower response rate and shorter PFS and OS when treated with gefitinib. Moreover, TP53 exon 5 mutation divided TP53 mutations in disruptive and non-disruptive types.",_,_,_,_,_
174,31394872,PIK3CA,Breast Cancer,plasma,NGS,"The aim of the present study was to investigate whether ctDNA analysis can be used in early breast cancer diagnosis, by sequencing plasma DNA taken before tumor biopsy in patients with mammographic findings. Then, we have compared PIK3CA and TP53 mutations between tumor biopsies and pre-biopsy circulating DNA as well as we have explored clinicopathological variables that may affect the detectability of these tumor-derived mutations in blood.",_,"the presence of ctDNA mutations was significantly associated with a lower age of the patients (p = 0.040), higher tumor size (p = 0.033) and tumor grade (p = 0.041), the presence of lymph node positivity (p < 0.001), a BIRADS category 5 (p = 0.004) and the IHC cancer subtype (p = 0.025).",_,_,_,_,_
175,31394872,TP53,Breast Cancer,plasma,NGS,"The aim of the present study was to investigate whether ctDNA analysis can be used in early breast cancer diagnosis, by sequencing plasma DNA taken before tumor biopsy in patients with mammographic findings. Then, we have compared PIK3CA and TP53 mutations between tumor biopsies and pre-biopsy circulating DNA as well as we have explored clinicopathological variables that may affect the detectability of these tumor-derived mutations in blood.",_,"the presence of ctDNA mutations was significantly associated with a lower age of the patients (p = 0.040), higher tumor size (p = 0.033) and tumor grade (p = 0.041), the presence of lymph node positivity (p < 0.001), a BIRADS category 5 (p = 0.004) and the IHC cancer subtype (p = 0.025).",_,_,_,_,_
176,34306573,BCL7A,Colorectal Cancer,plasma,"Illumina MiSeq sequencer (Illumina Inc., San Diego, CA, USA)","This study aimed to identify CRC driver genes to assist in the design of a cancer panel to detect gene mutations during clinical early-stage screening and identify genes for use in prognostic assessments and the evaluation of appropriate treatment options. First, we utilized bioinformatics approaches to analyze 354 paired sequencing profiles from The Cancer Genome Atlas (TCGA) to identify CRC driver genes and analyzed the sequencing profiles of 38 patients with >5 years of follow-up data to search for prognostic genes. ",_,BCL7A gene mutation was correlated with prognosis in CRC (worse) (log-rank p-value = 0.02).,_,_,_,_,_
177,34306573,FAT4,Colorectal Cancer,plasma,"Illumina MiSeq sequencer (Illumina Inc., San Diego, CA, USA)","This study aimed to identify CRC driver genes to assist in the design of a cancer panel to detect gene mutations during clinical early-stage screening and identify genes for use in prognostic assessments and the evaluation of appropriate treatment options. First, we utilized bioinformatics approaches to analyze 354 paired sequencing profiles from The Cancer Genome Atlas (TCGA) to identify CRC driver genes and analyzed the sequencing profiles of 38 patients with >5 years of follow-up data to search for prognostic genes. ",_,_,_,could be new targets for ctDNA analysis development in CRC,_,_,_
178,34306573,PIK3CA,Colorectal Cancer,plasma,"Illumina MiSeq sequencer (Illumina Inc., San Diego, CA, USA)","This study aimed to identify CRC driver genes to assist in the design of a cancer panel to detect gene mutations during clinical early-stage screening and identify genes for use in prognostic assessments and the evaluation of appropriate treatment options. First, we utilized bioinformatics approaches to analyze 354 paired sequencing profiles from The Cancer Genome Atlas (TCGA) to identify CRC driver genes and analyzed the sequencing profiles of 38 patients with >5 years of follow-up data to search for prognostic genes. ",_,_,_,could be new targets for ctDNA analysis development in CRC,_,_,_
179,32953487,EGFR,Non-Small Cell Lung Cancer,plasma,ddpcr( Bio-Rad QX200),"Following extraction of cell-free DNA from plasma using the QIAamp Circulating Nucleic Acid Kit, custom droplet digital polymerase chair reaction (ddPCR) assays were used to assess EGFR ctDNA using the Bio-Rad QX200 system. The ddPCR assay has a limit of detection of ¡Ü0.15% variant allele fraction. Baseline characteristics and imaging reports at time of EGFR ctDNA testing were reviewed retrospectively for a 1 year period.",_,"Patients with liver or bone progression and 3-5 progressing sites are more likely to have informative EGFR ctDNA testing. Detection of EGFR ctDNA is a negative prognostic indicator in the absence of a T790M resistance mutation, potentially reflecting the disease burden in the absence of targeted therapy options.",_,_,_,_,_
180,32884537,EGFR,Lung Adenocarcinoma,plasma,ARMS,"an association between a detectable pre-radiotherapy plasma EGFR ctDNA and early tumour relapse (155 days vs. NR, p = 0.004) was noted. ",_,"an association between a detectable pre-radiotherapy plasma EGFR ctDNA and early tumour relapse (155 days vs. NR, p = 0.004) was noted.",_,_,_,_,_
181,35282050,TP53,Breast Cancer,plasma,Oncomine Breast,Targeted sequencing of ctDNA was performed in 38 patients using commercially available Oncomine Breast cfDNA panel. Whole exome sequencing was performed on matched tumor DNA (n=20). Survival analysis and response to chemotherapy in the study population were evaluated. The detected genomic variants were validated and serially monitored with droplet digital polymerase chain reaction (ddPCR) in 5 patients.,_,"The patients with variants in TP53 showed significantly poorer overall survival than those without [hazard ratio (HR) =3.90, 95% confidence interval (CI): 1.10-13.84, P=0.035] and its impact was also statistically significant in multivariate analysis with breast cancer subtype included. In serially monitored results, changes in the allele frequency of somatic variants (PI3KCA, TP53) of ctDNA were found to be reflective of response to chemotherapy.",_,_,_,_,_
182,29464111,EGFR,Lung Adenocarcinoma,plasma,ddpcr,"Forty-four plasma samples from 37 patients with LADC receiving EGFR-TKI therapy, including 20 who developed resistance, were prospectively subjected to droplet digital PCR-cfDNA analysis to detect EGFR mutations and analysed according to clinical features.",_,_,_,_,_,_,"cfDNA analysis from patients with acquired TKI-resistance disease or extrathoracic disease progression correlated with a high detection rate of TKI sensitive mutations (acquired resistance: risk ratio=2.53, 95% CI 1.50 to 4.29; extrathoracic disease progression: risk ratio=5.71, 95% CI 0.84 to 36.74)."
183,36339926,MET,Non-Small Cell Lung Cancer,plasma,NGS,"All enrolled patients with baseline plasma samples were included. Outcomes were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) by baseline METex14 and post-treatment clearance, coexisting gene alterations at baseline and disease progression.",_,"atients with detectable baseline METex14 exhibited worse PFS [hazard ratio (HR), 1.77; 95% confidence interval (CI), 0.88-3.57; p = 0.108] and OS (HR, 3.26; 95% CI, 1.35-7.89; p = 0.006) than those without;METex14 post-treatment clearance was associated with better ORR (92.3%; 95% CI, 64.0-99.8 versus 36.4%; 95% CI, 10.9-69.2; p = 0.0078), PFS (HR, 0.44; 95% CI, 0.2-1.3; p = 0.1225) and OS (HR, 0.31; 95% CI, 0.1-1.0; p = 0.0397) versus non-clearance. Among 22 patients with disease progression, 10 acquired pathway alterations (e.g. in RAS/RAF and PI3K/PTEN) alone or with secondary MET mutations (D1228H/N and Y1230C/H/S).",_,_,_,_,_
184,34557222,ABL1,Non-Small Cell Lung Cancer,plasma,_,"In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP2A) and clinical information were further integrated.",_,"patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (¨C)",_,_,_,atezolizumab therapy,_
185,34557222,APC,Non-Small Cell Lung Cancer,plasma,_,"In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP3A) and clinical information were further integrated.",_,"patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (¨C)",_,_,_,atezolizumab therapy,_
186,34557222,LRP6,Non-Small Cell Lung Cancer,plasma,_,"In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP4A) and clinical information were further integrated.",_,"patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (¨C)",_,_,_,atezolizumab therapy,_
187,34557222,FUBP1,Non-Small Cell Lung Cancer,plasma,_,"In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP5A) and clinical information were further integrated.",_,"patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (¨C)",_,_,_,atezolizumab therapy,_
188,34557222,KEAP1,Non-Small Cell Lung Cancer,plasma,_,"In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP6A) and clinical information were further integrated.",_,"patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (¨C)",_,_,_,atezolizumab therapy,_
189,34557222,TOP2A,Non-Small Cell Lung Cancer,plasma,_,"In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP7A) and clinical information were further integrated.",_,"patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (¨C)",_,_,_,atezolizumab therapy,_
190,34169282,H3F3A,Diffuse Midline Glioma,plasma/serum/cerebrospinal fluid,next-generation sequencing (whole-exome sequencing and capture panel sequencing assays,"Liquid biopsies from multiple biological sources (plasma, serum, cerebrospinal fluid [CSF], and cystic fluid) were collected from 32 pHGG and DIPG patients with known molecular alterations from the sequencing of their tumor tissue",_,"In anecdotal cases where sufficient material was available, cfDNA concentration correlated with disease progression in two examples each of poor response in H3F3A_K27M-mutant DMG, and longer survival times in hemispheric BRAF_V600E-mutant cases.",_,_,_,_,_
191,34169282,BRAF,Diffuse Midline Glioma,plasma/serum/cerebrospinal fluid,next-generation sequencing (whole-exome sequencing and capture panel sequencing assays,"Liquid biopsies from multiple biological sources (plasma, serum, cerebrospinal fluid [CSF], and cystic fluid) were collected from 32 pHGG and DIPG patients with known molecular alterations from the sequencing of their tumor tissue",_,"In anecdotal cases where sufficient material was available, cfDNA concentration correlated with disease progression in two examples each of poor response in H3F3A_K27M-mutant DMG, and longer survival times in hemispheric BRAF_V600E-mutant cases.",_,_,_,_,_
192,29525631,EGFR,Lung Adenocarcinoma,plasma,super amplification refractory mutation system (SuperARMS),"A total of 79 tumor tissues and paired plasma samples were collected. The EGFR mutation status in tissue was tested by ADx-ARMS, matched plasma was detected by ddPCR and SuperARMS, respectively.",_,"the ORR was 67.6% (25/37) and 28.6% (4/14) respectively in patients with or without EGFR mutation, P = .025. Median PFS was significantly prolonged in EGFR mutation patients compared with EGFR wild-type patients (12.0months vs 5.0 months, P = .009).",_,_,_,TKI therapy,_
193,35117215,BRAF,Non-Small Cell Lung Cancer,plasma,HiSeq3000 sequencing system (Illumina),Kaplan-Meier survival curves were used to compare the prognostic difference of progression-free survival (PFS) and overall survival (OS) in different classes of BRAF mutations. Multivariate Cox proportional-hazards regression was used to determine the hazard ratio (HR) of different prognostic factors in survival.,_,"A significant improvement of OS was observed in patients with class 1 BRAF mutation than other groups (25 vs. 12, 15 and 14 months, P<0.0001). Multivariate analysis showed that first-line pemetrexed-based chemotherapy was associated with better PFS and OS (HR =0.16 and 0.31, respectively; P<0.001 and 0.02, respectively), as well as improved OS in patients with class 1 BRAF mutation than other classes (HR =2.15, P<0.001).",_,_,_,_,_
194,33126883,PREX2,Gastric Cancer,plasma,NGS,_,_,_,"Patients with PREX2 mutation tended to have lower PD-L1 CPS and fewer CD8+ T cells (Although not statistically significant, it might due to the limited PREX2 mutant samples), which indicated PREX2 mutation might have potential influence on tumor immune microenvironment and this is worthy of further exploring",_,_,_,_
195,36232820,KRAS,Pancreatic Cancer,plasma,NGS,_,_,"patients who had detectable KRAS mutations from plasma cfTNA that was concordant with tumor tissue had significantly shorter RFS (p < 0.0001, Figure 4b) than those who were ctDNA negative. This result indicates that screening of KRAS ctDNA alone might help to predict patients who have a higher risk of recurrence. Notably, among the patients who had detectable mutations in both TP53 and KRAS from plasma cfTNA were found to have the shortest RFS compared to those who did not have detectable TP53 or KRAS mutations (p = 0.0005) (Figure 4c). These high-risk patients had median RFS as short as 85 days",_,_,_,_,_
196,33432066,KRAS,Colorectal Cancer,plasma,ddpcr,"In this study, we measured the preoperative KRAS mutated ctDNA and evaluated any association with clinicopathologic factors. We also evaluated the usefulness of preoperative KRAS mutated ctDNA detection as a predictive marker of recurrence after CRC surgery.",_,"In Kaplan-Meier analysis, preoperative detection of KRAS mutated ctDNA was associated with inferior recurrence-free interval (RFI) (p = 0.002) and recurrence-free survival (RFS) (p = 0.025). In a multivariate Cox proportional hazards model, preoperative detection of KRAS mutated ctDNA was an independent factor related to both RFI (HR = 3.08; p = 0.012) and RFS (HR = 2.18; p = 0.044). Preoperative measurement of KRAS mutated ctDNA could be useful to decide postoperative treatment",_,_,_,_,_
197,31350822,BRAF,Colorectal Cancer,plasma,NGS/ddPCR,"this prospective multicenter study followed 34 patients with metastatic colorectal cancer who were tissue©\tested as RAS wild©\type (exons 2¨C4) during routine work©\up and received third©\line cetuximab monotherapy. BRAF mutation status was also tested but did not exclude patients from therapy. At baseline and upon disease progression, cell©\free DNA (cfDNA) was isolated for targeted next©\generation sequencing (NGS).",_,"Patients with any RAS/BRAF mutations in either tumor tissue or ctDNA had less treatment benefit than patients who had a negative test result. Eight of 13 (61.5%) patients without clinical benefit had a RAS/BRAF mutation versus one out of 21 (4.8%) patients with clinical benefit (P = 0.001). PFS was shorter for patients with RAS/BRAF mutations, with a median PFS of 1.8 months versus 4.9 months in wild©\type patients (P < 0.001, HR 4.3; 95% CI 1.8¨C10.0, ). In multivariate analysis, correcting for WHO performance status (0 versus 1¨C2) and left versus right©\sidedness, any RAS or BRAF mutation remained correlated with PFS (P = 0.004, HR 4.3; 95% CI 1.6¨C11.6). In line with PFS, OS was shorter in patients with RAS©\/BRAF©\mutated disease, with a median of 3.1 versus 9.4 months (P = 0.001, HR 3.9; 95% CI 1.6¨C9.3). Also, with multivariate analysis, corrected for sidedness and WHO performance status, any RAS/BRAF mutation remained correlated with OS (P = 0.007, HR 5.8; 95% CI 1.6¨C20.7).",_,_,_,_,_
198,31350822,RAS,Colorectal Cancer,plasma,NGS/ddPCR,"this prospective multicenter study followed 34 patients with metastatic colorectal cancer who were tissue©\tested as RAS wild©\type (exons 2¨C4) during routine work©\up and received third©\line cetuximab monotherapy. BRAF mutation status was also tested but did not exclude patients from therapy. At baseline and upon disease progression, cell©\free DNA (cfDNA) was isolated for targeted next©\generation sequencing (NGS).",_,"Patients with any RAS/BRAF mutations in either tumor tissue or ctDNA had less treatment benefit than patients who had a negative test result. Eight of 13 (61.5%) patients without clinical benefit had a RAS/BRAF mutation versus one out of 21 (4.8%) patients with clinical benefit (P = 0.001). PFS was shorter for patients with RAS/BRAF mutations, with a median PFS of 1.8 months versus 4.9 months in wild©\type patients (P < 0.001, HR 4.3; 95% CI 1.8¨C10.0, ). In multivariate analysis, correcting for WHO performance status (0 versus 1¨C2) and left versus right©\sidedness, any RAS or BRAF mutation remained correlated with PFS (P = 0.004, HR 4.3; 95% CI 1.6¨C11.6). In line with PFS, OS was shorter in patients with RAS©\/BRAF©\mutated disease, with a median of 3.1 versus 9.4 months (P = 0.001, HR 3.9; 95% CI 1.6¨C9.3). Also, with multivariate analysis, corrected for sidedness and WHO performance status, any RAS/BRAF mutation remained correlated with OS (P = 0.007, HR 5.8; 95% CI 1.6¨C20.7).",_,_,_,_,_
199,34134723,GNA11,Uveal Melanoma,plasma,ddPCR,"We used the highly sensitive digital droplet PCR (ddPCR) assay to quantify UM driver mutations (GNAQ, GNA11, PLCÎ²4 and CYSTLR2) in cell-free DNA (cfDNA). cfDNA was analyzed in six well established human UM cell lines with known mutational status. cfDNA was analyzed in the blood and aqueous humor of an UM rabbit model and in the blood of patients. Rabbits were inoculated with human UM cells into the suprachoroidal space, and mutated ctDNA was quantified from longitudinal peripheral blood and aqueous humor draws. Blood clinical specimens were obtained from primary UM patients (n = 14), patients presenting with choroidal nevi (n = 16) and healthy individuals (n = 15).",_,these data bring strong evidence that blood biopsy screening for human mutated GNA11/Q ctDNA biomarkers is a valuable and feasible tool for the early diagnosis of UM and the monitoring of disease progression.,"we found a significant positive correlation between ctDNA level and tumor size in all the rabbits (r = 0.60, P < 0.0001)",_,_,_,"a negative correlation between ctDNA level and body weight (r =   0.37, P < 0.0001);the levels of mutated ctDNA positively and significantly correlated with the presence of factors predisposing to nevus transformation (r = 0.92, P < 0.0001)"
200,34134723,GNAQ,Uveal Melanoma,plasma,ddPCR,"We used the highly sensitive digital droplet PCR (ddPCR) assay to quantify UM driver mutations (GNAQ, GNA11, PLCÎ²4 and CYSTLR2) in cell-free DNA (cfDNA). cfDNA was analyzed in six well established human UM cell lines with known mutational status. cfDNA was analyzed in the blood and aqueous humor of an UM rabbit model and in the blood of patients. Rabbits were inoculated with human UM cells into the suprachoroidal space, and mutated ctDNA was quantified from longitudinal peripheral blood and aqueous humor draws. Blood clinical specimens were obtained from primary UM patients (n = 14), patients presenting with choroidal nevi (n = 16) and healthy individuals (n = 15).",_,these data bring strong evidence that blood biopsy screening for human mutated GNA12/Q ctDNA biomarkers is a valuable and feasible tool for the early diagnosis of UM and the monitoring of disease progression.,"we found a significant positive correlation between ctDNA level and tumor size in all the rabbits (r = 0.60, P < 0.0001)",_,_,_,"a negative correlation between ctDNA level and body weight (r =   0.37, P < 0.0001);the levels of mutated ctDNA positively and significantly correlated with the presence of factors predisposing to nevus transformation (r = 0.92, P < 0.0002)"
201,34381078,KRAS,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"The PFS of the patients with pathogenic hotspot KRAS or NRAS mutations (N = 5) in baseline ctDNA was significantly shorter (p = 0.029, median PFS 3.7 months in mutants vs. 10.8 months in wild type). These KRAS/NRAS mutant patients showed tendency towards lower response rate (40.0% in mutants vs. 77.1% in wild type, p = 0.098)",_,_,_,_,_
202,34381078,NRAS,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"The PFS of the patients with pathogenic hotspot KRAS or NRAS mutations (N = 5) in baseline ctDNA was significantly shorter (p = 0.029, median PFS 3.7 months in mutants vs. 10.8 months in wild type). These KRAS/NRAS mutant patients showed tendency towards lower response rate (40.0% in mutants vs. 77.1% in wild type, p = 0.098)",_,_,_,_,_
203,34381078,BRAF,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"Among the ctDNA KRAS/NRAS wild type patients, patients with BRAF or MAP2K1 mutations (N = 3) showed trend towards shorter PFS (p = 0.14, median PFS 4.8 months in mutants vs. 10.8 months in wild type).",_,_,_,_,_
204,34381078,MAP2K1,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"Among the ctDNA KRAS/NRAS wild type patients, patients with BRAF or MAP2K1 mutations (N = 3) showed trend towards shorter PFS (p = 0.14, median PFS 4.8 months in mutants vs. 10.8 months in wild type).",_,_,_,_,_
205,32718341,RNF213,Cervical Cancers,plasma,NGS,"Using a bioinformatics approach, we designed a panel of 24 genes associated with CC to detect and characterize patterns of somatic single-nucleotide variations, indels, and copy number variations. Our NGS CC panel covers most of the genes in The Cancer Genome Atlas (TCGA) as well as additional cancer driver and tumor suppressor genes. We profiled the variants in ctDNA from 24 CC patients who were being treated with systemic chemotherapy and local radiotherapy at the Jeonbuk National University Hospital, Korea.",_,monitoring marker for response to chemo- and radiotherapy,_,_,_,_,_
206,36372873,EGFR,Non-Small Cell Lung Cancer,cerebrospinal fluid/plasma,NGS(Illumina HiSeq4000),"We conducted a prospective study of 92 newly diagnosed NSCLC patients with brain metastases. Paired CSF and plasma samples were collected at baseline, 8 weeks after treatment initiation, and disease progression. All samples underwent next-generation sequencing of 425 cancer-related genes.",_,"the detection of baseline-defined clonal EGFR mutations in the paired CSF samples 8 weeks after treatment was a poor predictive factor for intracranial PFS (HR = 7.76, P = 0.033),while the differences in the extracranial PFS were not statistically significant,A trend of shorter extracranial PFS was also observed in patients with clonal EGFR mutations in plasma 8 weeks after treatment compared to patients negative for clonal EGFR mutations (9.07 months vs 27.50 months, HR = 2.472, P = 0.265;)",_,_,_,_,_
207,29718453,ERBB2,Colorectal Cancer,plasma,NGS(Guardant360),"In once clincal study,We performed a retrospective analysis of 419 CRC patients from MD Anderson (MDACC) and 619 patients from the Nurses' Health Study (NHS)/Health Professionals Follow-Up Study (HPFS) with tissue sequencing, clinicopathologic, mutational, and consensus molecular subtype (CMS) profiles of ERBB2/ERBB3 mutant patients. A third cohort of 1623 CRC patients with ctDNA assays characterized the ctDNA profile of ERBB2 mutants. All statistical tests were two-sided.",_,"ERBB2 (hazard ratio [HR] = 1.82, 95% CI = 1.23 to 4.03, P = .009) mutations were associated with worse overall survival.",_,_,_,_,"PIK3CA mutations were strongly associated with ERBB2 mutations in all three cohorts (OR = 3.68, 95% CI = 1.83 to 7.41, P = .001; OR = 2.25, 95% CI = 1.11 to 4.58, P = .02; OR = 2.11, 95% CI = 1.25 to 3.58, P = .004)"
208,29718453,PIK3CA,Colorectal Cancer,plasma,NGS(Guardant360),"In once clincal study,We performed a retrospective analysis of 419 CRC patients from MD Anderson (MDACC) and 619 patients from the Nurses' Health Study (NHS)/Health Professionals Follow-Up Study (HPFS) with tissue sequencing, clinicopathologic, mutational, and consensus molecular subtype (CMS) profiles of ERBB2/ERBB3 mutant patients. A third cohort of 1623 CRC patients with ctDNA assays characterized the ctDNA profile of ERBB2 mutants. All statistical tests were two-sided.",_,_,_,_,_,_,"PIK3CA mutations were strongly associated with ERBB2 mutations in all three cohorts (OR = 3.68, 95% CI = 1.83 to 7.41, P = .001; OR = 2.25, 95% CI = 1.11 to 4.58, P = .02; OR = 2.11, 95% CI = 1.25 to 3.58, P = .004)"
209,31980592,PIK3CA,Breast Cancer,plasma,NGS,_,_,"MBC patients with PIK3CA mutations in helical domain had a specific ctDNA profile with high TMB and high FGFR aberration rate, which might lead to poor PFS for late-line therapy.",_,_,_,_,_
210,30333000,BRCA2,Metastatic Castration-Resistant Prostate Cancer,plasma,NGS,case report,_,_,_,_,_,"mCRPC with BRCA2 germline mutations could response to PARP inhibitor, which improves patient's outcome",_
211,33502820,KRAS,Lung Adenocarcinoma,plasma,ddPCR(QX201),"In once clinical study,we considered KRAS a relevant biomarker for investigating the prognostic role of ctDNA in patients with lung adenocarcinomas harbouring KRAS mutations. Using droplet digital polymerase chain reaction (ddPCR) technology for accurate quantification of mutated KRAS, we aimed to explore whether there was a difference in progression©\free survival (PFS) and overall survival (OS) between patients with and without detectable KRAS mutations in plasma at baseline. We also explored whether there was an association between the plasma concentration of mutated KRAS and PFS and OS.",_,The presence of detectable KRAS mutation in plasma at baseline was associated with worse PFS and OS. High concentration of mutated KRAS in ctDNA was an independent negative prognostic factor for both PFS and OS.,_,_,_,_,_
212,32297439,AR,Prostate Cancer,plasma,NGS(Guardant360),"This study included a heterogeneous group of 892 patients with advanced PCa (predominantly castrate-resistant prostate cancer) with AR alterations detected in ctDNA that underwent next-generation sequencing of 54 to 73 genes via Guardant360 testing (Guardant Health, Inc., Redwood City, CA). Distribution and summary of AR alterations detected, the association of AR alterations with other genes, and a pathway analysis are reported.",_,_,Alterations in APC were significantly associated with mutations in AR (p < .001).,_,_,_,_
213,32207862,KRAS,Colorectal Cancer,plasma,real-time PCR,"Templates harboring hotspot mutations of the KRAS gene were constructed, and primers were designed for evaluation of the specificity, and sensitivity of detection system consisted of exonuclease polymerase-mediated on/off switch; then, gel electrophoresis and real-time PCR were performed for verification. The assay was verified by testing the DNA pool of normal controls and circulating DNA (ctDNA) samples from 14 tumor patients, as compared to Sanger sequencing.",_,The total survival rate of colorectal cancer patients harboring KRAS mutations was significantly lower than that of the patients without KRAS mutations,_,_,_,_,_
214,34894454,EGFR,Non-Small Cell Lung Cancer,plasma,cobas 4800 system v2,"In FASTACT-2, patients with advanced NSCLC received platinum/gemcitabine intercalated with erlotinib or placebo. EGFR mutation (tumor and plasma ctDNA) was detected using cobas v2. Patients selected for this hypothesis-generating analysis had EGFR mutations (on either tumor or plasma) at baseline and evaluable week 8 plasma EGFR. Week 8 ctDNA and radiologic response status were correlated with survival using landmark cox regression analyses.",_,"Amongst those with SD at week 8, there was significantly longer survival for those with undetectable vs detectable ctDNA (PFS HR 0.27, 95% CI 0.13-0.57, p < 0.0001; OS HR 0.40, 95% CI 0.20-0.80, p = 0.009).",_,_,_,_,_
215,31945708,EGFR,Non-Small Cell Lung Cancer,plasma,ddpcr,"A total of 225 patients with advanced EGFR mutated NSCLC were included for consecutive blood sampling in this prospective multicentre study. Out of these, 146 patients received first line TKI and had a baseline blood sample available for EGFR mutation testing with the CobasÂ® EGFR mutation test V2. For examinations on clearing and clinical outcome, 98 patients who had detectable ctDNA at baseline and at least one follow-up blood sample were included.",_,"clearing of mutations from the blood during first line TKI served as a positive predictor for objective response rate (p = 0.0008), progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001). This was seen both for patients who cleared the ctDNA within the first 7 weeks of treatment and patients who cleared the ctDNA at a slower pace.",_,_,_,_,_
216,36103364,HTERT,Hepatocellular Carcinoma,plasma,NGS,_,_,_,mutation presence related to bTMB,_,_,_,_
217,36103364,TP53,Hepatocellular Carcinoma,plasma,NGS,_,_,_,mutation presence related to bTMB,_,_,_,_
218,33588113,TP53,Non-Small Cell Lung Cancer,plasma,NGS(Illumina HiSeq-X10),"In a multicenter phase 2 trial, patients with ALK-positive NSCLC who progressed on crizotinib were treated with ensartinib. Blood samples for ctDNA analysis were collected at baseline, cycle 3 day 1, and progression disease (PD) and analyzed with a 212-gene panel.",_,"Baseline TP53 mutations (20.2%) significantly correlated with inferior progression-free survival (4.2 mo versus 11.7 mo, p < 0.0001).","patients with TP53 mutations had significantly higher incidence of resistant secondary ALK mutations than those without TP53 mutations (TP53 mutations detected group, 15 of 29 [51.7%] versus TP53 mutations undetected group, 25 of 86 [29.1%], p = 0.027).",_,_,_,_
219,33414135,BRCA2,Prostate Cancer,plasma,NGS(associated with poor clinical outcomes.),"We performed targeted sequencing of 1,615 plasma cell-free DNA samples from 879 patients with metastatic prostate cancer. Depth-based copy-number calls and heterozygous SNP imbalance were leveraged to expose DDR-mutant allelic configuration and categorize mechanisms of biallelic loss. We used split-read structural variation analysis to characterize tumor suppressor rearrangements. Patient-matched archival primary tissue was analyzed identically.",_,associated with poor clinical outcomes.,_,_,_,_,_
220,33414135,CDK12,Prostate Cancer,plasma,NGS(associated with poor clinical outcomes.),"We performed targeted sequencing of 1,615 plasma cell-free DNA samples from 879 patients with metastatic prostate cancer. Depth-based copy-number calls and heterozygous SNP imbalance were leveraged to expose DDR-mutant allelic configuration and categorize mechanisms of biallelic loss. We used split-read structural variation analysis to characterize tumor suppressor rearrangements. Patient-matched archival primary tissue was analyzed identically.",_,associated with poor clinical outcomes.,_,_,_,_,_
221,35101045,HER2,Lung Adenocarcinoma,plasma,NGS,"In this multicenter, single-arm, phase II trial, stage IIIB-IV NSCLC patients harboring HER2 mutations, as determined using next-generation sequencing, were enrolled and treated with pyrotinib at a dose of 400 mg/day. The primary endpoint was 6-month progression-free survival (PFS) rate, and secondary endpoints were objective response rate (ORR), PFS, overall survival (OS), disease control rate (DCR), and safety. The impact of different HER2 mutation types on sensitivity to pyrotinib and the potential of utilizing mutational profile derived from circulating tumor DNA (ctDNA) to predict disease progression were also explored.",_,_,_,_,_,Pyrotinib exhibited promising efficacy and acceptable safety in NSCLC patients carrying exon 20 and non-exon 20 HER2 mutations,_
222,34381078,MAP2K1,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"Among the ctDNA KRAS/NRAS wild type patients, patients with BRAF or MAP2K1 mutations (N = 3) showed trend towards shorter PFS (p = 0.14, median PFS 4.8 months in mutants vs. 10.8 months in wild type).",_,_,_,_,_
223,34381078,BRAF,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"Among the ctDNA KRAS/NRAS wild type patients, patients with BRAF or MAP2K1 mutations (N = 3) showed trend towards shorter PFS (p = 0.14, median PFS 4.8 months in mutants vs. 10.8 months in wild type).",_,_,_,_,_
224,34452870,AR,Castrate Resistant Prostate Cancer,plasma,NGS(Illumina HiSeq 2500),"In this retrospective analysis, we analyzed 63 patients who underwent ctDNA genomic profiling during their mCRPC disease course using a CLIA-certified commercial assay. The primary objective was to assess the feasibility of commercial ctDNA analysis in a real world mCRPC cohort. Key secondary objectives included assessment of the landscape of pathogenic ctDNA alterations and the prognostic significance of ctDNA detection on overall survival (OS).",_,"in univariate analysis, the presence of an AR alteration was associated with inferior OS (HR-2.22, P = .014)",_,_,_,_,_
225,32629391,EGFR,Non-Small Cell Lung Cancer,plasma,PCR,"Plasma samples were collected from patients enrolled in NEJ026 at the start of treatment (P0), 6 weeks after the start of treatment (P1), and upon confirmation of progressive disease (P2). Plasma ctDNA was analyzed using a modified PNA-LNA PCR clamp method. PFS and OS according to EGFR status at the time of plasma collection were evaluated.",_,patients without plasma aEGFR had longer PFS.,_,_,_,_,_
226,34131001,BRCA,Breast Cancer,plasma,NGS,"Eligible patients (N = 513) were randomized 2:1 to veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel; patients had variable platinum-free intervals (PFI) at progression. In the placebo arm, patients were eligible to receive crossover veliparib monotherapy (300-400 mg twice daily continuous). Antitumor activity and adverse events were assessed during crossover veliparib treatment. BRCA reversion mutations at crossover were analyzed retrospectively using next-generation sequencing on plasma circulating tumor DNA (ctDNA).",BRCA reversion mutations may promote cross-resistance and limit veliparib activity following progression on platinum.,_,_,_,_,_,_
227,29707525,RAS,Colorectal Cancer,plasma,NGS(Illumina Hiseq 2500),"76 mCRC patients treated in Beijing Chao-Yang Hospital from 2011 to 2017 were enrolled. Genotyping of RAS/BRAF in tumor tissue and ctDNA was determined by ARMS PCR and with a 40-gene panel using NGS, respectively. Patient clinicopathologic features and RAS/BRAF gene mutation status were evaluated by survival analysis for disease-free survival (DFS) and progression-free survival (PFS).",_,"Mutations of RAS/BRAF had no significant impact on DFS after surgery (hazard ratio (HR), 1.205; 95% CI, 0.618 to 2.349; P = 0.5837) but prognosticated poorer PFS in subsequent first-line therapy (HR, 3.351; 95% CI, 1.172 to 9.576; P = 0.024).",_,_,_,_,_
228,29707525,BRAF,Colorectal Cancer,plasma,NGS(Illumina Hiseq 2500),"76 mCRC patients treated in Beijing Chao-Yang Hospital from 2011 to 2017 were enrolled. Genotyping of RAS/BRAF in tumor tissue and ctDNA was determined by ARMS PCR and with a 40-gene panel using NGS, respectively. Patient clinicopathologic features and RAS/BRAF gene mutation status were evaluated by survival analysis for disease-free survival (DFS) and progression-free survival (PFS).",_,"Mutations of RAS/BRAF had no significant impact on DFS after surgery (hazard ratio (HR), 1.205; 95% CI, 0.618 to 2.349; P = 0.5837) but prognosticated poorer PFS in subsequent first-line therapy (HR, 3.351; 95% CI, 1.172 to 9.576; P = 0.024).",_,_,_,_,_
229,32304999,KDM2B,Classical Hodgkin Lymphoma,plasma,NGS,A total of 192 plasma samples from 75 patients with r/r cHL were collected at baseline and upon therapeutic evaluation. ctDNA were sequenced by targeting panels capturing frequently mutated genes in cHL and other hematological malignancies and then quantified. Analysis on: 1) Gene mutation profile and association of the gene mutations with progression-free survival; 2) Association of pre- and post-treatment ctDNA variant allelic frequencies with clinical outcome; (3) Correlation of the mutated genes with treatment resistance; were performed.,may be resistance to anti-PD-1 immunotherapy,_,_,_,_,_,_
230,32304999,TNFRSF14,Classical Hodgkin Lymphoma,plasma,NGS,A total of 192 plasma samples from 75 patients with r/r cHL were collected at baseline and upon therapeutic evaluation. ctDNA were sequenced by targeting panels capturing frequently mutated genes in cHL and other hematological malignancies and then quantified. Analysis on: 1) Gene mutation profile and association of the gene mutations with progression-free survival; 2) Association of pre- and post-treatment ctDNA variant allelic frequencies with clinical outcome; (3) Correlation of the mutated genes with treatment resistance; were performed.,may be resistance to anti-PD-1 immunotherapy,_,_,_,_,_,_
231,34743450,TP53,Pancreatic Cancer,plasma,NGS,"A prospective cohort of 239 prostate cancer patients diagnosed in the Department of Urology, Fudan University Shanghai Cancer Center from May 2018 to June 2019 was included. The age of diagnosis was(65.4¡À7.6) years(range: 45 to 85 years). Clinical data were collected from patient diagnosis and treatment records as well as follow-up surveys. TP53 mutations in plasma were detected by target sequence capture and second-generation sequencing. The relationship between TP53 mutation status and progression-free survival(PFS) was analyzed in patients who received any treatment lines. Kaplan-Meier analysis was performed in different subgroups, survival curves were drawn, and Log-rank test was used for comparison. Cox regression models were used to estimate multivariate adjusted HR and 95%CI associated with PFS.",_,an independent prognostic factor for progression-free survival in patients treated with abiraterone and docetaxel.,_,_,TP53 mutations were associated with the presence of metastasis and castration resistance,_,_
232,35091442,KIT,Gastrointestinal Stromal Tumor,plasma,_,"This single-arm phase II trial enrolled patients with metastatic and/or unresectable GIST with failure of prior tyrosine kinase inhibitor (TKI) treatment into two cohorts based on presence or absence of KIT exon 11 (ex11) primary mutations. Patients initially received ponatinib 45 mg once daily. Following a temporary clinical hold in October 2013, dose reductions were implemented to reduce risk of arterial occlusive events (AOE). Primary endpoint was 16-week clinical benefit rate (CBR) in KIT ex11-positive cohort. KIT mutations in circulating tumor DNA (ctDNA) were assessed.",_,_,_,_,_,Ponatinib,_
233,31526460,EGFR,Lung Adenocarcinoma,plasma,_,"Our center enrolled 22 patients with EGFR mutation detected by tissue or peripheral blood, and collect 8 mL of peripheral blood of the patients for ctDNA sequencing in different phases, before systematic prior treatment, followed-up by 2 months and disease progression after TKI administration.",_,"Patients who has lower mutation abundance with EGFR sensitive mutations after TKI treatment may have a longer survival period (P<0.05), and the mutation abundance were not significantly dropping or accompanied by other mutations may indicating TKI resistance.",_,_,_,_,_
234,33122747,BRAF,Melanoma,plasma,dPCR,"In once clinical study,We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to clinical outcome.",_,ctDNA detection was associated with shorter progression free survival (p = 0.01).,_,_,_,_,_
235,33122747,NRAS,Melanoma,plasma,dPCR,"In once clinical study,We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to clinical outcome.",_,ctDNA detection was associated with shorter progression free survival (p = 0.01).,_,_,_,_,_
236,33122747,TERT,Melanoma,plasma,dPCR,"In once clinical study,We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to clinical outcome.",_,ctDNA detection was associated with shorter progression free survival (p = 0.01).,_,_,_,_,_
237,36357680,RICTOR,Non-Small Cell Lung Cancer,plasma,dPCR,_,_,"These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival",_,_,_,_,_
238,36357680,PIK3CA,Non-Small Cell Lung Cancer,plasma,dPCR,_,_,"These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival",_,_,_,_,_
239,34210686,E7,Cervical Cancers,Serum,ddPCR,"We analyzed serum samples from 94 HPV16- or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV E7 gene as a marker for residual disease compared to HPV integration site and PIK3CA mutations. Finally, the prognostic impact of circulating HPV E7 gene was assessed with its prediction value of relapse.",_,"Complete clearance of HPV ctDNA by the end of treatment was significantly associated with a longer PFS (P < 0.0001). Patients with persistent HPV ctDNA in serum relapsed with a median time of 10 months (range, 2-15) from HPV ctDNA detection.",HPV ctDNA detection in serum sample was associated with high FIGO stage (P = 0.02).,_,associated with para-aortic lymph node involvement (P = 0.01).,_,"The level of HPV ctDNA was positively correlated with HPV copy number in the tumor (R = 0.39, P < 0.001)."
240,31877464,TP53,Breast Cancer,plasma,NGS,"We performed longitudinal dynamic mutation analyses of plasma samples from 45 patients with metastatic breast cancer (MBC) and sequencing paired biopsy tissues, using a targeted NGS panel of 425 genes.",_,"the presence of TP53 mutations also demonstrated worse OS than wild type patients (P = 0.0135, P = 0.0299)",_,_,_,_,_
241,30150316,APC,Colorectal Cancer,plasma,ddPCR\NGS,SureSelectXT-HS (Agilent) was used to prepare sequencing libraries using our optimized protocol  and a custom designed SureSelect bait-library . Sequencing libraries were clustered using the cBot and sequenced with paired-end 75 reads on an Illumina HiSeq2500 in rapid mode.Low coverage whole genome sequencing (lcWGS).,_,_,_,_,_,_,all variants in the tumour suppressor genes APC and FBXW7 were truncating and hence likely driver mutations.
242,30150316,FBXW7,Colorectal Cancer,plasma,ddPCR\NGS,SureSelectXT-HS (Agilent) was used to prepare sequencing libraries using our optimized protocol  and a custom designed SureSelect bait-library . Sequencing libraries were clustered using the cBot and sequenced with paired-end 75 reads on an Illumina HiSeq2500 in rapid mode.Low coverage whole genome sequencing (lcWGS).,_,_,_,_,_,_,all variants in the tumour suppressor genes APC and FBXW7 were truncating and hence likely driver mutations.
243,33044511,PIK3CA,Breast Cancer,plasma/urine,ddPCR(QX200),"In a longitudinal analysis of 250 patients with early breast cancer, we compared the circulating cell-free DNA recovered from both plasma and urine specimens. For comparison, 50 healthy controls were also recruited. Specific mutations associated with the disease were profiled to determine the clinical sensitivity and specificity. Correlations of recovered concentrations of cell-free DNA with outcomes were examined to address early prognostication.",_,"For plasma cell-free DNA, the patient group with higher recovered content was linked to worse outcome and had an HR of 1.72 (95% CI: 1.29¨C2.29). Comparatively, the urine sample analysis showed similar trends with an HR value of 1.71 (95% CI: 1.28¨C2.28);For plasma DNA, patients with greater declines were less susceptible to relapse within the 3-year follow-up period (HR: 2.16; 95% CI: 1.62¨C2.89). A similar result was observed urinary DNA (HR: 2.48; 95% CI: 1.85¨C3.33). Overall, we observed that urinary DNA may be slightly better for risk stratification in this setting.",_,_,_,_,_
244,36562592,PIK3CA,Anal Squamous Cell Carcinoma,plasma,NGS,"We analyzed real-world data from 251 patients (817 plasma samples) with stages I-IV SCCA, collected between 11/5/19 and 5/31/22. The tumor genomic landscape and feasibility of ctDNA testing was examined for all patients. The prognostic value of longitudinal ctDNA testing was assessed in patients with clinical follow-up (N = 37).",_,"For patients with stages I-III disease, anytime ctDNA-positivity after definitive treatment was associated with reduced DFS (HR: 28.0; P = .005).",_,_,Anytime ctDNA positivity and higher ctDNA levels (MTM/mL) were associated with metastatic disease (P = .004).,_,_
245,32466779,ESR1,Breast Cancer,plasma,ddPCR,Patients with MBC treated with a first-line AI were prospectively included. Circulating biomarker assessment was performed every 3 months. The primary objective was to determine the risk of progression or death at the next follow-up visit (after 3 months) in case of circulating ESR1 mutation detection among patients treated with a first-line AI for HR+MBC.,_,"The present prospective study led to the quantification of the risk of early PD when circulating ESR1 mutations emerge under AI treatment in HR+MBC, with an increase in the risk of progression of 4.9-folds at 3 months and 3.3-folds at 6 months compared to patients without ESR1 mutations.",_,_,_,_,_
246,36959222,KRAS,Pancreatic Cancer,plasma,ddPCR,"We measured progression-free survival (PFS) and overall survival (OS) to assess prognosis. PFS was defined as the time from the start of chemotherapy to confirmation of progression based on initial radiological findings. OS was defined as the time from the start of chemotherapy to the occurrence of the event. A Cox proportional hazards regression model was used to evaluate the association between overall mortality and other factors in univariate and multivariate analyses. The following variables were analyzed in patients: sex; age at the start of chemotherapy (¡Ü 68 years vs. > 68 years); unresectable factor (stage III + stage IV vs. recurrence); chemotherapy (gemcitabine plus nab-paclitaxel vs. FOLFIRINOX); and the change in CA19-9 levels after chemotherapy. PFS and OS curves were constructed using the Kaplan¨CMeier method. Several factors with a P-value of < 0.1 in univariate analysis were subjected to multivariate analysis, and a P-value of 0.05 was considered statistically significant. All statistical analyses were performed using EZR version 1.31 (Saitama Medical Center, Jichi Medical University, Saitama, Japan). We also used R version 3.1.1 (The R Foundation for Statistical Computing, Vienna, Austria) as a graphical interface.",_,"The multivariate Cox proportional hazards regression model indicated that the presence of ctDNA (mPD + mSD) determined at initial molecular assessment was the only significant independent factor for prognosis in these patients (Hazard ratio = 2.973, P = 0.04056). In all 61 patients, the presence of ctDNA (detectable of ctDNA) also impacted on clinical outcomes including PFS and OS (PFS; P = 0.00174 by log-rank test, hazard ratio = 2.68, OS; P = 0.0000012 by log-rank test, hazard ratio = 5.22).",_,_,_,_,_
247,31199508,BRCA2,Pulmonary Lymphangioleiomyomatosis,plasma,NGS (Illumina NextSeq500 platform),"In our study, paired cfDNA and genomic DNA (gDNA) in blood samples were obtained from 23 LAM patients and seven healthy controls to explore mutations profiles of targeted 70 cancer-related genes.",_,_,_,_,_,_,potential driver genes
248,31199508,RAD50,Pulmonary Lymphangioleiomyomatosis,plasma,NGS (Illumina NextSeq500 platform),"In our study, paired cfDNA and genomic DNA (gDNA) in blood samples were obtained from 23 LAM patients and seven healthy controls to explore mutations profiles of targeted 70 cancer-related genes.",_,_,_,_,_,_,potential driver genes
249,37105452,ESR1,Breast Cancer,plasma,Multiplex digital PCR,"Using the naica  three-color digital PCR platform, we developed a screening assay allowing the detection of 11 ESR1 mutations and designed a sequential strategy for precise mutation identification. We then applied this strategy in the analysis of plasma circulating cell-free DNA from 109 HR+/HER2- MBC patients and performed a double-blind comparison study on a subset of patients with the multiplex assay used at the Institut Curie (IC) for the PADA-1 study.",_,_,_,_,"Thirty-one patients (28.4%) harboured at least one ESR1 mutation, with the following frequencies: D538G (41.03%), Y537S (25.64%), E380Q (10.26%), Y537N (10.26%), ""(536-540)"" (7.69%), Y537C (2.56%), and L536R (2.56%). The presence of ESR1 mutation(s) was significantly associated with liver metastases (p = 0.0091). A very good agreement (91%) was observed with the IC assay.",_,_
250,37175518,DNMT3A,Endometrial Cancer,plasma,NGS,"Circulating tumour DNA was extracted from 2 mL of blood plasma samples using the QiaSymphony SP automated system (QIAGEN, Redwood City, CA, USA) with magnetic bead extraction (QIASymphony DSP Circulating DNA kit). The TruSight Oncology 500 and TruSight Oncology 500 ctDNA protocols (Illumina) were used to prepare genomic sequencing libraries.The libraries were then sequenced on the NovaSeq 6000 platform (Illumina), and primary analysis, tumour mutational load, microsatellite instability status, and mapping were performed according to the TSO500 alignment and variant calling described by and annotated using Ingenuity Variant Analysis (IVA) software (QIAGEN, Redwood City, CA, USA, Software Build: 9.1.1.20230406).",_,_,"we identified 144 protein variants for the DNMT3A gene from the ctDNA samples, 33 of which were assigned as pathogenic. Almost 70% of identified pathogenic variants were localised in functional domains: 9% in the PWWP domain, 18% in the ADD domain, and 42% in the SAM-dependent MTase C5-type domain",_,_,_,_
251,32571788,BRCA1,Metastatic Breast Cancer,plasma,NGS,"Patients with MBC undergoing routine cell-free DNA (cfDNA) next generation sequencing (73 gene panel) before starting a new therapy were included. Somatic BRCA1/2 mutations were classified as known germline-pathogenic mutations or novel variants, and linked to clinicopathological characteristics. The effect of the PARP inhibitor olaparib was assessed in vitro, using cultured circulating tumor cells (CTCs) from a patient with a somatically acquired BRCA1 mutation and a second patient with an acquired BRCA2 mutation.",_,_,_,_,_,PARP inhibitors(olaparib),_
252,32571788,BRCA2,Metastatic Breast Cancer,plasma,NGS,"Patients with MBC undergoing routine cell-free DNA (cfDNA) next generation sequencing (73 gene panel) before starting a new therapy were included. Somatic BRCA1/2 mutations were classified as known germline-pathogenic mutations or novel variants, and linked to clinicopathological characteristics. The effect of the PARP inhibitor olaparib was assessed in vitro, using cultured circulating tumor cells (CTCs) from a patient with a somatically acquired BRCA1 mutation and a second patient with an acquired BRCA2 mutation.",_,_,_,_,_,PARP inhibitors(olaparib),_
253,35971249,TP53,Breast Cancer,plasma,NGS(Illumina Hiseq40000),"Formalin©\fixed paraffin©\embedded baseline tumor tissue biopsies of the primary tumor were collected. Genomic DNA from FFPE samples was extracted using QIAamp DNA FFPR Tissue Kit (QIAGEN, Hilden, Nordrhein Westfalen, Gernmany) .Cell©\free DNA (cfDNA) from plasma was extracted using QIAamp Circulating Nucleic Acid Kit (QIAGEN, Hilden, Nordrhein Westfalen, Gernmany). All samples were analyzed with NGS tests at a centralized clinical testing center (Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China), according to the protocols approved by the ethics committees of three hospitals. Enriched libraries were sequenced on Illumina Hiseq4000 NGS platforms (Illumina, San Diego, CA, USA). Kaplan¨CMeier curves for OS were generated, and log©\rank tests were used to compare differences between independent subgroups. Cox proportional hazards models were used to estimate hazard ratios of prognostic factors, and the proportionality of hazards was assessed using log( log) survival plots.",_,"Newly identified TP53 mutations after relapse and/or metastasis was another potential prognostic biomarker of poor prognosis; Of 35 patients in the baseline cohort, patients with TP53 mutations (P &lt; 0.01), or CTCF/GNAS mutations (P &lt; 0.01) displayed inferior disease-free survival, and patients harboring TP53 (P = 0.06) or NOTCH1 (P = 0.06) mutations showed relatively poor overall survival (OS), compared to patients with wild-type counterparts. Of the 59 patients with serial plasma samples, 11 patients who were newly detected with TP53 mutations had worse OS than patients whose TP53 mutational status remained negative (P &lt; 0.01).",_,_,_,_,_
254,35971249,CTCF,Breast Cancer,plasma,NGS(Illumina Hiseq40000),"Formalin©\fixed paraffin©\embedded baseline tumor tissue biopsies of the primary tumor were collected. Genomic DNA from FFPE samples was extracted using QIAamp DNA FFPR Tissue Kit (QIAGEN, Hilden, Nordrhein Westfalen, Gernmany) .Cell©\free DNA (cfDNA) from plasma was extracted using QIAamp Circulating Nucleic Acid Kit (QIAGEN, Hilden, Nordrhein Westfalen, Gernmany). All samples were analyzed with NGS tests at a centralized clinical testing center (Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China), according to the protocols approved by the ethics committees of three hospitals. Enriched libraries were sequenced on Illumina Hiseq4000 NGS platforms (Illumina, San Diego, CA, USA). Kaplan¨CMeier curves for OS were generated, and log©\rank tests were used to compare differences between independent subgroups. Cox proportional hazards models were used to estimate hazard ratios of prognostic factors, and the proportionality of hazards was assessed using log( log) survival plots.",_,CTCF/GNAS mutations (P &lt; 0.01) displayed inferior disease-free survival,_,_,_,_,_
255,35971249,NOTCH1,Breast Cancer,plasma,NGS(Illumina Hiseq40000),"Formalin©\fixed paraffin©\embedded baseline tumor tissue biopsies of the primary tumor were collected. Genomic DNA from FFPE samples was extracted using QIAamp DNA FFPR Tissue Kit (QIAGEN, Hilden, Nordrhein Westfalen, Gernmany) .Cell©\free DNA (cfDNA) from plasma was extracted using QIAamp Circulating Nucleic Acid Kit (QIAGEN, Hilden, Nordrhein Westfalen, Gernmany). All samples were analyzed with NGS tests at a centralized clinical testing center (Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China), according to the protocols approved by the ethics committees of three hospitals. Enriched libraries were sequenced on Illumina Hiseq4000 NGS platforms (Illumina, San Diego, CA, USA). Kaplan¨CMeier curves for OS were generated, and log©\rank tests were used to compare differences between independent subgroups. Cox proportional hazards models were used to estimate hazard ratios of prognostic factors, and the proportionality of hazards was assessed using log( log) survival plots.",_,"NOTCH1 (P = 0.06) mutations showed relatively poor overall survival (OS), compared to patients with wild-type counterparts.",_,_,_,_,_
256,35301118,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,_,_,"In the univariable analysis, log(VAF) (HR, 1.183; P = 0.001) was significantly associated with worse OS. In the multivariable analysis, after adjusting age and previous therapy treatment, log(VAF) (HR, 1.236; P = 0.000) was significantly associated with worse OS",_,_,_,_,_
257,35301118,KRAS,Non-Small Cell Lung Cancer,plasma,NGS,_,_,"In the univariable analysis, log(VAF) (HR, 1.241; P = 0.000) was significantly associated with worse OS. In the multivariable analysis, after adjusting sex and smoking status, log(VAF) (HR, 1.245; P = 0.000) was significantly associated with worse OS",_,_,_,_,_
258,29628508,JAK1,Liver Cancer,plasma,ddPCR\NGS,_,_,_,_,_,_,_,JAK1 mutations are potentially druggable and oncogenic potential
259,34511398,KRAS,Pancreatic Cancer,plasma,NGS,"Serial plasma samples from 42 patients with KRAS mutated pancreatic cancer were prospectively collected and the ctKRAS Mutation Assay (Idylla , Biocartis, Mechelen, Belgium) of cft-DNA was performed on 29 patients that did not receive curative surgery and went on to palliative chemotherapy. To monitor cft-DNA KRAS mutation levels during treatment quantitative assessment of cft-DNA was performed at baseline and during follow up at predetermined times.",_,"All 29 patients included in our analyses had a detected KRAS mutation in the tumor biopsy. In almost half (48.2%) of patients a KRAS mutation could also be detected in peripheral plasma. Patients with detectable KRAS mutations before treatment start in plasma had a significantly worse survival (16.8 months vs not reached, p < 0.031 and HR 3.303). Looking for a dynamic assessment of tumor response, we found a statistically significant association between the KRAS mutant ratio from first staging CT scan to basal levels with tumor response or progress (p = 0.014).",significant inverse correlation between KRAS mutation ratio and tumor marker (CA 19-9) ratio (p < 0.001).,_,_,_,_
260,31322322,RAS,Colorectal Cancer,plasma,BEAMing,"Blood samples (4 mL) were collected in CellSave  Preservative Tubes (Menarini©\Silicon Biosystems, Bologna, Italy), and plasma was isolated within 48 h. For nontrial patients, 10 mL of blood was collected in EDTA tubes and plasma was isolated within 1 h. Circulating free DNA (cfDNA) was performed with the QIAamp Circulating Nucleic Acid Kit (QIAGEN, Venlo, Netherlands) according to the manufacturer's instructions. DNA quality and concentration were measured with a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham, MA, USA). RAS status was determined in plasma using BEAMing (Sysmex Corporation, Kobe, Japan). The commercially available, and previously validated (Grasselli et al., 2017), CE©\IVD BEAMing RAS plasma panel of mutations was evaluated. Statistical analyses were performed using r 3.4.1, r studio and the cran r survival package. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Survival curves were estimated using the Kaplan¨CMeier method. Log©\rank tests, including univariate and multivariate Cox proportional hazards models, were performed for key endpoints.",_,Multivariate analysis showed RAS MAFs as an independent prognostic factor in both OS (HR = 2.73; P = 0.006) and first-line PFS (HR = 3.74; P = 0.049). Tumor response to treatment in patients with higher MAF was progression disease (P = 0.007). Patients with low MAFs at baseline in the CAPRI-GOIM group also showed better OS [HR = 3.84; 95% confidence intervals (CI) 1.5-9.6; P = 0.004] and better PFS (HR = 2.5; 95% CI: 1.07-5.62; P = 0.033). This minimally invasive test may help in adding an independent factor to better estimate outcomes before initiating treatment.,"MAF median values were calculated according to metastatic spread involving the liver, lung, lymph nodes, or peritoneum (most patients had more than one metastatic site). Median MAF was significantly lower in patients with metastases in the peritoneum compared to those with metastases in the liver (P = 0.0003), lung (P = 0.044), or lymph nodes (P = 0.025;)",_,_,_,_
261,27640882,KRAS,Non-Small Cell Lung Cancer,plasma,dPCR,"Serial plasma samples from lung adenocarcinoma patients treated with TKIs were used to quantify EGFR and KRAS mutations in circulating DNA by digital PCR. Mutant DNA levels were compared with the courses of responses to treatment with TKIs, conventional chemotherapy, radiotherapy, or combinations thereof. We quantified prominent mutations in EGFR and KRAS genes in cell free DNA using digital PCR assays and compared these to the clinical progression data of the same patients.",_,related to worse prognosis,_,_,_,_,_
262,27576846,TP53,De-Differentiated Liposarcoma,plasma,dPCR,_,inhibitor of the HDM2-p53 interaction (SAR405838),_,increase in tumour size by computed tomography significantly correlated with increased TP53 mutation burden,_,_,"Given the rapidity with which TP53 mutations emerged, we hypothesize that HDM2 antagonists will likely require development in combination with other agents. Various combination partners, including a mutant p53 activating drug like APR-246, MEK or PI3K inhibitors, or Bcl-2 inhibitors, have been proposed",_
263,37176143,PIK3CA,Colorectal Cancer,plasma,NGS,"In this study, we systematically analyzed the mutations of RAS, PIK3CA and BRAF genes in circulating tumor DNA (ctDNA) and tumoral tissue DNA (ttDNA) from 51 synchronous metastatic colorectal carcinoma (SMCC) patients by real-time PCR, and their relationship with the clinical, biological and histological features of disease at diagnosis. The highest frequency of mutations detected was in the KRAS gene, in tumor biopsies and plasma samples, followed by mutations of the PIK3CA, NRAS and BRAF genes.",_,"the presence of mutations in the RAS, PIK3CA and/or BRAF genes in the plasma of patients with SMCC is an independent prognostic factor for OS. The data also provide evidence that the number of mutations is negatively correlated with the OS of patients, regardless of the treatment they receive.",_,the best method for predicting the disease prognosis is the mutational characterization of the EGFR signaling pathway genes in the patient¡¯s plasma (vs. tumor tissue). Testing ctDNA in peripheral blood (liquid biopsy) has emerged as a new and useful tool in the diagnosis and follow-up of sCRC patients. Detection of the mutational status of genes involved in the EGFR signaling pathway genes in ctDNA from blood samples seems to be a simple and non-invasive alternative to testing primary tumors.,_,_,_
264,37176143,RAS,Colorectal Cancer,plasma,NGS,"In this study, we systematically analyzed the mutations of RAS, PIK3CA and BRAF genes in circulating tumor DNA (ctDNA) and tumoral tissue DNA (ttDNA) from 51 synchronous metastatic colorectal carcinoma (SMCC) patients by real-time PCR, and their relationship with the clinical, biological and histological features of disease at diagnosis. The highest frequency of mutations detected was in the KRAS gene, in tumor biopsies and plasma samples, followed by mutations of the PIK3CA, NRAS and BRAF genes.",_,"the presence of mutations in the RAS, PIK3CA and/or BRAF genes in the plasma of patients with SMCC is an independent prognostic factor for OS. The data also provide evidence that the number of mutations is negatively correlated with the OS of patients, regardless of the treatment they receive.",_,the best method for predicting the disease prognosis is the mutational characterization of the EGFR signaling pathway genes in the patient¡¯s plasma (vs. tumor tissue). Testing ctDNA in peripheral blood (liquid biopsy) has emerged as a new and useful tool in the diagnosis and follow-up of sCRC patients. Detection of the mutational status of genes involved in the EGFR signaling pathway genes in ctDNA from blood samples seems to be a simple and non-invasive alternative to testing primary tumors.,_,_,_
265,37176143,BRAF,Colorectal Cancer,plasma,NGS,"In this study, we systematically analyzed the mutations of RAS, PIK3CA and BRAF genes in circulating tumor DNA (ctDNA) and tumoral tissue DNA (ttDNA) from 51 synchronous metastatic colorectal carcinoma (SMCC) patients by real-time PCR, and their relationship with the clinical, biological and histological features of disease at diagnosis. The highest frequency of mutations detected was in the KRAS gene, in tumor biopsies and plasma samples, followed by mutations of the PIK3CA, NRAS and BRAF genes.",_,"the presence of mutations in the RAS, PIK3CA and/or BRAF genes in the plasma of patients with SMCC is an independent prognostic factor for OS. The data also provide evidence that the number of mutations is negatively correlated with the OS of patients, regardless of the treatment they receive.",_,the best method for predicting the disease prognosis is the mutational characterization of the EGFR signaling pathway genes in the patient¡¯s plasma (vs. tumor tissue). Testing ctDNA in peripheral blood (liquid biopsy) has emerged as a new and useful tool in the diagnosis and follow-up of sCRC patients. Detection of the mutational status of genes involved in the EGFR signaling pathway genes in ctDNA from blood samples seems to be a simple and non-invasive alternative to testing primary tumors.,_,_,_
266,30425037,BRCA,High-Grade Ovarian Carcinoma,plasma,NGS,"To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA.",BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment.,"Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001).",_,_,_,_,_
267,36543146,ARID1A,Urothelial Cancer,plasma,NGS,"we performed genomic analyses of primary tumors, metastases, and plasma collected from individual patients to define the concordance of actionable genomic alterations and to identify drivers of metastatic disease progression.","Our finding of frequent discordance in ARID1A mutational status in primary and metastatic samples may have therapeutic implications, as ARID1A has emerged as a potential biomarker of immune checkpoint inhibitor sensitivity and may also be predictive of EZH2 inhibitor sensitivity.","cfDNA analysis also identified a V553M FGFR3 mutation, a previously unreported FGFR3 mutation that is near the putative gatekeeper and therefore a likely contributor to acquired erdafitinib resistance in this patient.","We observed a high degree of discordance of actionable genomic alterations, with 23% discordant between primary and metastatic disease sites. Among chromatin-modifying genes, ARID1A mutations, when discordant, were exclusive to the metastatic tumor samples. ARID1A was the only chromatin-modifying gene more commonly mutated in high-grade invasive and metastatic samples (25% and 28%, respectively) compared with low- and high-grade non-invasive tumors (14% and 19% respectively; 4-group comparison q = 0.06)",plasma cell-free DNA (cfDNA) can identify alterations not detected by tumor sequencing. the results suggest that cfDNA analysis is complementary to analyses of archival primary tumor tissue or biopsy of a single metastatic site for guiding treatment selection in patients with metastatic urothelial cancer and that analysis of both tissue and cfDNA may be required for some patients.,_,_,_
268,31870098,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,"Somatic mutation of EGFR gene was studied in both tissue specimens and plasma. Then, mutations were detected by polymerase chain reaction(PCR) and sequencing.",_,_,_,"We observed a high concordance (90%) between tissue samples and cfDNA for EGFR gene mutation. The sensitivity, accuracy, and positive precision value were 90%, 90% and 100%, respectively. A false negative rate of 10% was also demonstrated in this study.",_,_,_
269,33770081,KRAS,Colorectal Cancer,plasma,NGS\dPCR,"Literature search was performed in Pubmed, Embase, and Cochrane Library. After removing duplicates from the 170 publications found by literature search, eligible studies were identified using pre-defined criteria. Quality of the publications and relevant data were assessed and extracted thereafter. Meta-DiSc and STATA softwares were used to pool the accuracy parameters from the extracted data.","The first finding was that mutations in KRAS exon 2 were linked to poor response in mCRC patients treated by anti-EGFR therapy. Later, mutations in KRAS exon 3 and 4 (codons 61, 117, and 146), and in NRAS exons 2, 3, 4 were also found to be associated with resistance to anti-EGFR therapy in mCRC patients .",_,_,_,_,_,_
270,32379795,KRAS,Colorectal Cancer,plasma,ddPCR\NGS,"To evaluate the concordance in a clinical setting, we enrolled 54 patients with metastatic colorectal cancer and analyzed their plasma cfDNA, gDNA from peripheral blood mononuclear cells (PBMC), and gDNA from available matched tumor tissues using ultra-deep sequencing targeting 10 genes (38-kb size) recurrently mutated in colorectal cancer. We first established a highly reliable cut-off value using reference material. The sensitivity of detecting KRAS hotspot mutations in plasma was calculated as 100%, according to digital droplet PCR. We could selectively detect clinically important somatic alterations with a variant allele frequency as low as 0.18%. We next compared somatic mutations of the 10 genes between cfDNA and genomic DNA from tumor tissues and observed an overall 93% concordance rate between the two types of samples.",_,the concordance rate of patients with the time interval between liquid biopsy and tumor tissue biopsy within 6 months and no prior exposure to chemotherapy was much higher than those without. The patients with KRAS mutant fragments in plasma had poor prognosis than those without the mutant fragments (33 months vs. 63 months; p<0.05).,_,_,"a positive correlation between plasma levels of mutated KRAS fragments and burden of metastatic liver lesions (n = 12, R2 = 0.55, Spearman¡¯s ¦Ñ = 0.69). A positive correlation was also observed between metastatic burden in the liver and plasma KRAS VAF. Meanwhile, among patients with at least one metastatic liver lesion, the results of the samples were analyzed according to the time interval between liquid and tumor tissue biopsies . The concentration of cfDNA was positively correlated with the fraction of ctDNA. In addition, KRAS VAF (%) correlated positively with liver metastatic burden. Overall, these results suggest that KRAS mutant fragments in plasma can reflect the status of patients with metastatic colorectal cancer.",_,_
271,31900123,APC,Colorectal Cancer,plasma,NGS Illumina NextSeq 500,case report,_,_,_,_,_,FOLFIRI + Bevacizumab,_
272,31900123,TP53,Colorectal Cancer,plasma,NGS Illumina NextSeq 500,case report,_,_,_,_,_,FOLFIRI + Bevacizumab,_
273,31900123,THSD7B,Colorectal Cancer,plasma,NGS Illumina NextSeq 500,case report,_,_,_,_,_,FOLFIRI + Bevacizumab,_
274,25994408,ESR1,Breast Cancer,plasma,NGS,"DNA was extracted from primary and metastatic tumors,PCR amplification and Sanger sequencing,Plasma DNA extraction,Digital fluorescence quantitative PCR analysis,In this study, 0.1% of the mutant copies were considered to be the relevant threshold for distinguishing positive from negative samples",Aromatase inhibitors,_,_,dPCR is a promising tool for biopsy-free and Next Generation Sequencing (NGS)-free monitoring for HR+ metastatic tumors and may assist in determining the treatment strategy.,_,_,_
275,28385781,NRAS,Multiple Myeloma,Serum,WES(The target coverage of > 85 ¡Á was achieved for 100% of exonic regions),Mutations of interest were identified in bone marrow biopsies or purified bone marrow plasma cells and subsequently measured in serum by mutation-specific digital droplet polymerase chain reaction (DDPCR) .,_,_,"The concentration of mutated alleles in serum correlated with the fraction in bone marrow plasma cells (r=0.507, n=34, P<0.002).",_,_,_,There was a striking covariation between circulating mutation levels and M protein in ten out of 11 patients with sequential samples.
276,28385781,KRAS,Multiple Myeloma,Serum,WES(The target coverage of > 85 ¡Á was achieved for 100% of exonic regions),Mutations of interest were identified in bone marrow biopsies or purified bone marrow plasma cells and subsequently measured in serum by mutation-specific digital droplet polymerase chain reaction (DDPCR) .,_,_,"The concentration of mutated alleles in serum correlated with the fraction in bone marrow plasma cells (r=0.507, n=34, P<0.002).",_,_,_,There was a striking covariation between circulating mutation levels and M protein in ten out of 11 patients with sequential samples.
277,28385781,BRAF,Multiple Myeloma,Serum,WES(The target coverage of > 85 ¡Á was achieved for 100% of exonic regions),Mutations of interest were identified in bone marrow biopsies or purified bone marrow plasma cells and subsequently measured in serum by mutation-specific digital droplet polymerase chain reaction (DDPCR) .,_,_,"The concentration of mutated alleles in serum correlated with the fraction in bone marrow plasma cells (r=0.507, n=34, P<0.002).",_,_,_,There was a striking covariation between circulating mutation levels and M protein in ten out of 11 patients with sequential samples.
278,37131253,PREX2,Gastric Cancer,plasma/cerebrospinal fluid,NGS,"In once clinical study,We retrospectively studied 15 patients with GCLM, all of whom had primary tumor tissue samples paired with postLM CSF samples, while 5 patients also had postLM plasma samples. All samples were analyzed using second-generation sequencing (NGS), and their molecular and clinical characteristics correlated with clinical outcomes",_,_,_,_,potential Leptomeningeal metastases(LM) progression-related markers(P = 0.014),_,_
279,37131253,IGF1R,Gastric Cancer,plasma/cerebrospinal fluid,NGS,"In once clinical study,We retrospectively studied 15 patients with GCLM, all of whom had primary tumor tissue samples paired with postLM CSF samples, while 5 patients also had postLM plasma samples. All samples were analyzed using second-generation sequencing (NGS), and their molecular and clinical characteristics correlated with clinical outcomes",_,_,_,_,potential Leptomeningeal metastases(LM) progression-related markers(P = 0.034),_,_
280,37131253,AR,Gastric Cancer,plasma/cerebrospinal fluid,NGS,"In once clinical study,We retrospectively studied 15 patients with GCLM, all of whom had primary tumor tissue samples paired with postLM CSF samples, while 5 patients also had postLM plasma samples. All samples were analyzed using second-generation sequencing (NGS), and their molecular and clinical characteristics correlated with clinical outcomes",_,_,_,_,potential Leptomeningeal metastases(LM) progression-related markers(P = 0.038),_,_
281,33122107,CDK4,Non-Small Cell Lung Cancer,cerebrospinal fluid,NGS,"Patients with EGFR-mutated advanced NSCLC with LM were included: cohort 1, patients with LM who were treated with osimertinib with CSF and plasma genotyping performed before the first dosing of osimertinib (baseline, n = 45); cohort 2, CSF genotyping on progression on osimertinib and development of LM (the progression event on osimertinib is the diagnosis of LM, n = 38). Circulating tumor DNA in CSF underwent next-generation sequencing.",_,"Concurrent CDK4 (2.8 versus 11.6 mo, p = 0.002) and CDKN2A (2.5 versus 9.6 mo, p = 0.04) mutation with EGFR-sensitizing mutations indicated lower median iPFS.",_,_,_,_,_
282,33122107,CDKN2A,Non-Small Cell Lung Cancer,cerebrospinal fluid,NGS,"Patients with EGFR-mutated advanced NSCLC with LM were included: cohort 1, patients with LM who were treated with osimertinib with CSF and plasma genotyping performed before the first dosing of osimertinib (baseline, n = 45); cohort 2, CSF genotyping on progression on osimertinib and development of LM (the progression event on osimertinib is the diagnosis of LM, n = 39). Circulating tumor DNA in CSF underwent next-generation sequencing.",_,"Concurrent CDK4 (2.8 versus 11.6 mo, p = 0.002) and CDKN2A (2.5 versus 9.6 mo, p = 0.04) mutation with EGFR-sensitizing mutations indicated lower median iPFS.",_,_,_,_,_
283,31548343,KRAS,Non-Small Cell Lung Cancer,plasma,ddPCR,Targeted sequencing of cell-free tumor DNA obtained from 289 patients with advanced METex14 mutant NSCLC was performed.,_,_,more common in METex14-mutated NSCLC than in EGFR-mutated NSCLC,_,_,_,_
284,27919627,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,"Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m2 provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2¨C17) every 21 days. EGFR genotype was centrally confirmed by Sequenom multiplex oncogenotyping assay. The primary end point was progression-free survival (PFS), which would be considered promising for future study if median PFS was ¡Ý 4.5 months.",_,_,_,_,_,pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns,_
285,34503977,KIT,Gastrointestinal Stromal Tumor,plasma,NGS(Guardant360),Tumor tissue and liquid biopsy samples that captured circulating tumor DNA were collected prior to study enrollment and sequenced using next-generation sequencing. Subgroups were determined by KIT/PDGFRA mutations and correlation of clinical outcomes and KIT/PDGFRA mutational status was assessed.,_,_,_,_,_,Ripretinib,_
286,34503977,PDGFRA,Gastrointestinal Stromal Tumor,plasma,NGS(Guardant360),Tumor tissue and liquid biopsy samples that captured circulating tumor DNA were collected prior to study enrollment and sequenced using next-generation sequencing. Subgroups were determined by KIT/PDGFRA mutations and correlation of clinical outcomes and KIT/PDGFRA mutational status was assessed.,_,_,_,_,_,Ripretinib,_
287,26484608,EGFR,Lung Adenocarcinoma,plasma,_,"One hundred and twelve advanced pulmonary adenocarcinoma patients who were going to receive epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were included. Tumor tissue and plasma specimens were collected before treatment and analyzed for EGFR mutation and plasma IL-6 and IL-8. Pre-treatment peripheral blood CD146+/CD3- cells (as circulating endothelial cells, CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), and CD133+ cells (as cancer stem cells, CSCs) were measured with flow cytometry.",_,Multivariate analysis showed that mutant plasma EGFR (pEGFR) was a poor prognostic factor in EGFR-mutated patients (p = 0.048),_,_,_,_,_
288,30487126,EGFR,Colorectal Cancer,plasma,NGS,Plasma samples collected from panitumumab-treated patients in the ASPECCT study at baseline and safety follow-up (SFU) were analyzed by a next-generation sequencing¨Cbased approach for extended RAS mutant allele frequency as a continuous variable and their association with clinical outcomes and the mutational prevalence of 63 cancer-related genes. The correlation between patient outcome and baseline mutational status of EGFR pathway genes was also examined.,_,"Baseline mutations in EGFR pathway genes, when analyzed both categorically and continuously, were associated with shorter survival.When mutations in EGFR pathway genes were analyzed continuously, higher mutant allele frequency correlated with poorer outcomes. However, extended RAS mutation, by itself, did not preclude clinical responses to panitumumab in a monotherapy setting.",_,_,_,_,_
289,35296442,PIK3CA,Colorectal Cancer,plasma,ARMS-qPCR,"Primary CRC tissue samples and paired plasma samples were collected from 70 patients. After DNA extraction, PCR-direct sequencing was used to screen for mutations in PIK3CA exon 9 and APC exon 15 in tumor tissues. Amplification Refractory Mutation System (ARMS)-quantitative PCR (qPCR) was used to evaluate KRAS codon 12 and 13, BRAF V600E, and PIK3CA exon 9 hotspot mutations.",_,_,The co-existence of KRAS/PIK3CA/APC gene mutations encompassed the highest frequency among all combinations of mutations; PIK3CA mutations were significantly more frequent in older patients.,_,_,_,_
290,35296442,APC,Colorectal Cancer,plasma,ARMS-qPCR,"Primary CRC tissue samples and paired plasma samples were collected from 70 patients. After DNA extraction, PCR-direct sequencing was used to screen for mutations in PIK3CA exon 9 and APC exon 15 in tumor tissues. Amplification Refractory Mutation System (ARMS)-quantitative PCR (qPCR) was used to evaluate KRAS codon 12 and 13, BRAF V600E, and PIK3CA exon 9 hotspot mutations.",_,_,The co-existence of KRAS/PIK4CA/APC gene mutations encompassed the highest frequency among all combinations of mutations.,_,_,_,_
291,35296442,KRAS,Colorectal Cancer,plasma,ARMS-qPCR,"Primary CRC tissue samples and paired plasma samples were collected from 70 patients. After DNA extraction, PCR-direct sequencing was used to screen for mutations in PIK3CA exon 9 and APC exon 15 in tumor tissues. Amplification Refractory Mutation System (ARMS)-quantitative PCR (qPCR) was used to evaluate KRAS codon 12 and 13, BRAF V600E, and PIK3CA exon 9 hotspot mutations.",_,_,The co-existence of KRAS/PIK5CA/APC gene mutations encompassed the highest frequency among all combinations of mutations.,_,_,_,_
292,37101291,PIK3CA,Breast Cancer,plasma,_,"To understand the role of multiple PIK3CAmut in predicting response to p110Î± inhibition, we estimated the clonality of multiple PIK3CAmut in circulating tumor DNA (ctDNA) from patients with HR+/HER2- metastatic breast cancer enrolled to a prospectively registered clinical trial of fulvestrant Â± taselisib, and analyzed the subgroups against co-altered genes, pathways, and outcomes.",_,patients whose ctDNA harbored clonal multiple PIK3CAmut exhibited a significantly higher response rate and longer progression-free survival vs subclonal multiple PIK3CAmut.,_,_,_,fulvestrant ¡À taselisib,an important molecular determinant of response to p110¦Á inhibition
293,29848757,EGFR,Non-Small Cell Lung Cancer,plasma,dPCR,"In once clinical study,We performed tagged©\amplicon deep sequencing (TAm©\Seq; Forshew et al, 2012) for de novo identification and quantification of mutations in EGFR exons 18¨C21, coding regions of TP53 and PTEN, and selected hotspot regions of PIK3CA, KRAS and BRAF; and digital PCR for detection and quantification of hotspot mutations in EGFR. For a subset of patients, we also performed shallow whole©\genome sequencing to analyse global copy number changes during treatment",_,Patients with both TP53 and EGFR mutations before treatment had worse overall survival than those with only EGFR Patients who progressed without T790M had worse PFS during TKI continuation,_,_,_,_,_
294,29848757,TP53,Non-Small Cell Lung Cancer,plasma,dPCR,"In once clinical study,We performed tagged©\amplicon deep sequencing (TAm©\Seq; Forshew et al, 2012) for de novo identification and quantification of mutations in EGFR exons 18¨C21, coding regions of TP53 and PTEN, and selected hotspot regions of PIK3CA, KRAS and BRAF; and digital PCR for detection and quantification of hotspot mutations in EGFR. For a subset of patients, we also performed shallow whole©\genome sequencing to analyse global copy number changes during treatment",_,Patients with both TP53 and EGFR mutations before treatment had worse overall survival than those with only EGFR Patients who progressed without T790M had worse PFS during TKI continuation,_,_,_,_,_
295,36644936,KRAS,Pancreatic Ductal Adenocarcinoma,plasma,ddPCR(QX100),"221 blood samples from 108 PDAC patients (65 curative, 43 palliative) were analyzed. Baseline peripheral and tumor-draining portal venous (PV), postoperative, and follow-up blood were analyzed and correlated with prognosis.",_,"KRAS detection in pre- and postoperative and PV blood were significantly associated with shorter recurrence-free survival (all P < 0.015) and identified as independent prognostic markers. KRAS ctDNA status was also an independent unfavorable prognostic factor for shorter overall survival in both palliative and curative cohorts(hazard ratio [HR] 4.9, P = 0.011; HR 6.9, P = 0.008)",_,_,_,_,_
296,18379354,TP53,Non-Small Cell Lung Cancer,plasma,_,"Plasma samples, adjacent lung tissue, and lung tumor tissue specimens were collected from consecutive patients with stage I-III NSCLC. Blood samples of 66 matched healthy donors with positive smoking history were collected as controls. The plasma DNA amount was determined by real-time PCR. The analysis of MA on chromosome 3p was performed by radiolabeled PCR. p53 Mutations (exons 5, 6, 7, and 8) were detected by PCR-single-strand conformational polymorphism assay.",_,p53 mutations was found to be significantly associated with recurrence of disease (p = 0.026).,_,"MA (microsatellite alterations) and p52 mutations in tumor DNA have a potential prognostic role for disease recurrence in NSCLC patients, and elevated levels of plasma circulating DNA identify patients with possible systemic disease at diagnosis. This might be proposed as an early detection test of disease recurrence.",_,_,_
297,36578946,KRAS,Colorectal Cancer,plasma,NGS,"In this prospective multi-center study, 103 CRC patients eligible for curative-intent surgery were recruited. Genomic DNA from tumor tissue and paired white blood cells were sequenced to profile all tumor-derived somatic mutations in 95 cancer-associated genes. Our bioinformatic algorithm identified top mutations unique for individual patient, which were then used to monitor the presence of circulating tumor DNA (ctDNA) in serial plasma samples.",predictive of resistance to Cetuximab,_,ctDNA appeared to be a more sensitive and reliable signal than CEA to reflect the dynamics of tumor burden.,_,_,_,_
298,36578946,NRAS,Colorectal Cancer,plasma,NGS,"In this prospective multi-center study, 103 CRC patients eligible for curative-intent surgery were recruited. Genomic DNA from tumor tissue and paired white blood cells were sequenced to profile all tumor-derived somatic mutations in 95 cancer-associated genes. Our bioinformatic algorithm identified top mutations unique for individual patient, which were then used to monitor the presence of circulating tumor DNA (ctDNA) in serial plasma samples.",predictive of resistance to Panitumumab,_,ctDNA appeared to be a more sensitive and reliable signal than CEA to reflect the dynamics of tumor burden.,_,_,_,_
299,27312529,BRAF,Colorectal Cancer,plasma,ddPCR Supermix for Probes\GoTaq QPCR Master Mix,_,_,_,_,_,_,"combinations of ERK, BRAF, and EGFR inhibitors",_
300,10080602,KRAS,Pancreatic Cancer,plasma,_,"Forty-four consecutive patients with histologically confirmed primary pancreatic ductal adenocarcinoma were included. A control group of 37 patients with chronic pancreatitis, 10 patients with other tumors of the pancreatic area, nine patients with acute pancreatitis, and four healthy volunteers was also included. Plasma DNA was isolated and K-ras codon-12 mutations were analyzed by means of restriction fragment length polymorphism-polymerase chain reaction and single-strand conformation polymorphism techniques. Patients were followed up to establish their clinical outcome.",_,"Pancreatic carcinoma patients with the mutant-type K-ras gene in plasma DNA exhibited a shorter survival time than patients with the wild-type gene (P<.005), and plasma K-ras mutations were identified as the only independent prognostic factor (odds ratio, 1.51; 95% confidence interval, 1.02 to 2.23).",related to the tumor stage (P = .05),_,mainly in the presence of distant metastases (P = .02),_,_
301,36600247,NARS,Melanoma,plasma,NovaSeq 6000 Illumina,"This was a multicenter phase 1 study. HL-085 was administered twice daily in a standard 3 + 3 dose-escalation design (10 dose cohorts; 0.5-18 mg twice daily), followed by dose expansion at the recommended phase II dose (RP2D). The primary endpoints included tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and RP2D.",_,_,_,_,_,HL-085(MEK1/2 inhibitor),_
302,34719670,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,"This phase Ib/II open-label, single-arm, multi-center study investigated the efficacy, safety, biomarker, and resistance mechanisms of mefatinib in the first-line treatment of patients with advanced EGFR-mutant NSCLC. This study included 106 patients with EGFR-mutant stage IIIB-IV NSCLC who received first-line mefatinib at a daily dose of either 60 mg (n = 51) or 80 mg (n = 55). The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR), disease control rate (DCR), overall survival (OS), and safety",_,"Analyses of mutation profiles were performed using targeted sequencing of plasma samples at baseline, first follow-up 6 weeks from starting mefatinib therapy (F1), and at progression. Patients with concurrent TP53 mutations had comparable PFS as wild-type TP53 (14.0 vs 15.4 months; p = 0.315). Furthermore, circulating tumor DNA clearance was associated with longer PFS (p = 0.040) and OS (p = 0.002).",_,_,_,Mefatinib,_
303,30885342,EGFR,Non-Small Cell Lung Cancer,plasma,_,Forty-five of the 175 patients included in the follow-up analysis experienced progressive disease (PD). Those with PD on first-line erlotinib (n = 24) received gemcitabine/cisplatin while those who failed first-line chemotherapy (n = 21) received erlotinib until second-line PD. The primary endpoint was PFS in the crossover subpopulation. Post-hoc analysis of survival outcomes was also measured for the overall population of 175 Chinese patients.,_,_,_,_,_,"In advanced EGFR mutation-positive NSCLC, first-line erlotinib followed by chemotherapy at progression demonstrated comparable PFS benefit with the inverse treatment sequence, irrespective of mutation subtype. Utilizing both EGFR-TKIs and chemotherapy, irrespective of the sequence, maximizes survival benefits for patients.",_
304,37064137,RAS,Metastatic Colorectal Cancer,plasma,NGS(iSeq platform),"70 patients with stage IV RAS mutant colorectal cancer were prospectively enrolled. Plasma samples were collected at progression from first-line treatment. RAS/BRAF mutations in plasma were assessed by RT-PCR. In RAS/BRAF wild-type samples, ctDNA was used to generate libraries using a 17 genes panel whose alteration has clinical relevance. To investigate the prognostic significance of RAS mutation clearance, test curves for PFS and OS were represented by Kaplan-Meier estimator plot and Log-rank test.",_,Both OS and post-progression survival were longer in patients with "neo-RAS wild-type" compared to those who remained RAS mutant (p<0.001 for both).,_,_,_,_,_
305,36139605,EGFR,Non-Small Cell Lung Cancer,plasma,dPCR,"In this study, we performed a thorough explorative analysis of EGFR-positive NSCLC through NGS profiling of the plasma sample collected upon disease progression of 124 patients in order to characterize the molecular mechanisms via which tumors may progress and to identify the molecular mechanisms underlying different prognoses.",_,_,_,_,_,_,"the detection of the p.T790M mutation was significantly associated with the presence of exon 19 mutations in EGFR (Fisher p-value: 0.028). All KRAS activating mutations (n = 8) were detected in tumors with EGFR mutations in exons 18 and 21 (Fisher p-value < 0.001). Similarly, mutations in NRAS and HRAS were more frequently detected in samples from tumors harboring mutations in exons 18 or 21 (Fisher p-value: 0.050 and Fisher p-value: 0.099, respectively)."
306,31008436,B2M,Colorectal Cancer,plasma,_,"Associations were assessed using Pearson¡¯s ¦Ö2 test with simulated P value based on 2,000 replicates for low count data. A Cox proportional hazards model was fitted to the data to calculate survival using the covariates of B2M mutation status, age at diagnosis, pathologic stage, MSI status, proximal versus distal status, and KRAS, NRAS, BRAF, and PIK3CA mutation status. These were each assessed through both univariable and multivariable Cox regressions. R survival and survminer software packages were used to perform this analysis (R Foundation, Vienna, Austria).",_,_,_,_,_,immune checkpoint inhibitors (IOs)(programmed death-1 or PD-L1),Microsatellite instability-high
307,35149538,BRCA,Triple Negative Breast Cancer,plasma,_,"Eligible patients had recurrent triple-negative breast cancer (TNBC) or recurrent breast cancer of any subtype with a germline BRCA mutation and were enrolled to a dose-escalation or -expansion cohort. After definition of the RP2D, secondary end points included safety and objective response rate (ORR). Exploratory analyses were performed using circulating-free DNA (cfDNA).",Alpelisib in combination with olaparib,_,_,_,_,_,_
308,32225029,EWSR1,Ewing Sarcoma,plasma,NGS/ddPCR,"In 20 ES patients, ctDNA was evaluated during the treatment by droplet digital PCR (ddPCR) using as a probe the  specific GF variant present in the primary tumor",_,ctDNA was detected in 52.1% of ES patients (EWSR1¨CERG n = 5; EWSR1¨CFLI1 n = 43) and could be associated with lower event-free survival and overall survival. ES patients with metastasis at diagnosis with detectable ctDNA presented inferior event-free survival than patients with no detectable ctDNA.,_,"Fluctuations on the ctDNA of EWSR1 fusion were correlated with response to treatment, ctDNA was reduced after chemotherapy, and early relapse was detected by an increment on the ctDNA levels in patients who later developed metastases. This biomarker was more sensitive in the detection of early relapse and minimal residual disease than PET/SCAN, which represents the current standard method",_,_,_
309,30572461,SMARCA4,Alveolar Soft Part Sarcoma,_,_,case report,_,_,_,_,_,sunitinib,_
310,28498781,PIK3CA,Breast Cancer,blood,NGS,"Pyrotinib was administered continuously, orally, once per day to patients who did not have prior exposure to tyrosine kinase inhibitors of HER2. Planned dose escalation was 80, 160, 240, 320, 400, and 480 mg. For pharmacokinetic analysis, timed blood samples were collected on day 1 and day 28. Next-generation sequencing was performed on circulating tumor DNA and genomic DNA from tumor samples.",pyrotinib: PIK3CA and TP53 mutations in circulating tumor DNA (P = .013) rather than in archival tumor tissues (P = .474) may predict the efficacy of pyrotinib.,_,_,_,_,_,dynamic ctDNA monitoring might contribute to more accurate response assessments; baseline ctDNA profiling might serve as predictive as well as prognostic biomarker of antiHER2 treatment.
311,28498781,TP53,Breast Cancer,blood,NGS,"Pyrotinib was administered continuously, orally, once per day to patients who did not have prior exposure to tyrosine kinase inhibitors of HER2. Planned dose escalation was 80, 160, 240, 320, 400, and 480 mg. For pharmacokinetic analysis, timed blood samples were collected on day 1 and day 28. Next-generation sequencing was performed on circulating tumor DNA and genomic DNA from tumor samples.",pyrotinib: PIK3CA and TP53 mutations in circulating tumor DNA (P = .013) rather than in archival tumor tissues (P = .474) may predict the efficacy of pyrotinib.,_,_,_,_,_,dynamic ctDNA monitoring might contribute to more accurate response assessments; baseline ctDNA profiling might serve as predictive as well as prognostic biomarker of antiHER2 treatment.
312,36895385,CDK12,Prostate Cancer,blood,"NGS(GloriousMed Clinical Laboratory Co., Ltd.)","We retrospectively included  genomic and clinical data from 147 patients with mPC from a single clinical center, with a total of  102 circulating tumor DNA (ctDNA) samples and 60 tissue samples. The frequency of genomic  mutations was analyzed and compared with that in Western cohorts",less responsive to androgen receptor signaling inhibitors (ARSIs),_,_,_,_,_,_
313,36895385,BRCA2,Prostate Cancer,blood,"NGS(GloriousMed Clinical Laboratory Co., Ltd.)","We retrospectively included  genomic and clinical data from 147 patients with mPC from a single clinical center, with a total of  102 circulating tumor DNA (ctDNA) samples and 60 tissue samples. The frequency of genomic  mutations was analyzed and compared with that in Western cohorts",predict PARPi efficacy,_,_,_,_,_,_
314,36895385,PTEN,Prostate Cancer,blood,"NGS(GloriousMed Clinical Laboratory Co., Ltd.)","We retrospectively included  genomic and clinical data from 147 patients with mPC from a single clinical center, with a total of  102 circulating tumor DNA (ctDNA) samples and 60 tissue samples. The frequency of genomic  mutations was analyzed and compared with that in Western cohorts",associated with poorer docetaxel response,_,_,_,_,_,_
315,33569305,TP53,Non-Small Cell Lung Cancer,plasma,NGS,"Between January 2017 and October 2019, advanced NSCLC patients were prospectively  screened with plasma next-generation sequencing (NGS) while included in two trials: VISION  (NCT02864992), using Guardant360  test, and MAGIC (Monitoring Advanced NSCLC through plasma  Genotyping during Immunotherapy: Clinical feasibility and application), using Myriapod NGS-IL 56G  Assay. A control group of patients not receiving ICIs was analyzed.",_,"TP53 mutations in plasma negatively affected OS both in patients treated with ICIs and in control  group (P=0.001 and P=0.009), indicating a prognostic role. The presence of KRAS/STK11 co-mutation and KRAS/STK11/TP53  co-mutation affected OS only in patients treated with ICIs (HR =10.936, 95% CI: 2.337¨C51.164, P=0.002;  HR =17.609, 95% CI: 3.777¨C82.089, P<0.001, respectively), indicating a predictive role",_,_,_,_,_
316,33569305,KRAS,Non-Small Cell Lung Cancer,plasma,NGS,"Between January 2017 and October 2019, advanced NSCLC patients were prospectively  screened with plasma next-generation sequencing (NGS) while included in two trials: VISION  (NCT02864992), using Guardant360  test, and MAGIC (Monitoring Advanced NSCLC through plasma  Genotyping during Immunotherapy: Clinical feasibility and application), using Myriapod NGS-IL 56G  Assay. A control group of patients not receiving ICIs was analyzed.",_,"The presence of KRAS/STK11 co-mutation and KRAS/STK11/TP53  co-mutation affected OS only in patients treated with ICIs (HR =10.936, 95% CI: 2.337¨C51.164, P=0.002;  HR =17.609, 95% CI: 3.777¨C82.089, P<0.001, respectively), indicating a predictive role",_,_,_,_,_
317,33569305,STK11,Non-Small Cell Lung Cancer,plasma,NGS,"Between January 2017 and October 2019, advanced NSCLC patients were prospectively  screened with plasma next-generation sequencing (NGS) while included in two trials: VISION  (NCT02864992), using Guardant360  test, and MAGIC (Monitoring Advanced NSCLC through plasma  Genotyping during Immunotherapy: Clinical feasibility and application), using Myriapod NGS-IL 56G  Assay. A control group of patients not receiving ICIs was analyzed.",_,"STK11 mutated patients (n=9) showed a trend for  worse OS only if treated with ICIs. The presence of KRAS/STK11 co-mutation and KRAS/STK11/TP53  co-mutation affected OS only in patients treated with ICIs (HR =10.936, 95% CI: 2.337¨C51.164, P=0.002;  HR =17.609, 95% CI: 3.777¨C82.089, P<0.001, respectively), indicating a predictive role",_,_,_,_,_
318,36959766,TP53,Prostate Cancer,plasma,_,"mCRPC patients were assessed for response or no response to BAT. Patients with PSA declines of greater than 50% from baseline after 2 or more doses of testosterone were considered to be responders. Whereas, nonresponders had no PSA decline after 2 doses of testosterone and subsequently manifest a PSA increase of >50%. Differences between these two groups of patients were analyzed using clinical and laboratory parameters. All patients underwent genomic testing using circulating tumor DNA (ctDNA) and germline testing pre©\BAT.",_,_,_,_,Duration of prior enzalutamide therapy was longer in responders. Nonresponders were more likely to have bone©\only metastases and responders were more likely to have nodal metastases.,_,"on ctDNA analyses, responders were more likely to have a documented AR amplification (p = 0.045). There was a strong trend toward a TP53 mutations in the ctDNA in the responder group (p = 0.054)."
319,36579573,BRAF,Melanoma,plasma,ddPCR,_,_,ddPCR assays were performed to detect BRAF/NRAS mutations in plasma from 161 stage II/III melanoma patients enrolled in the AVAST-M adjuvant trial. Patients with detectable ctDNA had significantly decreased disease-free and overall survival,_,_,_,_,_
320,36579573,NRAS,Melanoma,plasma,ddPCR,_,_,ddPCR assays were performed to detect BRAF/NRAS mutations in plasma from 161 stage II/III melanoma patients enrolled in the AVAST-M adjuvant trial. Patients with detectable ctDNA had significantly decreased disease-free and overall survival,_,_,_,_,_
321,27975152,KRAS,Pancreatic Cancer,plasma,BEAMing,"Phase I comprised dose escalation, followed by phase II expansion. Refametinib and gemcitabine plasma levels were analyzed for pharmacokinetics. KRAS mutational status was determined from circulating tumor DNA.",Refametinib plus gemcitabine,"OS was greater in patients with wild-type versus mutant KRAS (413 vs 276 days, respectively), suggesting a negative prognostic role for KRAS mutations detected in circulating tumour DNA",_,_,_,_,_
322,36791768,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,"This multicenter clinical trial was conducted in China from June 15, 2018 to May 31, 2019.  A total of 92 NSCLC patients harboring EGFR sensitive mutations were included and  divided into concomitant and non-concomitant groups. Patients in each group were  randomly treated with EGFR-TKI monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. Progression free survival (PFS) was recorded as the primary endpoint.",_,_,_,_,_,"EGFR-TKI monotherapy is applicable to EGFR sensitive patients without concomitant  alterations, while a TKI combined chemotherapy is applicable to EGFR sensitive  patients with concomitant alterations. CtDNA MRD may be a potential biomarker for  predicting therapeutic efficacy.",_
323,25528496,KRAS,Advanced Or Recurrent Endometrial Carcinoma,plasma,NGS,"This Phase II, multicenter, single-arm, open-label study enrolled patients with histologically confirmed advanced or recurrent endometrial carcinoma, who had received one or two prior chemotherapy regimens. Patients received pilaralisib 600 mg capsules or 400 mg tablets once daily. Primary endpoints were objective response rate (ORR), proportion of patients with progression-free survival (PFS) N6 months and safety. Molecular profiling in archival tumor tissue and circulating tumor DNA were performed to identify molecular markers associated with response or resistance to pilaralisib.",pilaralisib monotherapy demonstrated only minimal antitumor activity (ORR 6%; two CRs and two PRs),_,_,_,_,_,_
324,25528496,PIK3CA,Advanced Or Recurrent Endometrial Carcinoma,plasma,NGS,"This Phase II, multicenter, single-arm, open-label study enrolled patients with histologically confirmed advanced or recurrent endometrial carcinoma, who had received one or two prior chemotherapy regimens. Patients received pilaralisib 600 mg capsules or 400 mg tablets once daily. Primary endpoints were objective response rate (ORR), proportion of patients with progression-free survival (PFS) N6 months and safety. Molecular profiling in archival tumor tissue and circulating tumor DNA were performed to identify molecular markers associated with response or resistance to pilaralisib.",pilaralisib monotherapy demonstrated only minimal antitumor activity (ORR 6%; two CRs and two PRs),_,_,_,_,_,_
325,25528496,BRAF,Advanced Or Recurrent Endometrial Carcinoma,plasma,NGS,"This Phase II, multicenter, single-arm, open-label study enrolled patients with histologically confirmed advanced or recurrent endometrial carcinoma, who had received one or two prior chemotherapy regimens. Patients received pilaralisib 600 mg capsules or 400 mg tablets once daily. Primary endpoints were objective response rate (ORR), proportion of patients with progression-free survival (PFS) N6 months and safety. Molecular profiling in archival tumor tissue and circulating tumor DNA were performed to identify molecular markers associated with response or resistance to pilaralisib.",pilaralisib monotherapy demonstrated only minimal antitumor activity (ORR 6%; two CRs and two PRs),_,_,_,_,_,_
326,37105265,KIT,Gastrointestinal Stromal Tumor,plasma,_,VOYAGER (N = 476) compared avapritinib with regorafenib in patients with KIT/PDGFRA-mutant GIST previously treated with imatinib and one or two additional TKIs (NCT03465722). KIT/PDGFRA ctDNA mutation profiling of plasma samples at baseline and end of treatment was assessed with 74-gene Guardant360 CDx. Molecular subgroups were determined and correlated with outcomes.,_,"ctDNA-detected KIT ATP-BP mutations negatively prognosticated avapritinib activity, with a median progression-free survival (mPFS) of 1.9 versus 5.6 months for regorafenib. mPFS for regorafenib did not vary regardless of the presence or absence of ATP-BP/A-loop mutants and was greater than mPFS with avapritinib in this population.",_,_,_,_,_
327,33953400,ARAF,Melanoma,_,_,"Here we report the first-in-human phase I study investigating the maximum tolerated dose, and assessing the safety and preliminary efficacy of belvarafenib in BRAFV600E- and RAS-mutated advanced solid tumours",Belvarafenib;ARAF mutations may serve as a general resistance mechanism for RAF dimer inhibitors as the mutants exhibit reduced sensitivity to a panel of type II RAF inhibitors.,_,_,_,_,The combination of RAF plus MEK inhibition may be used to delay ARAF-driven resistance and suggests a rational combination for clinical use.,_
328,12124803,KRAS,Colorectal Cancer,plasma,_,_,_,"The 2-year overall survival rate was 48% in the group where free-circulating tumor-associated DNA was detected in plasma and 100% in the one where free-circulating tumor-associated DNA was not detected in plasma (p < 0.03). In this subgroup of patients, the 2-year recurrence-free survival rate for the 17 patients with free-circulating tumor-associated DNA detected in plasma was 66%, compared to 100% for the 8 patients without free-circulating tumor-associated DNA detected in plasma (p<0.044). The presence of free-circulating tumor-associated DNA in plasma seems to be a relevant prognostic marker for patients with colorectal cancer and may be used to identify patients with a high risk of recurrence.",_,_,_,_,_
329,37007962,GNAS,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
330,37007962,H3F3C,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
331,37007962,BCL2L1,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
332,37007962,LAG3,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
333,37007962,FGF23,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
334,37007962,CCND2,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
335,37007962,SESN1,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
336,37007962,SNHG16,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
337,37007962,MYC,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
338,37007962,HLA-E,Triple Negative Breast Cancer,blood,NGS(Illumina NovaSeq 6000 platform),"From May 2018 to October 2020, patients with advanced TNBC treated with ICIs at Shandong Cancer Hospital were included prospectively. Patient blood samples were obtained at the pretreatment baseline, first response evaluation, and disease progression timepoints. Furthermore, 457 cancer-related genes were evaluated by NGS, and patients¡¯ ctDNA mutations, gene mutation rates, and other indicators were determined and coupled with clinical data for statistical analysis.",_,"univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05). To some extent, dynamic changes of ctDNA might indicate the efficacy of ICIs.",_,_,_,_,_
339,36915247,TP53,Colorectal Cancer,plasma,NGS,"In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease (PD) were sequenced using a targeted next-generation sequencing platform which included 106 genes.",_,"Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ¡Ý 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p<0.001).",_,_,_,regorafenib,Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib
340,36915247,APC,Colorectal Cancer,plasma,NGS,"In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease (PD) were sequenced using a targeted next-generation sequencing platform which included 106 genes.",_,"Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ¡Ý 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p<0.001).",_,_,_,regorafenib,Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib
341,36915247,TCF7L2,Colorectal Cancer,plasma,NGS,"In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease (PD) were sequenced using a targeted next-generation sequencing platform which included 106 genes.",_,"Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ¡Ý 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p<0.001).",_,_,_,regorafenib,Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib
342,36915247,ROS1,Colorectal Cancer,plasma,NGS,"In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease (PD) were sequenced using a targeted next-generation sequencing platform which included 106 genes.",_,"Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ¡Ý 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p<0.001).",_,_,_,regorafenib,Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib
343,37139665,KRAS,Pancreatic Cancer,plasma,_,"Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.",_,"Patients with somatic KRAS mutations detected at baseline (n=6) had significantly worse overall survival (median 8.5 months vs. not applicable, log-rank p=0.003) than those without. Among 13 patients with post-operative plasma ctDNA data, 8 patients (61.5%) had detectable somatic alterations.",_,Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of patients with borderline resectable PDAC treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.,_,_,_
344,37139665,ATM,Pancreatic Cancer,plasma,_,"Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.",_,_,_,Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of patients with borderline resectable PDAC treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.,_,_,_
345,37139665,BRCA1,Pancreatic Cancer,plasma,_,"Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.",_,_,_,Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of patients with borderline resectable PDAC treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.,_,_,_
346,37139665,BRCA2,Pancreatic Cancer,plasma,_,"Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.",_,_,_,Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of patients with borderline resectable PDAC treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.,_,_,_
347,37139665,MLH1,Pancreatic Cancer,plasma,_,"Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.",_,_,_,Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of patients with borderline resectable PDAC treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.,_,_,_
348,37046778,RAS,Metastatic Colorectal Cancer,plasma,NGS,We performed the pooled analysis of the CAVE and VELO studies to evaluate the percentage of patients with WT circulating tumor DNA (ctDNA) tumors and the association of mutational status with time from the last anti-EGFR drug administration.,_,"The study was positive, with a median overall survival (mOS) of 11.6 months (95% CI, 8.4¨C14.8 months) and a median PFS (mPFS) of 3.6 months (95% CI, 3.2¨C4.1 months) in the intention to treat the population. Interestingly, mOS exceeded 17 months in the pretreatment plasma ctDNA RAS/BRAF WT population; At baseline, 97/129 patients had RAS/BRAF WT plasma ctDNA, while 32/129 had RAS/BRAF mutated plasma ctDNA. Median anti-EGFR drug-free interval was 10.6 (CI 95%, 8.9¨C13.4) months in the plasma RAS/BRAF mutant group as compared to 13.0 (CI 95%, 11.1¨C16.6) months in RAS/BRAF WT group (p = 0.169)",_,_,_,"On the basis of this rationale, our group and others showed that retreatment with anti-EGFR monoclonal antibodies (mAbs) alone or in combination with chemotherapy or immunotherapy has clinically relevant antitumor activity in a subset of patients with plasma circulating tumor DNA (ctDNA) RAS/BRAF wild-type (WT) tumors",_
349,37046778,BRAF,Metastatic Colorectal Cancer,plasma,NGS,We performed the pooled analysis of the CAVE and VELO studies to evaluate the percentage of patients with WT circulating tumor DNA (ctDNA) tumors and the association of mutational status with time from the last anti-EGFR drug administration.,_,"The study was positive, with a median overall survival (mOS) of 11.6 months (95% CI, 8.4¨C14.8 months) and a median PFS (mPFS) of 3.6 months (95% CI, 3.2¨C4.1 months) in the intention to treat the population. Interestingly, mOS exceeded 17 months in the pretreatment plasma ctDNA RAS/BRAF WT population; At baseline, 97/129 patients had RAS/BRAF WT plasma ctDNA, while 32/129 had RAS/BRAF mutated plasma ctDNA. Median anti-EGFR drug-free interval was 10.6 (CI 95%, 8.9¨C13.4) months in the plasma RAS/BRAF mutant group as compared to 13.0 (CI 95%, 11.1¨C16.6) months in RAS/BRAF WT group (p = 0.169)",_,_,_,"On the basis of this rationale, our group and others showed that retreatment with anti-EGFR monoclonal antibodies (mAbs) alone or in combination with chemotherapy or immunotherapy has clinically relevant antitumor activity in a subset of patients with plasma circulating tumor DNA (ctDNA) RAS/BRAF wild-type (WT) tumors",_
350,34381078,NRAS,Colorectal Cancer,plasma,NGS(Illumina HiSeq 2500),"In once clinical study,We conducted serial ctDNA analysis to investigate potential association with clinical outcome in metastatic colorectal cancer (mCRC) patients receiving chemotherapy. Tissue KRAS/NRAS wild-type mCRC patients were enrolled and treated with first-line cetuximab-containing chemotherapy. ctDNA isolated from plasma were analyzed by next generation sequencing (NGS) with 16 targeted gene panel.",_,"The PFS of the patients with pathogenic hotspot KRAS or NRAS mutations (N = 5) in baseline ctDNA was significantly shorter (p = 0.029, median PFS 3.7 months in mutants vs. 10.8 months in wild type, Fig. 1A). These KRAS/NRAS mutant patients showed tendency towards lower response rate (40.0% in mutants vs. 77.1% in wild type, p = 0.098).",_,_,_,_,_
351,38083992,TERT,Upper Tract Urothelial Carcinoma,plasma/urine,digital PCR (dPCR),"In once clinical study,Twenty-three patients who underwent radical nephroureterectomy (RNU) were included. In each patient, whole exome sequencing by next-generation sequencing and TERT promoter sequencing of tumor DNA were carried out. Case-specific gene mutations were selected from sequencing analysis to examine ctDNA by dPCR analysis. We also prospectively collected plasma and urine ctDNA from each patient. The longitudinal variant allele frequencies of ctDNA during the perioperative period were plotted.",_,"In the univariate analysis, we identified urine cytology in the preoperative samples and the change rate of urinary ctDNA as prognostic factors associated with short RFS. In the multivariate analysis, only the change rate of urinary ctDNA was identified as a prognostic factor associated with short RFS.",_,_,_,_,_
352,38049331,MUC16,Diffuse Large B-Cell Lymphoma,plasma/urine,NGS(Next seq500),"In this study, 48 patients with R/R DLBCL who received CAR-T-cell therapy at the First Affiliated Hospital of Zhejiang University School of Medicine between December 2017 and March 2022 were included. Furthermore, ctDNA testing of 187 lymphoma-related gene sets was performed on peripheral blood samples obtained before treatment. The patients were divided into complete remission and noncomplete remission groups. The chi-square test and t-test were used to compare group differences, and the Log-rank test was used to compare the differences in survival.",_,"patients with MUC16 mutation positivity before treatment(chimeric antigen receptor T-cell (CAR-T) therapy) had better OS (2-year OS rate: 56.8% vs 26.7%, P=0.046)",_,_,_,_,_
353,38049331,BTG2,Diffuse Large B-Cell Lymphoma,plasma/urine,NGS(Next seq500),"In this study, 48 patients with R/R DLBCL who received CAR-T-cell therapy at the First Affiliated Hospital of Zhejiang University School of Medicine between December 2017 and March 2022 were included. Furthermore, ctDNA testing of 187 lymphoma-related gene sets was performed on peripheral blood samples obtained before treatment. The patients were divided into complete remission and noncomplete remission groups. The chi-square test and t-test were used to compare group differences, and the Log-rank test was used to compare the differences in survival.",_,"patients with BTG2 mutation positivity had poorer OS (1-year OS rate: 0 vs 72.5%, P=0.005)(under chimeric antigen receptor T-cell (CAR-T) therapy)",_,_,_,_,_
354,38038965,TP53,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
355,38038965,BRCA1,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
356,38038965,BRCA2,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
357,38038965,ARID1A,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
358,38038965,CCNE1,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
359,38038965,KRAS,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
360,38038965,MYC,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
361,38038965,PIK3CA,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
362,38038965,PTEN,Ovarian Cancer,plasma,NGS Panel,"A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples.",_,Detection of ctDNA at baseline and/or at 6 months follow-up was predictive of Progression-free survival (PFS). PFS was significantly poorer in patients with detectable pathogenic mutations at baseline that persisted at follow-up than in patients that converted from having detectable ctDNA at baseline to being undetectable at follow-up;,_,"serial ctDNA testing could effectively monitor patients and detect minimal residual disease, facilitating early detection of disease progression and tailoring of adjuvant therapies for ovarian cancer treatment.",_,_,_
363,38027900,KRAS,Metastatic Colorectal Cancer,plasma,_,We collected blood samples at specific time points from patients who received a first-line chemotherapy (CT) for KRAS-mutated mCRC. CTC quantification was performed by CellSearch  system. Libraries from cfDNA were prepared using the Oncomine  Colon cfDNA Assay to detect tumour-derived DNA in cfDNA. The analysis involved >240 hotspots in 14 genes.,_,"In patients with a short (<9 months) progression-free survival (PFS) we registered, at 6 weeks, an increase in cfDNA levels and in KRAS mutations or other co-mutations, i.e. PIK3CA, FBXW7, GNAS, and TP53.",_,_,_,_,_
364,38027900,PIK3CA,Metastatic Colorectal Cancer,plasma,_,We collected blood samples at specific time points from patients who received a first-line chemotherapy (CT) for KRAS-mutated mCRC. CTC quantification was performed by CellSearch  system. Libraries from cfDNA were prepared using the Oncomine  Colon cfDNA Assay to detect tumour-derived DNA in cfDNA. The analysis involved >240 hotspots in 14 genes.,_,"In patients with a short (<9 months) progression-free survival (PFS) we registered, at 6 weeks, an increase in cfDNA levels and in KRAS mutations or other co-mutations, i.e. PIK3CA, FBXW7, GNAS, and TP53.",_,_,_,_,_
365,38027900,FBXW7,Metastatic Colorectal Cancer,plasma,_,We collected blood samples at specific time points from patients who received a first-line chemotherapy (CT) for KRAS-mutated mCRC. CTC quantification was performed by CellSearch  system. Libraries from cfDNA were prepared using the Oncomine  Colon cfDNA Assay to detect tumour-derived DNA in cfDNA. The analysis involved >240 hotspots in 14 genes.,_,"In patients with a short (<9 months) progression-free survival (PFS) we registered, at 6 weeks, an increase in cfDNA levels and in KRAS mutations or other co-mutations, i.e. PIK3CA, FBXW7, GNAS, and TP53.",_,_,_,_,_
366,38027900,GNAS,Metastatic Colorectal Cancer,plasma,_,We collected blood samples at specific time points from patients who received a first-line chemotherapy (CT) for KRAS-mutated mCRC. CTC quantification was performed by CellSearch  system. Libraries from cfDNA were prepared using the Oncomine  Colon cfDNA Assay to detect tumour-derived DNA in cfDNA. The analysis involved >240 hotspots in 14 genes.,_,"In patients with a short (<9 months) progression-free survival (PFS) we registered, at 6 weeks, an increase in cfDNA levels and in KRAS mutations or other co-mutations, i.e. PIK3CA, FBXW7, GNAS, and TP53.",_,_,_,_,_
367,38027900,TP53,Metastatic Colorectal Cancer,plasma,_,We collected blood samples at specific time points from patients who received a first-line chemotherapy (CT) for KRAS-mutated mCRC. CTC quantification was performed by CellSearch  system. Libraries from cfDNA were prepared using the Oncomine  Colon cfDNA Assay to detect tumour-derived DNA in cfDNA. The analysis involved >240 hotspots in 14 genes.,_,"In patients with a short (<9 months) progression-free survival (PFS) we registered, at 6 weeks, an increase in cfDNA levels and in KRAS mutations or other co-mutations, i.e. PIK3CA, FBXW7, GNAS, and TP53.",_,_,_,_,_
368,37932736,BRCA1,Epithelial Ovarian Cancer,plasma,NGS,"In once clinical study,We collected ascites/peritoneal washings from 53 EOC patients (19 from retrospective cohort and 34 from prospective cohort) and performed a Cancer Gene Panel (CGP) using NGS for TP53/HR genes and shallow Whole Genome Sequencing (sWGS) for genomic instability on cfDNA.",_,_,_,"Profiling cftDNA from peritoneal fluid is feasible, providing a significant amount of tumor DNA. This fast and reliable approach enables HRD testing, including BRCA1/2 mutations and genomic instability assessment. HRD testing on cfDNA from peritoneal fluid should be offered to all primary laparoscopy patients.",_,_,_
369,37932736,BRCA2,Epithelial Ovarian Cancer,plasma,NGS,"In once clinical study,We collected ascites/peritoneal washings from 53 EOC patients (19 from retrospective cohort and 34 from prospective cohort) and performed a Cancer Gene Panel (CGP) using NGS for TP53/HR genes and shallow Whole Genome Sequencing (sWGS) for genomic instability on cfDNA.",_,_,_,"Profiling cftDNA from peritoneal fluid is feasible, providing a significant amount of tumor DNA. This fast and reliable approach enables HRD testing, including BRCA1/2 mutations and genomic instability assessment. HRD testing on cfDNA from peritoneal fluid should be offered to all primary laparoscopy patients.",_,_,_
370,37924564,TP53,High-Grade Serous Ovarian Carcinoma,plasma,Oseq  panel,"We collected 152 longitudinal plasma and 92 fresh tissue samples from 29 HGSC patients, sequencing and detecting mutations with a gene panel of more than 700 cancer-related genes. Tumor content was measured using TP53 VAF. We analyzed the concordance between the mutations in tissue and plasma samples and calculated correlations to patient outcomes. We also searched for novel mutations appearing at relapse.",_,The TP53 VAF in ctDNA from plasma samples before the third cycle of primary chemotherapy showed a negative correlation to patient outcome.,_,_,_,_,_
371,37897866,FGFR3,Metastatic Urothelial Cancer,plasma,_,"Patients with mUC were prospectively enroled in the STING trial (NCT04932525), in which ctDNA was profiled using the Foundation One Liquid CDx Assay (324 genes, blood tumour mutational burden [bTMB], microsatellite instability status). Each genomic report was reviewed by a multidisciplinary tumor board (MTB).",_,FGFR3 alterations were associated with a shorter PFS in patients treated with immunotherapy.,_,_,_,_,_
372,37897649,TERT,Lung Adenocarcinoma,cerebrospinal fluid,NGS,"We conducted a retrospective study of 35 lung adenocarcinoma (LUAD) patients with LM, and matched CSF and plasma samples were collected from all patients. All paired samples underwent next-generation sequencing (NGS) of 139 lung cancer-associated genes. The clinical characteristics and genetic profiling of LM were analysed in association with survival prognosis.",_,CSF ctDNA mutation with TERT (P = 0.013) indicated a lower median OS.,_,_,_,_,_
373,37877742,TP53,Prostate Cancer,plasma,NGS,Concordance of genomic alterations was assessed between progressive tumor tissue and matched ctDNA by next-generation sequencing for 63 patients with AVPC. Associations of genomic alterations with progression-free survival (PFS) and overall survival (OS) were investigated using Kaplan-Meier and Cox regression analyses.,_,_,_,_,_,"platinum-based chemotherapy;Chemotherapy is associated with significantly better survival than NHT, and the benefit of additional platinum-based chemotherapy may depend on the presence of alterations in TP53, RB1, or PTEN and on a sufficiently high proportion of ctDNA in patients with AVPC.",_
374,37877742,RB1,Prostate Cancer,plasma,NGS,Concordance of genomic alterations was assessed between progressive tumor tissue and matched ctDNA by next-generation sequencing for 63 patients with AVPC. Associations of genomic alterations with progression-free survival (PFS) and overall survival (OS) were investigated using Kaplan-Meier and Cox regression analyses.,_,_,_,_,_,"platinum-based chemotherapy;Chemotherapy is associated with significantly better survival than NHT, and the benefit of additional platinum-based chemotherapy may depend on the presence of alterations in TP53, RB1, or PTEN and on a sufficiently high proportion of ctDNA in patients with AVPC.",_
375,37877742,PTEN,Prostate Cancer,plasma,NGS,Concordance of genomic alterations was assessed between progressive tumor tissue and matched ctDNA by next-generation sequencing for 63 patients with AVPC. Associations of genomic alterations with progression-free survival (PFS) and overall survival (OS) were investigated using Kaplan-Meier and Cox regression analyses.,_,_,_,_,_,"platinum-based chemotherapy;Chemotherapy is associated with significantly better survival than NHT, and the benefit of additional platinum-based chemotherapy may depend on the presence of alterations in TP53, RB1, or PTEN and on a sufficiently high proportion of ctDNA in patients with AVPC.",_
376,37862025,GNAQ,Uveal Melanoma,plasma,MiSeq£¨Illumina Inc.£©,"The study recruited 26 uveal melanoma patients referred to the department between February and October 2020. Blood samples were collected at various time points before, during, and after treatment, and deep amplicon sequencing was used to identify oncogenic variant alleles of the GNAQ and GNA11 genes, which serve as indicators for the presence of circulating tumor DNA (ctDNA).",_,_,The variant allele fraction of GNAQ or GNA11 alleles in ctDNA positive samples ranged from 0.24% to 2% and correlates with the largest basal diameter and thickness of the tumor.,_,_,_,_
377,37862025,GNA11,Uveal Melanoma,plasma,MiSeq£¨Illumina Inc.£©,"The study recruited 26 uveal melanoma patients referred to the department between February and October 2020. Blood samples were collected at various time points before, during, and after treatment, and deep amplicon sequencing was used to identify oncogenic variant alleles of the GNAQ and GNA11 genes, which serve as indicators for the presence of circulating tumor DNA (ctDNA).",_,_,The variant allele fraction of GNAQ or GNA11 alleles in ctDNA positive samples ranged from 0.24% to 2% and correlates with the largest basal diameter and thickness of the tumor.,_,_,_,_
378,37770113,CCNE1,Metastatic Castration-Resistant Prostate Cancer,plasma,NGS(Guardant360),Pretreatment circulating tumor DNA (ctDNA) samples were collected from 44 mCRPC patients receiving 177Lu-PSMA treatment. Prostate-specific antigen responders and nonresponders were assessed relative to the ctDNA findings at baseline.,_,"CDK12 mutations were more likely to be present in nonresponders (25% vs. 3.6%, P = 0.05)(177Lu-PSMA treatment).",_,_,_,_,_
379,37759818,TP53,Squamous Cell Carcinoma Of The Head And Neck,plasma,NGS(the Ion Torrent Personal Genome Machine (PGM) sequencer platform),"Detecting mutated TP53 ctDNA was associated with poor progression-free survival and regional metastases, indicating its potential role as a prognostic biomarker.",_,"Detecting mutated TP53 ctDNA was associated with poor progression-free survival and regional metastases, indicating its potential role as a prognostic biomarker.",_,_,_,_,_
380,37724484,RB1,Non-Small Cell Lung Cancer,plasma,GeneSeq2000,"From February 2017 to November 2020, pretreatment and on-treatment (3~6 weeks after first cycle of immunotherapy) dynamic plasma ctDNA samples from NSCLC patients receiving immune monotherapy or combination therapy were analyzed by targeted capture sequencing of 1021 genes. PyClone was used to infer the mTBI. The impact of pretreatment mTBI on survival outcomes was verified in the POPLAR/OAK trials.",_,RB1 and SMARCA4 mutations were remarkably associated with worse survival outcomes.,_,_,_,_,_
381,37724484,SMARCA4,Non-Small Cell Lung Cancer,plasma,GeneSeq2000,"From February 2017 to November 2020, pretreatment and on-treatment (3~6 weeks after first cycle of immunotherapy) dynamic plasma ctDNA samples from NSCLC patients receiving immune monotherapy or combination therapy were analyzed by targeted capture sequencing of 1021 genes. PyClone was used to infer the mTBI. The impact of pretreatment mTBI on survival outcomes was verified in the POPLAR/OAK trials.",_,RB1 and SMARCA4 mutations were remarkably associated with worse survival outcomes.,_,_,_,_,_
382,37673211,ERBB2,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,_,_,_,_,_,Associated with a greater PFS benefit with ribociclib versus placebo.,_
383,37673211,FAT3,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,_,_,_,_,_,Associated with a greater PFS benefit with ribociclib versus placebo.,_
384,37673211,FRS2,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,_,_,_,_,_,Associated with a greater PFS benefit with ribociclib versus placebo.,_
385,37673211,MDM2,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,_,_,_,_,_,Associated with a greater PFS benefit with ribociclib versus placebo.,_
386,37673211,SFRP1,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,_,_,_,_,_,Associated with a greater PFS benefit with ribociclib versus placebo.,_
387,37673211,ZNF217,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,_,_,_,_,_,Associated with a greater PFS benefit with ribociclib versus placebo.,_
388,37673211,ANO1,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,"Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo.",_,_,_,_,_,_
389,37673211,CDKN2A,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,"Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo.",_,_,_,_,_,_
390,37673211,CDKN2B,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,"Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo.",_,_,_,_,_,_
391,37673211,CDKN2C,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,"Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo.",_,_,_,_,_,_
392,37673211,RB1,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,"Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo.",_,_,_,_,_,_
393,37673211,NF1,Breast Cancer,plasma,Illumina HiSeq,Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib.,"Patients with NF1 alterations responded poorly to placebo versus ribociclib [median PFS 1.8 versus 13 months; HR = 0.32 (95% CI 0.15-0.68)], and this was particularly evident in those with nonsense/frameshift NF1 alterations (median PFS 1.8 versus 23.5 months; HR, not estimable).",_,_,_,_,_,_
394,37658484,AP3B1,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
395,37658484,ATM,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
396,37658484,BCL6,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
397,37658484,BRAF,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
398,37658484,CDKN2B,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
399,37658484,EPCAM,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
400,37658484,FBXO11,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
401,37658484,JAK1,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
402,37658484,MDM2,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
403,37658484,NF1,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
404,37658484,STAT5B,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
405,37658484,STAT6,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
406,37658484,TET2,T-Cell Lymphoma,plasma,_,_,_,"COX regression analysis identifies a subset of 13 genes in panel-TMB120, including AP3B1, ATM (Ataxia-telangiectasia mutated), BCL6, BRAF, CDKN2B, EPCAM, FBXO11, JAK1, MDM2, NF1, STAT5B, STAT6, and TET2, which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel-TMB13) are able to significantly predict unfavorable prognosis for these patients.",_,_,_,_,_
407,37656949,KRAS,Metastatic Colorectal Cancer,plasma,NGS,"Fifty-three patients were characterized for RAS and BRAF status on tumor tissue before the start of treatment. Plasma was collected at baseline, at first clinical evaluation, and at disease progression. ctDNA analysis was performed using Oncomine Colon cfDNA Assay on the Ion S5 XL instrument.",_,"Low baseline variant allele frequency (VAF) was found to be associated with longer median progression-free survival (PFS) compared with those with high VAF (15.9 v 12.2 months, P = .02). A higher PFS {12.29 months (95% CI, 9.03 to 17.9) v 8.15 months (95% CI, 2.76 to not available [NA]), P = .04} and overall survival (34.1 months [95% CI, 21.68 to NA] v 11.1 months [95% CI, 3.71 to NA], P = .003) were observed in patients with large decline in VAF at first evaluation.",_,_,_,_,_
408,37656949,NRAS,Metastatic Colorectal Cancer,plasma,NGS,"Fifty-three patients were characterized for RAS and BRAF status on tumor tissue before the start of treatment. Plasma was collected at baseline, at first clinical evaluation, and at disease progression. ctDNA analysis was performed using Oncomine Colon cfDNA Assay on the Ion S5 XL instrument.",_,"Low baseline variant allele frequency (VAF) was found to be associated with longer median progression-free survival (PFS) compared with those with high VAF (15.9 v 12.2 months, P = .02). A higher PFS {12.29 months (95% CI, 9.03 to 17.9) v 8.15 months (95% CI, 2.76 to not available [NA]), P = .04} and overall survival (34.1 months [95% CI, 21.68 to NA] v 11.1 months [95% CI, 3.71 to NA], P = .003) were observed in patients with large decline in VAF at first evaluation.",_,_,_,_,_
409,37656949,PIK3CA,Metastatic Colorectal Cancer,plasma,NGS,"Fifty-three patients were characterized for RAS and BRAF status on tumor tissue before the start of treatment. Plasma was collected at baseline, at first clinical evaluation, and at disease progression. ctDNA analysis was performed using Oncomine Colon cfDNA Assay on the Ion S5 XL instrument.",_,"Low baseline variant allele frequency (VAF) was found to be associated with longer median progression-free survival (PFS) compared with those with high VAF (15.9 v 12.2 months, P = .02). A higher PFS {12.29 months (95% CI, 9.03 to 17.9) v 8.15 months (95% CI, 2.76 to not available [NA]), P = .04} and overall survival (34.1 months [95% CI, 21.68 to NA] v 11.1 months [95% CI, 3.71 to NA], P = .003) were observed in patients with large decline in VAF at first evaluation.",_,_,_,_,_
410,37656949,BRAF,Metastatic Colorectal Cancer,plasma,NGS,"Fifty-three patients were characterized for RAS and BRAF status on tumor tissue before the start of treatment. Plasma was collected at baseline, at first clinical evaluation, and at disease progression. ctDNA analysis was performed using Oncomine Colon cfDNA Assay on the Ion S5 XL instrument.",_,"Low baseline variant allele frequency (VAF) was found to be associated with longer median progression-free survival (PFS) compared with those with high VAF (15.9 v 12.2 months, P = .02). A higher PFS {12.29 months (95% CI, 9.03 to 17.9) v 8.15 months (95% CI, 2.76 to not available [NA]), P = .04} and overall survival (34.1 months [95% CI, 21.68 to NA] v 11.1 months [95% CI, 3.71 to NA], P = .003) were observed in patients with large decline in VAF at first evaluation.",_,_,_,_,_
411,37559592,TP53,Metastatic Urothelial Cancer,plasma,"NGS(Next seq500,Illumina, Inc)",The present study retrospectively examined genomic alterations in 25 plasma circulating tumor DNA (ctDNA) samples using targeted sequencing of 77 genes from 16 patients with mUC during pembrolizumab treatment.,_,variant allele frequency decreases in TP53 during pembrolizumab treatment were mainly associated with therapeutic response;,_,_,_,better responders to pembrolizumab,_
412,37511178,TP53,Metastatic Breast Cancer,plasma,ddPCR,_,emerged as putative drivers of acquired resistance.,Baseline PIK3CA and TP53 mutations were prognostic of a shorter progression-free survival in our population.,_,_,_,_,_
413,37511178,PIK3CA,Metastatic Breast Cancer,plasma,ddPCR,_,_,"Baseline PIK3CA and TP53 mutations were prognostic of a shorter progression-free survival in our population;Mutant PIK3CA was prognostic in the subset of patients receiving fulvestrant monotherapy after progression to a CDK4/6 inhibitor (CDK4/6i)-containing regimen, and its suppression was predictive in a case of long-term benefit with alpelisib.",_,_,_,_,_
414,37511178,ESR1,Metastatic Breast Cancer,plasma,ddPCR,_,emerged as putative drivers of acquired resistance.,"Mutant ESR1 was prognostic in patients who did not receive concurrent CDK4/6i, an impact influenced by the variant allele frequency, and its early suppression was strongly predictive of efficacy and associated with long-term benefit in the whole cohort.",_,_,_,_,_
415,37511178,KRAS,Metastatic Breast Cancer,plasma,ddPCR,_,emerged as putative drivers of acquired resistance.,_,_,_,_,_,_
416,37510091,EGFR,Non-Small Cell Lung Cancer,plasma,Cobas 4800 EGFR mutation test v2,_,_,mean overall survival was significantly lower when a liquid biopsy was positive for the detection of EGFR mutations compared with wild-type patients in their liquid biopsy in both univariate (29 ¡À 4 vs. 104 ¡À 19 months; p = 0.004) and multivariate analysis (p = 0.008).,_,_,_,_,_
417,37509239,RAS,Metastatic Colorectal Cancer,plasma,ddPCR,_,_,_,_,_,_,_,_
418,37490393,TP53,Metastatic Breast Cancer,plasma,NGS( NovaSeq 6000 platform ),"Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model.",_,"Detectable TP53 mutation showed worse PFS and OS in both treatment arms, even after restricting population to baseline ctDNA detection.",_,_,_,_,_
419,37490393,ESR1,Metastatic Breast Cancer,plasma,NGS( NovaSeq 6000 platform ),"Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model.",_,"ESR1 mutations were associated with worse OS overall, which was lost when restricting population to baseline ctDNA detection.",_,_,_,_,_
420,37490393,PIK3CA,Metastatic Breast Cancer,plasma,NGS( NovaSeq 6000 platform ),"Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model.",_,PIK3CA mutations confer worse OS only to patients on the palbociclib+fulvestrant treatment arm.,_,_,_,_,_
421,37488448,RAS,Metastatic Colorectal Cancer,plasma,MassARRAY platform (Agena),"Only patients with concordant wild-type formalin-fixed, paraffin-embedded (FFPE) tumour tissue and baseline ctDNA RAS wild-type were included. RAS mutations in plasma were evaluated using MassARRAY platform. Blood samples were collected at baseline, every 3 months during first-line treatment, and at disease progression. The primary endpoint was the detection rate of RAS mutations during cetuximab treatment. The correlation between response and survival outcomes and the emergence of circulating RAS mutations was also analysed.",_,"The subgroup of patients with RAS mutations exhibited significantly inferior progression-free survival and overall survival (P = 0.002 and 0.027, respectively).",_,_,_,_,_
422,37441425,RB1,Non-Small Cell Lung Cancer,plasma,NGS( the HiSeq4000 Sequencing System),We enrolled 53 NSCLC patients treated with ICI combination therapy and collected their tissue and plasma samples to perform next-generation sequencing (NGS) with a 425-gene panel.,_,"Patients with mutated RB1 had shorter PFS than those with wild RB1 (134d vs 219d, p=0.018).",_,_,_,_,"Analysis showed the RB1 related mutated cell cycle and chromosomal instability were also deleterious to prognosis (103d vs 411d, p<0.001; 138d vs 505d, p=0.018)."
423,37390764,EGFR,Non-Small Cell Lung Cancer,plasma,NGS(Guardant360),"Eligible patients with EGFR+ mNSCLC were randomized 1 : 1 to ERL (150 mg/day) plus RAM (10 mg/kg)/PBO every 2 weeks. Liquid biopsies were to be prospectively collected at baseline, cycle 4 (C4), and postdiscontinuation follow-up. EGFR and co-occurring/treatment-emergent (TE) genomic alterations in ctDNA were analyzed using Guardant360 NGS platform.",_,Baseline aEGFR alterations in ctDNA were associated with shorter mPFS;aEGFR+ clearance by C4 was associated with improved PFS outcomes.Monitoring co-occurring alterations and aEGFR+ clearance may provide insights into mechanisms of EGFR tyrosine kinase inhibitor resistance and the patients who may benefit from intensified treatment schedules.,_,_,_,_,_
424,37379430,EGFR,Non-Small Cell Lung Cancer,plasma,ddPCR,"This was a retrospective, exploratory analysis of two phase III trials [AURA3 (NCT02151981), FLAURA (NCT02296125)]. All patients had EGFR mutation-positive (EGFRm; ex19del or L858R) advanced NSCLC; AURA3 also included T790M-positive NSCLC. Osimertinib (FLAURA, AURA3), or comparator EGFR-tyrosine kinase inhibitor (EGFR-TKI; gefitinib/erlotinib; FLAURA), or platinum-based doublet chemotherapy (AURA3) was given. Plasma EGFRm was analyzed at baseline and Weeks 3/6 by droplet digital PCR. Outcomes were assessed by detectable/non-detectable baseline plasma EGFRm and plasma EGFRm clearance (non-detection) at Weeks 3/6.",_,Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.,_,_,_,_,_
425,37341038,KRAS,Pancreatic Ductal Adenocarcinoma,plasma,Mx3005P real©\time PCR instrument,_,_,"Cox proportional hazard regression showed that ctDNA detection at baseline was an independent predictor of progression-free and overall survival. Joint modelling demonstrated that the dynamic ctDNA level was a strong predictor of time to first disease progression. Longitudinal ctDNA measurements during chemotherapy successfully revealed disease progression in 20 (67%) of 30 patients with ctDNA detected at baseline, with a median lead time of 23 days (P = 0.01) over radiological imaging.",_,_,_,_,_
426,37308396,KRAS,Pancreatic Adenocarcinoma,plasma,ddPCR( Bio-Rad QX200 ),Blood samples were collected just before first CT and at day 28. The primary endpoint was the kinetics of KRAS-mutated ctDNA by digital droplet PCR between D0 and D28 as a predictor of progression-free survival (PFS).,_,"presence or not of KRAS-mutated ctDNA at D28 was an optimal predictor of cDCR (OR=30.7, IC95% 4.31-218 P=.001), PFS (HR=6.79, IC95% 2.76-16.7, P<.001) and OS (HR=9.98, IC95% 4.14-24.1, P<.001).",_,_,_,_,_
427,37307947,ARID1A,Hepatocellular Carcinoma,plasma,NGS,"In once clinical study,We identified early stage (BCLC 0-A) HCC cases (n = 21) and patients without HCC (n = 14) from a cohort of Asian patients with HBV, undergoing surveillance between 2013 and 2017. Circulating cell-free DNA was isolated from blood samples, and assayed by next-generation sequencing of 23 genes implicated in HCC pathogenesis. Somatic mutations were identified using a computational pipeline. Using area under the curve (AUC) in receiver operating characteristic (ROC) analysis, we evaluated gene alterations and clinical factors in an exploratory early HCC detection model.",_,_,_,_,_,_,"Mutant ARID1A, CTNNB1, TP53 genes were increased in HCC cases vs. non-HCC patients (85.7% vs 42.9%, P = 0.011; 42.9% vs 0%, P = 0.005; 100% vs 71.4%, P = 0.019, respectively). Using these three genes, AUC for discriminating HCC from non-HCC patients was 0.844 (95% confidence interval [CI]: 0.7317-0.9553). When combining these genes with clinical factors in an exploratory early HCC detection model, AUC increased from 0.7415 (using clinical factors alone) to 0.9354 (P = 0.041)."
428,37307947,CTNNB1,Hepatocellular Carcinoma,plasma,NGS,"In once clinical study,We identified early stage (BCLC 0-A) HCC cases (n = 21) and patients without HCC (n = 14) from a cohort of Asian patients with HBV, undergoing surveillance between 2013 and 2017. Circulating cell-free DNA was isolated from blood samples, and assayed by next-generation sequencing of 23 genes implicated in HCC pathogenesis. Somatic mutations were identified using a computational pipeline. Using area under the curve (AUC) in receiver operating characteristic (ROC) analysis, we evaluated gene alterations and clinical factors in an exploratory early HCC detection model.",_,_,_,_,_,_,"Mutant ARID1A, CTNNB1, TP53 genes were increased in HCC cases vs. non-HCC patients (85.7% vs 42.9%, P = 0.011; 42.9% vs 0%, P = 0.005; 100% vs 71.4%, P = 0.019, respectively). Using these three genes, AUC for discriminating HCC from non-HCC patients was 0.844 (95% confidence interval [CI]: 0.7317-0.9553). When combining these genes with clinical factors in an exploratory early HCC detection model, AUC increased from 0.7415 (using clinical factors alone) to 0.9354 (P = 0.041)."
429,37307947,TP53,Hepatocellular Carcinoma,plasma,NGS,"In once clinical study,We identified early stage (BCLC 0-A) HCC cases (n = 21) and patients without HCC (n = 14) from a cohort of Asian patients with HBV, undergoing surveillance between 2013 and 2017. Circulating cell-free DNA was isolated from blood samples, and assayed by next-generation sequencing of 23 genes implicated in HCC pathogenesis. Somatic mutations were identified using a computational pipeline. Using area under the curve (AUC) in receiver operating characteristic (ROC) analysis, we evaluated gene alterations and clinical factors in an exploratory early HCC detection model.",_,_,_,_,_,_,"Mutant ARID1A, CTNNB1, TP53 genes were increased in HCC cases vs. non-HCC patients (85.7% vs 42.9%, P = 0.011; 42.9% vs 0%, P = 0.005; 100% vs 71.4%, P = 0.019, respectively). Using these three genes, AUC for discriminating HCC from non-HCC patients was 0.844 (95% confidence interval [CI]: 0.7317-0.9553). When combining these genes with clinical factors in an exploratory early HCC detection model, AUC increased from 0.7415 (using clinical factors alone) to 0.9354 (P = 0.041)."
430,37306927,CBLB,Gastric Cancer,plasma,NovaSeq 6000 Illumina,"Using next-generation sequencing (NGS) Multigene Panels, the mutational signatures associated with the prognosis of GC patients were identified. We calculated the survival probability with Kaplan-Meier and used the Log-rank test to compare survival curves between ctDNA-positive and ctDNA-negative groups. Potential application of radiology combined with tumor plasma biomarker analysis of ctDNA in GC patients was carried out.",_,CBLB mutations had shorter OS and PFS than wild-type patients (OS: P = 0.0036; PFS: P = 0.0027).,_,_,_,_,_
431,37296463,TP53,Non-Small Cell Lung Cancer,plasma,NovaSeq 6000 Illumina,"Patients from our two previous phase II trials were pooled analyzed. Their circulating tumor DNA (ctDNA) were detected by next-generation sequencing (NGS) panels, and the correlation with the efficacy of pyrotinib was investigated.",_,"Patients with TP53 wild type were significantly associated with higher disease control rate (97.1%vs. 68.8%, p = 0.010), PFS (median 8.4 vs. 2.8 months, p = 0.001) and overall survival (OS, median 26.7 vs. 10.4 months, p < 0.001) than those with mutations.",_,_,_,_,_
432,37294123,TERT,Metastatic Melanoma,plasma,NGS( the Illumina NovaSeq),_,_,related to worse prognosis,_,_,_,_,_
433,38023206,TP53,Non-Small Cell Lung Cancer,plasma,NGS,Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression. Serum was separated and sequenced using 425-panel next-generation sequencing analysis (NGS).,_,_,_,_,_,_,positively related to immunotherapy efficacy
434,38023206,SMARCA4,Non-Small Cell Lung Cancer,plasma,NGS,Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression. Serum was separated and sequenced using 425-panel next-generation sequencing analysis (NGS).,_,_,_,_,_,_,positively related to immunotherapy efficacy
435,38023206,KRAS,Non-Small Cell Lung Cancer,plasma,NGS,Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression. Serum was separated and sequenced using 425-panel next-generation sequencing analysis (NGS).,_,_,_,_,_,_,positively related to immunotherapy efficacy
436,38023206,JAK2,Non-Small Cell Lung Cancer,plasma,NGS,Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression. Serum was separated and sequenced using 425-panel next-generation sequencing analysis (NGS).,_,_,_,_,_,_,negatively related to immunotherapy efficacy
437,38023206,EGFR,Non-Small Cell Lung Cancer,plasma,NGS,Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression. Serum was separated and sequenced using 425-panel next-generation sequencing analysis (NGS).,_,_,_,_,_,_,negatively related to immunotherapy efficacy
438,38023206,DNMT3A,Non-Small Cell Lung Cancer,plasma,NGS,Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression. Serum was separated and sequenced using 425-panel next-generation sequencing analysis (NGS).,_,negatively related to immunotherapy efficacy,_,_,_,_,_
439,37344660,TP53,Metastatic Breast Cancer,plasma,NGS,"Blood samples prospectively collected from 163 ER-positive/HER2-negative female MBC patients, before ET, were used for cell-free tumor DNA (cfDNA) analysis. cfDNA was subjected to next-generation sequencing (NGS) to interrogate oncogenic PIK3CA hotspot and TP53 DNA-binding domain (DBD) mutations, including single nucleotide variants (SNVs) or small insertions and deletions (InDels). The variant calling threshold was set at 0.5%. Progression-free survival (PFS) was measured from the start of the ET treatment to the time of disease progression of the same treatment regimen.",_,"Patients with PIK3CA mutation (HR 1.74, p = 0.007), and TP53 mutation (HR 1.64, p = 0.047) in liquid biopsy conferred worse outcome after ET. Even for patients with low tumor burden, the detrimental effect of PIK3CA or TP53 mutation remained significant (p < 0.001).",_,_,_,_,_
440,37344660,PIK3CA,Metastatic Breast Cancer,plasma,NGS,"Blood samples prospectively collected from 163 ER-positive/HER2-negative female MBC patients, before ET, were used for cell-free tumor DNA (cfDNA) analysis. cfDNA was subjected to next-generation sequencing (NGS) to interrogate oncogenic PIK3CA hotspot and TP53 DNA-binding domain (DBD) mutations, including single nucleotide variants (SNVs) or small insertions and deletions (InDels). The variant calling threshold was set at 0.5%. Progression-free survival (PFS) was measured from the start of the ET treatment to the time of disease progression of the same treatment regimen.",_,"Patients with PIK3CA mutation (HR 1.74, p = 0.007), and TP53 mutation (HR 1.64, p = 0.047) in liquid biopsy conferred worse outcome after ET. Even for patients with low tumor burden, the detrimental effect of PIK3CA or TP53 mutation remained significant (p < 0.001).",_,_,_,_,_
441,37344331,EGFR,Non-Small Cell Lung Cancer,plasma,NGS Illumina NextSeq 500,Treatment-na ve patients with stage IV NSCLC harboring an activating EGFR mutation were enrolled. Alternating cycles of osimertinib (80 mg/day) followed by afatinib (20 mg/day) were administered every 8 weeks. Genomic analysis was performed using circulating tumor DNA obtained before and after the treatment.,_,_,_,_,_,"Alternating cycles of osimertinib followed by afatinib were administered,this treatment may prevent the emergence of EGFR secondary mutations that trigger drug resistance.",_
442,38697850,TP53,Metastatic Colorectal Cancer,plasma,_,"We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.",_,"In baseline-ctDNA,higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.",_,_,_,_,_
443,38697850,APC,Metastatic Colorectal Cancer,plasma,_,"We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.",_,"In baseline-ctDNA,higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.",_,_,_,_,_
444,38697850,KRAS,Metastatic Colorectal Cancer,plasma,_,"We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.",_,"In baseline-ctDNA,higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.",_,_,_,_,_
445,38596716,MSH2,Gliomas,plasma,CAPP-seq (AVENIO),"We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500.",plasma ctDNA detection of new MMR gene mutations not present in the initial tissue biopsy may provide an early indication of the development of chemotherapy (temozolomide) resistance.,_,_,_,_,_,_
446,38596716,MSH6,Gliomas,plasma,CAPP-seq (AVENIO),"We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500.",plasma ctDNA detection of new MMR gene mutations not present in the initial tissue biopsy may provide an early indication of the development of chemotherapy (temozolomide) resistance.,_,_,_,_,_,_
447,38596716,MLH1,Gliomas,plasma,CAPP-seq (AVENIO),"We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500.",plasma ctDNA detection of new MMR gene mutations not present in the initial tissue biopsy may provide an early indication of the development of chemotherapy (temozolomide) resistance.,_,_,_,_,_,_
448,38596716,PMS2,Gliomas,plasma,CAPP-seq (AVENIO),"We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500.",plasma ctDNA detection of new MMR gene mutations not present in the initial tissue biopsy may provide an early indication of the development of chemotherapy (temozolomide) resistance.,_,_,_,_,_,_
449,38548846,EGFR,Melanoma,plasma,ddPCR,"Seventeen stage IV cutaneous melanoma patients carrying a BRAF mutation at amino acid position 600 (with the exception of patient #48 who carries the BRAF p.T599dup mutation43, Table  Table1),1), as identified in tissue biopsy, were prospectively enrolled and addressed to targeted therapy with BRAFi/MEKi. Patients were followed for up to 28 months (January 2019 to March 2022) to monitor disease evolution and to understand the timing/mechanisms of resistance. Considering that resistance develops at a median time of 11-12 months4,75, blood samples were collected just before starting therapy (T0), after 6 (T1), and after 10 (T2) months (to test the ability of the time setting to detect early signs of tumor escape), and at the time of progression (P). Approximately two to four serially collected blood samples were available per patient for a total of 50 samples (Table  (Table1).1). Tumor response was determined by physical examination and imaging investigation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.176, and assessed between the first day of therapy until progression, death, or last follow-up: stable disease (SD), partial response (PR), complete response (CR), or progressive disease (PD). Responders (R) were defined as complete response or partial response. Non-responders (NR) were defined as stable disease or progressive disease. Decisions regarding treatment response or disease recurrence were made by the treating clinician who was blinded to the ctDNA results. All subjects involved in the study provided written informed consent.",_,"Detectable BRAF-mutant related to worse overall survival, not responding, and early progression.",_,_,_,_,_
450,38539518,TP53,Triple Negative Breast Cancer,plasma,the AVENIO ctDNA Targeted Kit (17 genes; Roche Diagnostics),"We conducted a retrospective study enrolling 95 female patients who had been newly diagnosed with breast cancer and had undergone primary surgery or neoadjuvant chemotherapy (NAC) between January 2017 and October 2020 at Kyushu University Hospital, Fukuoka, Japan. The patients received neoadjuvant treatment according to the National Comprehensive Cancer Network¡¯s (NCCN) Guidelines for the Treatment of Breast Cancer. We reviewed the patients¡¯ electronic medical records and pathological information according to the 8th edition of the Union for International Cancer Control staging system. Peripheral blood samples were obtained before the primary surgery. In NAC cases, blood samples were obtained before NAC and surgery.",_,Mutation related to poor recurrence-free survival. ctDNA with liquid biopsy could identify the poor prognosis group before treatment among TNBC patients,_,_,_,_,_
451,38539518,BRCA1,Triple Negative Breast Cancer,plasma,the AVENIO ctDNA Targeted Kit (17 genes; Roche Diagnostics),"We conducted a retrospective study enrolling 95 female patients who had been newly diagnosed with breast cancer and had undergone primary surgery or neoadjuvant chemotherapy (NAC) between January 2017 and October 2020 at Kyushu University Hospital, Fukuoka, Japan. The patients received neoadjuvant treatment according to the National Comprehensive Cancer Network¡¯s (NCCN) Guidelines for the Treatment of Breast Cancer. We reviewed the patients¡¯ electronic medical records and pathological information according to the 8th edition of the Union for International Cancer Control staging system. Peripheral blood samples were obtained before the primary surgery. In NAC cases, blood samples were obtained before NAC and surgery.",_,Mutation related to poor recurrence-free survival. ctDNA with liquid biopsy could identify the poor prognosis group before treatment among TNBC patients,_,_,_,_,_
452,38503018,TP53,Metastatic Colorectal Cancer,plasma,_,"We included mCRC patients from January 2018 to October 2020 as a studied cohort which were treated with cetuximab plus mFOLFOX as first line therapy. Blood samples were collected for circulating tumor DNA (ctDNA) test at three timepoints: before the first-line therapy(baseline), at the time of first-line progression and at the time of second-line progression. Progression-free survival was considered as the primary endpoint while objective response rate and overall survival were determined as the secondary endpoints.","TP53 and AMER1 mutations, tumor mutational burden (TMB) levels, and TP53/AMER1 co-mutation may predict the efficacy of the first-line cetuximab-contained treatment (worse in mutation group).",_,_,_,_,_,_
453,38503018,AMER1,Metastatic Colorectal Cancer,plasma,_,"We included mCRC patients from January 2018 to October 2020 as a studied cohort which were treated with cetuximab plus mFOLFOX as first line therapy. Blood samples were collected for circulating tumor DNA (ctDNA) test at three timepoints: before the first-line therapy(baseline), at the time of first-line progression and at the time of second-line progression. Progression-free survival was considered as the primary endpoint while objective response rate and overall survival were determined as the secondary endpoints.","TP53 and AMER1 mutations, tumor mutational burden (TMB) levels, and TP53/AMER1 co-mutation may predict the efficacy of the first-line cetuximab-contained treatment (worse in mutation group).",_,_,_,_,_,_
454,38496698,TP53,Small Cell Lung Cancer,plasma,NGS(Illumina NextSeq 550),"Targeted sequencing was conducted using pre-treatment and on-treatment blood samples from definitive CCRT-treated patients with LD-SCLC (n=50). Based on 12-month recurrence-free survival (RFS), patients were categorized into persistent-response (PeR, n=29) and non-PeR (n=21) groups. Fragmentome analysis was conducted using ctDNA fragments of different lengths: P1 (100-155 bp) and P2 (160-180 bp).",_,Patients with TP53 mutation in on-treatment samples demonstrated significantly shorter RFS than patients with wild-type(P=0.05).,_,_,_,_,_
455,38496698,RB1,Small Cell Lung Cancer,plasma,NGS(Illumina NextSeq 550),"Targeted sequencing was conducted using pre-treatment and on-treatment blood samples from definitive CCRT-treated patients with LD-SCLC (n=50). Based on 12-month recurrence-free survival (RFS), patients were categorized into persistent-response (PeR, n=29) and non-PeR (n=21) groups. Fragmentome analysis was conducted using ctDNA fragments of different lengths: P1 (100-155 bp) and P2 (160-180 bp).",_,Patients with TP53 mutation in on-treatment samples demonstrated significantly shorter RFS (P=0.0014) and OS (P=0.0018) than patients with wild-type.,_,_,_,_,_
456,38443094,IGLL5,Relapsed Or Refractory Large B-Cell Lymphoma,plasma,Custom capture-based target sequencing panel covering 188 lymphoma-related genes (Onco-LymScan panel),Longitudinal plasma samples were prospectively collected both before lymphodepletion and at multiple timepoints after CAR19 T-cell infusion. ctDNA was detected using a capture-based next-generation sequencing which has been validated in untreated LBCL.,_,Significant correlation between IGLL5 mutation and inferior PFS (p=0.008) and OS (p=0.014).,_,_,_,_,_
457,38427931,ESR1,Breast Cancer,plasma,dPCR,"Forty-six patients were enrolled in this substudy. Plasma was collected before treatment (T0), after the first cycle of therapy (T1), and at the time of progression (T2). ctDNA hybridization and capture were performed using the Illumina TruSight Tumor 170 Kit. Acquired mutations were confirmed by digital polymerase chain reaction. Progression-free survival analysis was estimated using the Kaplan-Meier method and compared with the log-rank test.",_,Mutations in ESR1 at before treatment (T0) conferred higher risk of progression in the entire population (P = .02) and in patients treated with palbociclib + endocrine treatment (ET) (P = .04). ESR1 mutation effect remained significant after correction for clinical variables (P = .03).,_,_,_,_,_
458,38427753,KRAS,Relapsed Or Refractory Multiple Myeloma,plasma,_,"Here we performed targeted-capture sequencing using bone marrow plasma cells (BMPC) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.",_,Associated with worse progression-free survival (PFS).,_,_,_,_,_
459,38427753,TP53,Relapsed Or Refractory Multiple Myeloma,plasma,_,"Here we performed targeted-capture sequencing using bone marrow plasma cells (BMPC) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.",_,Associated with worse progression-free survival (PFS).,_,_,_,_,_
460,38427753,DIS3,Relapsed Or Refractory Multiple Myeloma,plasma,_,"Here we performed targeted-capture sequencing using bone marrow plasma cells (BMPC) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.",_,Associated with worse progression-free survival (PFS).,_,_,_,_,_
461,38427753,BRAF,Relapsed Or Refractory Multiple Myeloma,plasma,_,"Here we performed targeted-capture sequencing using bone marrow plasma cells (BMPC) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.",_,Associated with worse progression-free survival (PFS).,_,_,_,_,_
462,38427753,NRAS,Relapsed Or Refractory Multiple Myeloma,plasma,_,"Here we performed targeted-capture sequencing using bone marrow plasma cells (BMPC) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.",_,Associated with worse progression-free survival (PFS).,_,_,_,_,_
463,38427753,ATM,Relapsed Or Refractory Multiple Myeloma,plasma,_,"Here we performed targeted-capture sequencing using bone marrow plasma cells (BMPC) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, and dexamethasone in a multicenter, prospective, observational study.",_,Associated with worse progression-free survival (PFS).,_,_,_,_,_
464,38421881,TP53,Non-Small Cell Lung Cancer,plasma,NGS,"In this study, 180 patients received 225 mg of ensartinib orally once daily until disease progression, death or withdrawal. OS was estimated by Kaplan Meier methods with two-sided 95% confidence intervals (CIs). Next-generation sequencing was employed to explore prognostic biomarkers based on plasma samples collected at baseline and after initiating ensartinib. Circulating tumor DNA (ctDNA) was detected to dynamically monitor the genomic alternations during treatment and indicate the existence of molecular residual disease, facilitating improvement of clinical management.",_,"An inferior OS correlated significantly with baseline tumor protein 53 (TP53) mutation.Specifically, patients with TP53 mutations (n = 34) had shorter OS than those without TP53 mutations (n = 134) (median 14.8 months, [95% CI: 9.3©\40.3 months] vs. NR [95% CI 44.0 months©\NR], HR: 3.1, 95% CI 2.0©\4.9, P < 0.001].",_,_,_,_,_
465,38421881,ALK,Non-Small Cell Lung Cancer,plasma,NGS,"In this study, 180 patients received 225 mg of ensartinib orally once daily until disease progression, death or withdrawal. OS was estimated by Kaplan Meier methods with two-sided 95% confidence intervals (CIs). Next-generation sequencing was employed to explore prognostic biomarkers based on plasma samples collected at baseline and after initiating ensartinib. Circulating tumor DNA (ctDNA) was detected to dynamically monitor the genomic alternations during treatment and indicate the existence of molecular residual disease, facilitating improvement of clinical management.",_,"An inferior OS correlated significantly with baseline ALK mutation. Specifically, patients with detected secondary ALK mutations at baseline showed significantly shorter OS than those with undetected secondary ALK mutations (median 17.8 months [95% CI: 9.4©\26.9 months] vs. NR [95% CI: 47.0 months©\NR], HR: 3.0, 95% CI: 1.9©\4.6, P < 0.001].",_,_,_,_,_
466,38418463,EGFR,Non-Small Cell Lung Cancer,plasma,NGS/ddPCR,"OSCILLATE is a phase 2, single-arm, multicentre, open-label trial of alternating osimertinib with gefitinib in patients with advanced EGFR T790M positive NSCLC. Participants were recruited from 12 tertiary centres in Australia, from September 4, 2017 to June 11, 2019. The cut-off date for data analysis for this publication was December 11, 2021. The primary objective of the trial was PFS measured at the 12-month landmark. Secondary objectives include median PFS, time to first and second progression, feasibility of alternating treatment as defined by no dose interruptions for 6 months, ORR as defined by CR and PR, OS and adverse events. Exploratory objectives included analysis of changes in ctDNA and correlation with response to alternating third and first-generation EGFR TKI. Unplanned analysis included difference in PFS and OS between those with an EGFR exon 19 deletion compared to with exon 21 L858R, 12-month PFS rate by sex, and difference in PFS and OS between sex.",_,"Participants with an EGFRm W4-BLR above the median had shorter PFS (median PFS 5 versus 12 months, HR 2.6, 95% CI 1.2¨C5.3, P = 0.013). Participants with an EGFRm W12-BL R above the median demonstrated both an inferior PFS and OS (median PFS 3 versus 10 months; HR 2.4, 95% CI 1.04¨C5.58, P = 0.02 and median OS 15 months versus NR; HR 4.2, 95% CI 1.69¨C10.6, P = 0.002); (week 4-baseline ratio (W4-BLR), week 12-baseline ratio (W12-BLR)).",_,_,_,_,_
467,38417447,KIT,Melanoma,plasma,ddPCR (Bio-Rad QX200),"NICAM is a multicentre, open-label, investigator-initiated, single-arm two-stage phase 2 study conducted across 16 UK sites. Eligible patients were 18 years or older, with KIT mutated histologically proven advanced (unresectable locally advanced or metastatic) mucosal or acral melanoma. Patients whose tumors harbored KIT mutation previously characterised as conferring resistance to nilotinib were excluded. Patients were required to have one or more clinically or radiologically measurable lesions (¡Ý10mm), Eastern Cooperative Oncology Group (ECOG) performance status 0¨C2, and adequate organ function. Patients with intracranial disease were excluded (unless present and stable for >6 months). Prior exposure to tyrosine kinase inhibitors was excluded.",_,_,_,_,_,"Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations.",_
468,38414861,PBRM1 ,Locally Advanced Cervical Cancers,plasma,"Illumina Hiseq X 10 sequencing platform (Illumina, USA)","In this study, to identify potential ctDNA markers to monitor response to NACT of patients with LACC, we analyzed genetic variants in pre- and post-NACT ctDNA and tumor tissue DNA (ttDNA) samples taken from patients by using targeted next-generation sequencing (NGS).",potential ctDNA marker of emerging resistance to NACT (Neoadjuvant chemotherapy).,Associated with poorer survival.,_,_,_,increasing sensitivity to olaparib,_
469,38414510,TSC2,Metastatic Esophageal Squamous Cell Carcinoma,plasma,"HiSeq4000 platform (Illumina, Inc.)","Our research center is one of the sub-centers of the RATIONALE-302 study (ClinicalTrials.gov identifier no. NCT03430843), of which 20 subjects were screened and 15 were enrolled, of which 12 patients were eligible for this exploratory study at Zhejiang Cancer Hospital (Hangzhou, China) between March 2018 and September 2020, whose tumor tissue or plasma was available for NGS. Eligible patients were aged 18-73 years and previously treated with systematic chemotherapy for stage IV ESCC, who were being treated with tislelizumab immuno-monotherapy 200 mg intravenous drip every 3 weeks until disease progression. Specific inclusion and exclusion criteria were those of the RATIONALE-302 study.",_,"The median OS for TSC2 gene mutation was significantly shorter than wide type [11.7 months vs. not reached (NR), P=0.004].",_,_,_,_,_
470,38414510,ZNF217,Metastatic Esophageal Squamous Cell Carcinoma,plasma,"HiSeq4000 platform (Illumina, Inc.)","Our research center is one of the sub-centers of the RATIONALE-302 study (ClinicalTrials.gov identifier no. NCT03430843), of which 20 subjects were screened and 15 were enrolled, of which 12 patients were eligible for this exploratory study at Zhejiang Cancer Hospital (Hangzhou, China) between March 2018 and September 2020, whose tumor tissue or plasma was available for NGS. Eligible patients were aged 18-73 years and previously treated with systematic chemotherapy for stage IV ESCC, who were being treated with tislelizumab immuno-monotherapy 200 mg intravenous drip every 3 weeks until disease progression. Specific inclusion and exclusion criteria were those of the RATIONALE-302 study.",_,"The median OS for ZNF217 gene mutation was significantly shorter than wide type [11.7 months vs. NR, P=0.022].",_,_,_,_,_
471,38413796,PIK3CA,Metastatic Breast Cancer,plasma,targeted-NGS/ddPCR(BioRad QX100),"Patients aged ¡Ý18 years with ER + /HER2- mBC (immunoreactive for ER in ¡Ý10% of tumor-cell nuclei by immunohistochemistry) treated at Institut Curie Hospitals (Paris and Saint Cloud), who progressed under prior CDK4/6i therapy (with no requirement for prior CDK4/6i duration). The presence of measurable disease (per RECIST criteria) was not a prerequisite for patient enrollment. All included patients were then treated with everolimus (10 mg/day, unless decided otherwise by physicians) and fulvestrant, per standard of care. Mucositis prophylaxis was left at the discretion of the physician. Tumor response to therapy was assessed at least every 3 months by CT-scan. The objective response rate (ORR) was calculated only with the patients with RECIST measurable disease, including those with unconfirmed responses. Any patient who did not achieve a complete/partial response or progressive disease (PD) within 6 months was considered as having a stable disease (SD). Adverse events were coded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0). Patient characteristics and survival data were prospectively registered. Patients who discontinued everolimus treatment for any reason other than progression were required to follow the same schedule of assessments until progression. For each patient, longitudinal blood samples were collected: at baseline, after 3¨C5 weeks (3¨C5 W) of therapy and at time of disease progression. Variation in ctDNA was calculated using copies/ml.",_,"In multivariate analysis, baseline ctDNA positivity and PIK3CA mutation were found as independent prognostic factors for PFS and OS (for PFS, HR = 2.36, 95%CI [1.38-4.04], p = 0.002; HR = 2.67, 95%CI [1.39-5.10], p = 0.003; for OS, HR = 6.33, 95%CI [2.07-19.36], p = 0.001; HR = 4.58, 95%CI [1.57-13.35], p = 0.005, respectively).",_,_,_,_,_
472,38398128,RAS,Metastatic Colorectal Cancer,plasma,NGS(Guardant360),"This study provides a comprehensive profile of BRAF variants in mCRC using a large genomic database of circulating tumor DNA (ctDNA) and analyzing clinical outcomes in a cohort of patients with atypical (non-V600) BRAF variants (aBRAF; class II, class III, unclassified).",_,"In patient with atypical BRAF, concurrent RAS mutations was associated with poorer prognosis.",_,_,_,_,_
473,38378604,KRAS,Pancreatic Ductal Adenocarcinoma,plasma,"HiSeq4000 platform (Illumina, Inc.)","Paired tumor tissue and blood samples were prospectively collected from patients with mPDAC receiving first-line NPS chemotherapy, and underwent next-generation sequencing with genomic profiling of 425 genes for ctDNA. High mutation allelic frequency (MAF) was defined as ¡Ý 30% and ¡Ý 5% in tumor tissue and blood, respectively. Kappa statistics were used to assess agreement between mutant genes in tumor and ctDNA. Associations of mutations in ctDNA and their dynamic changes with tumor response, overall survival (OS), and progression-free survival (PFS) were assessed using the Kaplan-Meier method, multivariable-adjusted Cox proportional hazards regression, and longitudinal data analysis.",_,"Through multivariable analysis, high mutation abundances of KRAS in both tumor (P = 0.007) and blood (P < 0.001) were significantly and independently associated with poorer OS.",_,_,_,_,_
474,38378604,TP53,Pancreatic Ductal Adenocarcinoma,plasma,"HiSeq4000 platform (Illumina, Inc.)","Paired tumor tissue and blood samples were prospectively collected from patients with mPDAC receiving first-line NPS chemotherapy, and underwent next-generation sequencing with genomic profiling of 425 genes for ctDNA. High mutation allelic frequency (MAF) was defined as ¡Ý 30% and ¡Ý 5% in tumor tissue and blood, respectively. Kappa statistics were used to assess agreement between mutant genes in tumor and ctDNA. Associations of mutations in ctDNA and their dynamic changes with tumor response, overall survival (OS), and progression-free survival (PFS) were assessed using the Kaplan-Meier method, multivariable-adjusted Cox proportional hazards regression, and longitudinal data analysis.",_,High mutation abundance of TP53 (P = 0.033) was significantly and independently associated with poorer OS.,_,_,_,_,_
475,38378604,SMAD4,Pancreatic Ductal Adenocarcinoma,plasma,"HiSeq4000 platform (Illumina, Inc.)","Paired tumor tissue and blood samples were prospectively collected from patients with mPDAC receiving first-line NPS chemotherapy, and underwent next-generation sequencing with genomic profiling of 425 genes for ctDNA. High mutation allelic frequency (MAF) was defined as ¡Ý 30% and ¡Ý 5% in tumor tissue and blood, respectively. Kappa statistics were used to assess agreement between mutant genes in tumor and ctDNA. Associations of mutations in ctDNA and their dynamic changes with tumor response, overall survival (OS), and progression-free survival (PFS) were assessed using the Kaplan-Meier method, multivariable-adjusted Cox proportional hazards regression, and longitudinal data analysis.",_,High mutation abundance of SMAD4 was significantly and independently associated with poorer OS (P = 0.015)/FPS (P = 0.020).,_,_,_,_,_
476,38378604,CDKN2A,Pancreatic Ductal Adenocarcinoma,plasma,"HiSeq4000 platform (Illumina, Inc.)","Paired tumor tissue and blood samples were prospectively collected from patients with mPDAC receiving first-line NPS chemotherapy, and underwent next-generation sequencing with genomic profiling of 425 genes for ctDNA. High mutation allelic frequency (MAF) was defined as ¡Ý 30% and ¡Ý 5% in tumor tissue and blood, respectively. Kappa statistics were used to assess agreement between mutant genes in tumor and ctDNA. Associations of mutations in ctDNA and their dynamic changes with tumor response, overall survival (OS), and progression-free survival (PFS) were assessed using the Kaplan-Meier method, multivariable-adjusted Cox proportional hazards regression, and longitudinal data analysis.",_,High mutation abundance of CDKN2A was significantly and independently associated with poorer FPS (P = 0.018).,_,_,_,_,_
477,38375997,EGFR,Non-Small Cell Lung Cancer,plasma,_,"In the current study, we aimed to develop a model to understand and characterize tumor dynamics and the development of drug resistance in patients with NSCLC treated with erlotinib. First, a population PK model of erlotinib was developed and thereafter applied to investigate the exposure©\tumor inhibition relationship of erlotinib. Tumor dynamics¡¯ models accounting for tumor heterogeneity, with or without a pre©\existing resistance component, and drug exposure©\dependent treatment effects, were evaluated. Subsequently, we aimed to explore the correlation of the extent of somatic driver mutation in ctDNA at baseline with the tumor dynamics in patients with NSCLC.",_,_,Higher baseline plasma EGFR mutation levels correlated with increased tumor growth rates.,_,_,_,_
478,38347302,KRAS,Metastatic Colorectal Cancer,plasma,NGS,"The PARADIGM study (NCT02394795) was a randomized, open-label, phase 3 trial conducted at 197 sites in Japan between May 2015 and January 2022. The study enrolled patients (age 20¨C79 years) with RAS WT unresectable adenocarcinoma originating in the colorectum who had not received previous chemotherapy for mCRC. Screening for KRAS and NRAS mutations was performed using approved in vitro diagnostic tests. KRAS and NRAS were required to be WT within exon 2 codons 12 and 13, exon 3 codons 59 and 61, and exon 4 codons 117 and 146. Other key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1 and presence of at least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1.Patients were randomly allocated (1:1) to panitumumab + mFOLFOX6 or to bevacizumab + mFOLFOX6. Randomization was stratified by study site, age (20¨C64 versus 65¨C79 years) and presence or absence of liver metastases. The primary endpoint of PARADIGM was OS, which was tested hierarchically; first in patients with left-sided tumors and then in the overall population. Secondary endpoints were PFS, response rate, duration of response and curative resection rate. Depth of response was an exploratory endpoint. The data cutoff date for these data from the final analysis was 14 January 2022. Patient sex was determined by patient report and was not considered in the study design. Clinical data were collected using EDC Classic Rave (v.2020.2.0).",_,"Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62-0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83-1.53), regardless of tumor sidedness.",_,_,_,panitumumab plus modified FOLFOX6 or bevacizumab plus modified FOLFOX6,_
479,38347302,NRAS,Metastatic Colorectal Cancer,plasma,NGS,"The PARADIGM study (NCT02394795) was a randomized, open-label, phase 3 trial conducted at 197 sites in Japan between May 2015 and January 2022. The study enrolled patients (age 20¨C79 years) with RAS WT unresectable adenocarcinoma originating in the colorectum who had not received previous chemotherapy for mCRC. Screening for KRAS and NRAS mutations was performed using approved in vitro diagnostic tests. KRAS and NRAS were required to be WT within exon 2 codons 12 and 13, exon 3 codons 59 and 61, and exon 4 codons 117 and 146. Other key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1 and presence of at least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1.Patients were randomly allocated (1:1) to panitumumab + mFOLFOX6 or to bevacizumab + mFOLFOX6. Randomization was stratified by study site, age (20¨C64 versus 65¨C79 years) and presence or absence of liver metastases. The primary endpoint of PARADIGM was OS, which was tested hierarchically; first in patients with left-sided tumors and then in the overall population. Secondary endpoints were PFS, response rate, duration of response and curative resection rate. Depth of response was an exploratory endpoint. The data cutoff date for these data from the final analysis was 14 January 2022. Patient sex was determined by patient report and was not considered in the study design. Clinical data were collected using EDC Classic Rave (v.2020.2.0).",_,"Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62-0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83-1.53), regardless of tumor sidedness.",_,_,_,panitumumab plus modified FOLFOX6 or bevacizumab plus modified FOLFOX6,_
480,38347302,PTEN,Metastatic Colorectal Cancer,plasma,NGS,"The PARADIGM study (NCT02394795) was a randomized, open-label, phase 3 trial conducted at 197 sites in Japan between May 2015 and January 2022. The study enrolled patients (age 20¨C79 years) with RAS WT unresectable adenocarcinoma originating in the colorectum who had not received previous chemotherapy for mCRC. Screening for KRAS and NRAS mutations was performed using approved in vitro diagnostic tests. KRAS and NRAS were required to be WT within exon 2 codons 12 and 13, exon 3 codons 59 and 61, and exon 4 codons 117 and 146. Other key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1 and presence of at least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1.Patients were randomly allocated (1:1) to panitumumab + mFOLFOX6 or to bevacizumab + mFOLFOX6. Randomization was stratified by study site, age (20¨C64 versus 65¨C79 years) and presence or absence of liver metastases. The primary endpoint of PARADIGM was OS, which was tested hierarchically; first in patients with left-sided tumors and then in the overall population. Secondary endpoints were PFS, response rate, duration of response and curative resection rate. Depth of response was an exploratory endpoint. The data cutoff date for these data from the final analysis was 14 January 2022. Patient sex was determined by patient report and was not considered in the study design. Clinical data were collected using EDC Classic Rave (v.2020.2.0).",_,"Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62-0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83-1.53), regardless of tumor sidedness.",_,_,_,panitumumab plus modified FOLFOX6 or bevacizumab plus modified FOLFOX6,_
481,38277079,KRAS,Pancreatic Cancer,plasma,ddPCR,"We collected 144 blood samples from 18 patients with locally advanced or metastatic cancer that were undergoing initial first-line chemotherapy of gemcitabine plus nab-paclitaxel (GEM plus nab-PTX). Analysis of KRAS-mutated ctDNA was quantified by digital droplet polymerase chain reaction (ddPCR) as mutant allele frequency (MAF). This study investigated pretreatment KRAS-mutated ctDNA status and ctDNA kinetics every few days (days 1, 3, 5 and 7) after initiation of chemotherapy and their potential as predictive indicators.",_,Increasement in KRAS-mutated ctDNA MAF values from day 0-7 after initiation of chemotherapy was significantly associated with disease progression (P < 0.001).,_,_,_,_,_
482,38258582,KRAS,Pancreatic Cancer,plasma,_,"Patients with localized PDAC were enrolled in a prospective study at Northwestern Medicine between October 2020 and October 2022. Blood samples were collected to perform targeted tumor agnostic NGS utilizing the Tempus x|F 105 gene panel at three timepoints: pre-therapy (at diagnosis), post-NAC, and after local therapy, including surgery. The relationship between ctDNA detection and CA19-9, and the prognostic significance of ctDNA detection were analyzed.",_,"In patients treated with neoadjuvant chemotherapy (NAC), the presence of KRAS ctDNA at diagnosis was associated with and independently predicted worse progression-free-survival.",_,_,_,_,_
483,38249327,TP53,Gastric Cancer,plasma,NGS( the Illumina NovaSeq 6000),"We enrolled 30 patients with gastric cancer peritoneal metastasis, treated with intraperitoneal and intravenous paclitaxel plus S-1. Peripheral blood samples of patients were prospectively collected at baseline, after treatment initiation accompanied by computed tomography scan and disease progression. Mutational profiles from ctDNA were analyzed to evaluate its association with chemotherapeutic response.",_,"Patients with TP53 mutation had worse progression-free survival (PFS) and overall survival (OS); Specifically, patients with TP53-wt had significantly longer PFS than those with TP53-mut (median PFS: 20.22 months in TP53-wt group, 7.63 months in TP53-mut group, HR = 0.148, 95% CI 0.036¨C0.603, p = 0.002]. The median OS was 29.26 months in patients with TP53-wt, which was longer than 15.78 months in those with TP53-mut [HR = 0.085, 95% CI 0.013¨C0.544, p = 0.001].",_,_,_,_,_
484,38238761,ESR1,Metastatic Breast Cancer,plasma,QX200TM Droplet Reader (Bio-Rad),Ninety-seven patients with HR+ mBC were prospectively enrolled during standard treatment at Samsung Medical Center. CTCs were isolated from blood using GenoCTC and EpCAM or c-MET CTC isolation kits. PIK3CA and ESR1 hotspot mutations were analyzed using droplet digital PCR. CfDNA concentrations were calculated using internal control copies from the ESR1 mutation test. Immunocytochemistry was performed to compare c-MET overexpression between primary and metastatic sites.,_,significantly associated with poor prognosis (p = 0.0064).,_,_,_,_,_
485,38228081,TP53,Follicular Lymphoma,plasma,_,We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.,_,The presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them.,_,_,_,_,_
486,38228081,CREBBP,Follicular Lymphoma,plasma,_,We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.,_,The presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them.,_,_,_,_,_
487,38217945,RAS,Metastatic Colorectal Cancer,plasma,NGS(targeted panel of 108 genes),"This is an open-label, single arm, multicenter, phase ¢ò study aiming to perform the efficacy, safety and genomic analysis of SCT200, a noval fully humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type mCRC. SCT200 (6 mg/kg) was given weekly for the first six weeks, followed by a higher dose of 8 mg/kg every two weeks until disease progression or unacceptable toxicity. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR) and secondary endpoints included ORR in patients with left-sided tumor, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety.",Possible resistance mechanisms of SCT200.,_,_,_,_,_,_
488,38217945,RAF,Metastatic Colorectal Cancer,plasma,NGS(targeted panel of 108 genes),"This is an open-label, single arm, multicenter, phase ¢ò study aiming to perform the efficacy, safety and genomic analysis of SCT200, a noval fully humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type mCRC. SCT200 (6 mg/kg) was given weekly for the first six weeks, followed by a higher dose of 8 mg/kg every two weeks until disease progression or unacceptable toxicity. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR) and secondary endpoints included ORR in patients with left-sided tumor, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety.",Possible resistance mechanisms of SCT200.,_,_,_,_,_,_
489,38201440,CTNNB1,Hepatoblastoma,plasma,ddPCR(QX200 ),"This prospective observational study sought to ascertain the feasibility of ctDNA detection in patients with hepatoblastoma and explore its associations with established clinical indicators and biomarkers, including serum Alpha-fetoprotein (AFP). We obtained 38 plasma samples and 17 tumor samples from 20 patients with hepatoblastoma. These samples were collected at various stages: 10 at initial diagnosis, 17 during neoadjuvant chemotherapy, 6 post-operatively, and 5 at disease recurrence. Utilizing a bespoke sequencing assay we developed called QUENCH, we identified single nucleotide variants and deletions in CTNNB1 ctDNA.",_,_,"a positive correlation between ctDNA positivity and tumor burden , as well as a correlation between VAF levels and tumor burden.",_,_,_,ctDNA VAF correlated with the order of magnitude of AFP (serum Alpha-fetoprotein) levels in most cases (R2 = 0.6713).
490,38197078,TP53,Squamous Cell Carcinoma Of The Head And Neck,plasma,"NovaSeq system (Illumina, USA)","Information on TP53 mutations, patient survival time, and clinical data in HNSCC were downloaded from The Cancer Genome Atlas database. The difference in immune infiltration between the TP53-mutant group and the wild-type group was compared. We applied the single-sample gene set enrichment analysis method on the transcriptome of HNSCC samples to assess the distribution of immune cell types between the two groups. The chemotherapy response was constructed using the R software package, ""pRRophetic"". Gene set enrichment analysis was performed based on the TP53 mutation. The next-generation sequencing was executed on cfDNA from nine patients with HNSCC to detect genetic alterations. Tumor biopsy (n=9) was sequenced using the same technique.",_,The TP53 mutation group showed lower response to immunotherapy compared with the wild-type group.,_,_,_,The TP53 mutation group showed high sensitivity to some chemotherapies compared with the wild-type group.,"The TP53 mutation was related to immune cells and the expression of immune-associated genes £¨PD-L1, PD-1, CTLA-4, LAG3, LGALS9, HAVCR2, and TIGIT)."
491,38190582,TET2,Non-Small Cell Lung Cancer,plasma,the FoundationOne Liquid Companion Diagnostic (F1LCDx) assay,"A total of 269 patients underwent FoundationOne Liquid Companion Diagnostic (F1LCDx) assay at the National Taiwan University Hospital, of whom 264 underwent tissue-based genetic testing also. We analyzed the actionable mutations and the concordance between tissue-based genetic testing, which was limited to EGFR, ALK, ROS1, and BRAF, in a real-life clinical setting and blood-based NGS in the clinical trial. Additionally, we analyzed the co-occurring genomic alterations from the blood-based ctDNA assay.",_,"Among the patients with EGFR-mutated NSCLC, TET2 co-occurring alterations correlated with shorter progression-free survival of EGFR tyrosine kinase inhibitor treatment (p = 0.01).",_,_,_,_,_
492,38148060,TP53,Diffuse Large B-Cell Lymphoma,plasma,"NextSeq500 instrument (Illumina, San Diego, CA, USA)","To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used.",_,_,_,_,_,"If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider autologous stem cell transplantation (auto-SCT).",_
493,38148060,SPEN,Diffuse Large B-Cell Lymphoma,plasma,"NextSeq500 instrument (Illumina, San Diego, CA, USA)","To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used.",_,_,_,_,_,"If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider autologous stem cell transplantation (auto-SCT).",_
494,38148060,BCOR,Diffuse Large B-Cell Lymphoma,plasma,"NextSeq500 instrument (Illumina, San Diego, CA, USA)","To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used.",_,_,_,_,_,"If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider autologous stem cell transplantation (auto-SCT).",_
495,38148060,IKBKB,Diffuse Large B-Cell Lymphoma,plasma,"NextSeq500 instrument (Illumina, San Diego, CA, USA)","To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used.",_,_,_,_,_,"If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider autologous stem cell transplantation (auto-SCT).",_
496,38148060,NOTCH2,Diffuse Large B-Cell Lymphoma,plasma,"NextSeq500 instrument (Illumina, San Diego, CA, USA)","To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used.",_,_,_,_,_,"If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider autologous stem cell transplantation (auto-SCT).",_
497,38015519,TP53,Breast Cancer,plasma,"HiSeq3000 Sequencing  System  (Illuminata,  SanDiego,  CA,  USA)","The gene mutation of peripheral blood ctDNA and tissue paraffin DNA (tDNA) of 50 patients was detected by high-throughput sequencing technology. The basic data of 50 cases of Medium to high-risk breast cancer diagnosed and were retrospectively collected, and the clinicopathological characteristics and survival results of TP53 mutant and wild-type patients were compared and analyzed according to the ctDNA detection results and relevant follow-up data. Analyze the impact of TP53 mutations on overall survival and progression-free survival using univariate and multivariate Cox regression models.",_,_,related to tumor size,_,"related to lymph node metastasis. After 3 years of follow-up, patients with TP53 gene Mutant had higher rates of bone metastasis, lung metasta-sis and liver metastasis than those with wild type (P<0.05).",_,related to vascular tumor thrombus.
498,38603927,PIK3CA,Breast Cancer,plasma,High resolution melting (HRM) PCR,"A cohort of patients with breast cancer undergoing curative surgery with available blood samples preoperatively and postoperatively (Post op) at either Post op time period; week 1-2, week 3-4 or weeks 5-12 were enrolled. PIK3CA gene mutations at exons 9 and 20 were detected in ctDNA with High resolution melting (HRM) PCR and Allele specific fluorescence probe-based PCR.",_,"PIK3CA gene mutations in ctDNA in postoperative period (hazard ratio (H.R: 18.05, p = 0.001) were a negative prognostic factor for recurrencefree survival (RFS) and overall survival (OS) (HR: 11.9, p = 0.01) in patients with breast cancer. Subgroup analysis of ctDNA indicate that positive ctDNA in both preoperative/postoperative period and post op period only were found to have prognostic effect on RFS and OS (RFS; p < 0.0001, OS; p = 0.0007).",_,_,_,_,_
499,38406801,ERBB2,Pancreatic Ductal Adenocarcinoma,plasma,NGS(Guardant360),"De-identified molecular test results for all patients with pancreatic cancer who received clinical cell-free circulating DNA analysis (Guardant360) between 06/2014 and 01/2018 were analyzed. Cell-free circulating DNA analysis included next-generation sequencing of up to 73 genes, including select small insertion/deletions, copy number amplifications, and fusions.",_,_,_,_,_,anti-HER2 therapy,_
500,38196198,EGFR,Non-Small Cell Lung Cancer,plasma,_,"A total of 120 patients with advanced NSCLC were retrospectively analyzed, and 56 patients with EGFR-mutation-positive NSCLC receiving osimertinib first-line therapy were eventually screened and included. The baseline status and abundance of plasma EGFR in patients with NSCLC were detected by cSMART, and the ratio of 0.1 was the critical value. Imaging examinations were performed every 8-12 weeks for the assessment of tumor response. The relationship between baseline EGFR mutation abundance and clinical outcomes of TKI therapy was analyzed.",_,"A much longer median progression-free survival (mPFS) was demonstrated in patients with high mutation abundance than in patients with low abundance (11.2 months vs 7.1 months, P = 0.0133). As for the median overall survival (mOS), it showed the same trend as mPFS in patients from different groups (15.5 vs 10.7 months, P = 0.0028). The role of plasma mutation abundance as an independent prognostic factor for both PFS (hazard ratios [HR]: 0.30, P = 0.006) and OS (HR: 0.35, P = 0.004) was demonstrated by multivariate Cox regression analysis.",_,_,_,_,_
501,38630555,PIK3CA,Non-Small Cell Lung Cancer,plasma,_,"ctDNA profiling analysis on-progression plasma samples from patients treated with osimertinib in both first (Phase 3, FLAURA trial) and second-line trials (Phase 3, AURA3 trial) revealed a high prevalence of PIK3CA/AKT/PTEN alterations. In vitro and in vivo evidence using CRISPR engineered NSCLC cell lines and PXD models support a functional role for PIK3CA and PTEN mutations in the development of osimertinib resistance.",osimertinib,_,_,_,_,can be re-sensitized by treatment with the combination of osimertinib and the AKT inhibitor capivasertib,_
502,38630555,ALK,Non-Small Cell Lung Cancer,plasma,_,"ctDNA profiling analysis on-progression plasma samples from patients treated with osimertinib in both first (Phase 3, FLAURA trial) and second-line trials (Phase 3, AURA3 trial) revealed a high prevalence of PIK3CA/AKT/PTEN alterations. In vitro and in vivo evidence using CRISPR engineered NSCLC cell lines and PXD models support a functional role for PIK3CA and PTEN mutations in the development of osimertinib resistance.",osimertinib,_,_,_,_,can be re-sensitized by treatment with the combination of osimertinib and the AKT inhibitor capivasertib,_
503,38630555,PTEN,Non-Small Cell Lung Cancer,plasma,_,"ctDNA profiling analysis on-progression plasma samples from patients treated with osimertinib in both first (Phase 3, FLAURA trial) and second-line trials (Phase 3, AURA3 trial) revealed a high prevalence of PIK3CA/AKT/PTEN alterations. In vitro and in vivo evidence using CRISPR engineered NSCLC cell lines and PXD models support a functional role for PIK3CA and PTEN mutations in the development of osimertinib resistance.",osimertinib,_,_,_,_,can be re-sensitized by treatment with the combination of osimertinib and the AKT inhibitor capivasertib,_
504,35852795,TP53,Diffuse Intrinsic Pontine Glioma,plasma,Illumina HiSeq 2500,"Patients (3-25 years) were enrolled on the basis of imaging consistent with DIPG. Biopsy tissue was collected for whole-exome and mRNA sequencing. After radiotherapy (RT), patients were assigned up to four FDA-approved drugs based on molecular tumor board recommendations. H3K27M-mutant circulating tumor DNA (ctDNA) was longitudinally measured. Tumor tissue and matched primary cell lines were characterized using whole-genome sequencing and DNA methylation profiling. When applicable, results were verified in an independent cohort from the Children's Brain Tumor Network (CBTN).","In H3K27-altered DIPGs, TP53 mutations was associated with RT resistance (P = 6.4e-4).","associated with worse OS (TP53mut 11.1 mo; 95% CI, 8.7-14; TP53wt 13.3 mo; 95% CI, 11.8-NA; P = 3.4e-2)",_,_,_,_,associated with genome instability (P = 3.1e-3).
